| Symbol | TEVA |
|---|---|
| Name | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Pharmaceutical Preparations |
| Address | TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, None None |
| Telephone | 972 (3) 914-8213 |
| Fax | 03-9267519 |
| yael.ashman@teva.co.il | |
| Website | https://www.tevapharm.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ;TASE |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000818686 |
| Description | Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines. Additional info from NASDAQ: |
2026-08-19 20:00
Lippman Evan 🔴 sold 18.6K shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $36.57 Transaction Date: Aug 17, 2026 | Filing ID: 356853
Read more
2026-08-19 12:31
Teva Pharmaceutical Industries Ltd. - U.S. FDA AcceptsTeva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Read more
2026-08-19 12:30
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Read more
2026-08-17 20:00
📋 Lippman Evan (Officer) plans to sell 19K shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (at $36.57 each, total $680K) Filed: Aug 17, 2026 | ID: 000296
Read more
2026-08-11 12:02
Teva Pharmaceutical Industries Ltd. -Moody’s Ratings Upgrades Teva to InvestmentGrade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
Read more
2026-08-11 12:00
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
Read more
2026-08-10 10:21
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Zaks Tal Zvi
Read more
2026-08-10 10:07
Zaks Tal Zvi 🔴 sold 17 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.87 Transaction Date: Aug 05, 2026 | Filing ID: 341086
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03539393 | Fremanezumab Compassionate Use Program for Pediatric Patients | — | Migraine | Available | — | — | ClinicalTrials.gov |
| NCT03539393 | Fremanezumab Compassionate Use Program for Pediatric Patients | — | Migraine | Available | — | — | ClinicalTrials.gov |
| NCT03539393 | Fremanezumab Compassionate Use Program for Pediatric Patients | — | Migraine | Available | — | — | ClinicalTrials.gov |
| NCT06997198 | Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental… | Phase4 | Tardive Dyskinesia | Recruiting | 2026-06-22 | 2027-10-01 | ClinicalTrials.gov |
| NCT06997198 | Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental… | Phase4 | Tardive Dyskinesia | Recruiting | 2026-06-22 | 2027-10-01 | ClinicalTrials.gov |
| NCT06997198 | Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental… | Phase4 | Tardive Dyskinesia | Recruiting | 2026-06-22 | 2027-10-01 | ClinicalTrials.gov |
| NCT06742957 | Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treat… | Phase3 | Plaque Type Psorisis | Completed | 2024-12-17 | 2025-11-12 | ClinicalTrials.gov |
| NCT06742957 | Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treat… | Phase3 | Plaque Type Psorisis | Completed | 2024-12-17 | 2025-11-12 | ClinicalTrials.gov |
| NCT06742957 | Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treat… | Phase3 | Plaque Type Psorisis | Completed | 2024-12-17 | 2025-11-12 | ClinicalTrials.gov |
| NCT06627231 | Mass Balance Clinical Trial With TEV-56286 | Phase1 | Healthy Participants | Completed | 2024-10-08 | 2024-11-29 | ClinicalTrials.gov |
| NCT06627231 | Mass Balance Clinical Trial With TEV-56286 | Phase1 | Healthy Participants | Completed | 2024-10-08 | 2024-11-29 | ClinicalTrials.gov |
| NCT06627231 | Mass Balance Clinical Trial With TEV-56286 | Phase1 | Healthy Participants | Completed | 2024-10-08 | 2024-11-29 | ClinicalTrials.gov |
| NCT07029126 | Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) … | — | Migraine | Recruiting | 2024-10-03 | 2026-03-30 | ClinicalTrials.gov |
| NCT07029126 | Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) … | — | Migraine | Recruiting | 2024-10-03 | 2026-03-30 | ClinicalTrials.gov |
| NCT07029126 | Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) … | — | Migraine | Recruiting | 2024-10-03 | 2026-03-30 | ClinicalTrials.gov |
| NCT06290102 | Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulf… | Phase1 | Asthma | Completed | 2024-05-16 | 2024-10-07 | ClinicalTrials.gov |
| NCT06290102 | Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulf… | Phase1 | Asthma | Completed | 2024-05-16 | 2024-10-07 | ClinicalTrials.gov |
| NCT06290102 | Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulf… | Phase1 | Asthma | Completed | 2024-05-16 | 2024-10-07 | ClinicalTrials.gov |
| NCT06253546 | Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients… | Phase1 | Schizophrenia | Completed | 2024-03-28 | 2025-06-12 | ClinicalTrials.gov |
| NCT06253546 | Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients… | Phase1 | Schizophrenia | Completed | 2024-03-28 | 2025-06-12 | ClinicalTrials.gov |
| NCT06253546 | Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients… | Phase1 | Schizophrenia | Completed | 2024-03-28 | 2025-06-12 | ClinicalTrials.gov |
| NCT06173661 | Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 | Phase4 | Migraine | Active_Not_Recruiting | 2024-03-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT06173661 | Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 | Phase4 | Migraine | Active_Not_Recruiting | 2024-03-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT06173661 | Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 | Phase4 | Migraine | Active_Not_Recruiting | 2024-03-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT05831566 | Expertise Asthma COPD Program with Digital Support | Phase3 | Asthma | Recruiting | 2023-01-31 | 2026-04-30 | ClinicalTrials.gov |
| NCT05831566 | Expertise Asthma COPD Program with Digital Support | Phase3 | Asthma | Recruiting | 2023-01-31 | 2026-04-30 | ClinicalTrials.gov |
| NCT05831566 | Expertise Asthma COPD Program with Digital Support | Phase3 | Asthma | Recruiting | 2023-01-31 | 2026-04-30 | ClinicalTrials.gov |
| NCT05617820 | Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal … | Phase3 | Dyspareunia | Completed | 2022-11-15 | 2024-03-15 | ClinicalTrials.gov |
| NCT05617820 | Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal … | Phase3 | Dyspareunia | Completed | 2022-11-15 | 2024-03-15 | ClinicalTrials.gov |
| NCT05617820 | Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal … | Phase3 | Dyspareunia | Completed | 2022-11-15 | 2024-03-15 | ClinicalTrials.gov |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Coliti… | Phase2 | Crohn Disease | Completed | 2022-09-30 | 2024-11-12 | ClinicalTrials.gov |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Coliti… | Phase2 | Crohn Disease | Completed | 2022-09-30 | 2024-11-12 | ClinicalTrials.gov |
| NCT05458011 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period … | Phase3 | Migraine | Completed | 2022-09-30 | 2024-06-13 | ClinicalTrials.gov |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Coliti… | Phase2 | Crohn Disease | Completed | 2022-09-30 | 2024-11-12 | ClinicalTrials.gov |
| NCT05458011 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period … | Phase3 | Migraine | Completed | 2022-09-30 | 2024-06-13 | ClinicalTrials.gov |
| NCT05458011 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period … | Phase3 | Migraine | Completed | 2022-09-30 | 2024-06-13 | ClinicalTrials.gov |
| NCT05550337 | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream… | Phase3 | Acne Vulgaris | Completed | 2022-09-19 | 2023-05-09 | ClinicalTrials.gov |
| NCT05550337 | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream… | Phase3 | Acne Vulgaris | Completed | 2022-09-19 | 2023-05-09 | ClinicalTrials.gov |
| NCT05550337 | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream… | Phase3 | Acne Vulgaris | Completed | 2022-09-19 | 2023-05-09 | ClinicalTrials.gov |
| NCT05241288 | Digihaler in Chronic Obstructive Pulmonary Disease (COPD) | Na | Pulmonary Disease, Chronic Obstructive | Completed | 2022-03-01 | 2023-02-13 | ClinicalTrials.gov |
| NCT05241288 | Digihaler in Chronic Obstructive Pulmonary Disease (COPD) | Na | Pulmonary Disease, Chronic Obstructive | Completed | 2022-03-01 | 2023-02-13 | ClinicalTrials.gov |
| NCT05241288 | Digihaler in Chronic Obstructive Pulmonary Disease (COPD) | Na | Pulmonary Disease, Chronic Obstructive | Completed | 2022-03-01 | 2023-02-13 | ClinicalTrials.gov |
| NCT04713982 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington… | Phase2 | Huntington Disease | Active_Not_Recruiting | 2021-11-19 | 2027-10-01 | ClinicalTrials.gov |
| NCT04713982 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington… | Phase2 | Huntington Disease | Active_Not_Recruiting | 2021-11-19 | 2027-10-01 | ClinicalTrials.gov |
| NCT04713982 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington… | Phase2 | Huntington Disease | Active_Not_Recruiting | 2021-11-19 | 2027-10-01 | ClinicalTrials.gov |
| NCT04976192 | Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in A… | Phase3 | Chronic Urticaria | Completed | 2021-08-30 | 2024-04-05 | ClinicalTrials.gov |
| NCT04976192 | Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in A… | Phase3 | Chronic Urticaria | Completed | 2021-08-30 | 2024-04-05 | ClinicalTrials.gov |
| NCT04976192 | Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in A… | Phase3 | Chronic Urticaria | Completed | 2021-08-30 | 2024-04-05 | ClinicalTrials.gov |
| NCT04693533 | Fremanezumab, Migraine and Sleep | Phase4 | Migraine Disorders | Terminated | 2021-07-29 | 2024-04-01 | ClinicalTrials.gov |
| NCT04693533 | Fremanezumab, Migraine and Sleep | Phase4 | Migraine Disorders | Terminated | 2021-07-29 | 2024-04-01 | ClinicalTrials.gov |
| NCT04693533 | Fremanezumab, Migraine and Sleep | Phase4 | Migraine Disorders | Terminated | 2021-07-29 | 2024-04-01 | ClinicalTrials.gov |
| NCT04997304 | Teva Asthma Predictive Analytics Study | Phase4 | Asthma | Completed | 2021-07-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT04997304 | Teva Asthma Predictive Analytics Study | Phase4 | Asthma | Completed | 2021-07-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT04997304 | Teva Asthma Predictive Analytics Study | Phase4 | Asthma | Completed | 2021-07-09 | 2023-12-14 | ClinicalTrials.gov |
| NCT04896645 | Albuterol Integrated Adherence Monitoring in Children With Asthma | Na | Asthma in Children | Completed | 2021-06-01 | 2022-06-22 | ClinicalTrials.gov |
| NCT04896645 | Albuterol Integrated Adherence Monitoring in Children With Asthma | Na | Asthma in Children | Completed | 2021-06-01 | 2022-06-22 | ClinicalTrials.gov |
| NCT04896645 | Albuterol Integrated Adherence Monitoring in Children With Asthma | Na | Asthma in Children | Completed | 2021-06-01 | 2022-06-22 | ClinicalTrials.gov |
| NCT04821869 | ProAir Digihaler in COPD Disease Management: A Real World Study | — | COPD | Completed | 2021-05-10 | 2022-06-21 | ClinicalTrials.gov |
| NCT04821869 | ProAir Digihaler in COPD Disease Management: A Real World Study | — | COPD | Completed | 2021-05-10 | 2022-06-21 | ClinicalTrials.gov |
| NCT04821869 | ProAir Digihaler in COPD Disease Management: A Real World Study | — | COPD | Completed | 2021-05-10 | 2022-06-21 | ClinicalTrials.gov |
| NCT04847674 | A Study to Test if TEV-53275 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2021-05-04 | 2022-04-28 | ClinicalTrials.gov |
| NCT04847674 | A Study to Test if TEV-53275 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2021-05-04 | 2022-04-28 | ClinicalTrials.gov |
| NCT04847674 | A Study to Test if TEV-53275 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2021-05-04 | 2022-04-28 | ClinicalTrials.gov |
| NCT04173260 | An Open-label Study to Define the Safety, Tolerability and Clinical Activity of… | Phase1 | Dystonia, Primary | Completed | 2021-04-29 | 2024-08-31 | ClinicalTrials.gov |
| NCT04173260 | An Open-label Study to Define the Safety, Tolerability and Clinical Activity of… | Phase1 | Dystonia, Primary | Completed | 2021-04-29 | 2024-08-31 | ClinicalTrials.gov |
| NCT04173260 | An Open-label Study to Define the Safety, Tolerability and Clinical Activity of… | Phase1 | Dystonia, Primary | Completed | 2021-04-29 | 2024-08-31 | ClinicalTrials.gov |
| NCT04729621 | A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporos… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2021-03-22 | 2023-06-19 | ClinicalTrials.gov |
| NCT04729621 | A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporos… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2021-03-22 | 2023-06-19 | ClinicalTrials.gov |
| NCT04729621 | A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporos… | Phase3 | Osteoporosis, Postmenopausal | Completed | 2021-03-22 | 2023-06-19 | ClinicalTrials.gov |
| NCT04677959 | A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Pa… | Phase4 | Asthma | Completed | 2021-02-16 | 2022-03-10 | ClinicalTrials.gov |
| NCT04677959 | A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Pa… | Phase4 | Asthma | Completed | 2021-02-16 | 2022-03-10 | ClinicalTrials.gov |
| NCT04677959 | A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Pa… | Phase4 | Asthma | Completed | 2021-02-16 | 2022-03-10 | ClinicalTrials.gov |
| NCT04682353 | A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Fo… | Phase1 | Contraception | Completed | 2020-12-14 | 2023-01-12 | ClinicalTrials.gov |
| NCT04682353 | A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Fo… | Phase1 | Contraception | Completed | 2020-12-14 | 2023-01-12 | ClinicalTrials.gov |
| NCT04682353 | A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Fo… | Phase1 | Contraception | Completed | 2020-12-14 | 2023-01-12 | ClinicalTrials.gov |
| NCT03890666 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose … | Phase4 | Asthma | Completed | 2020-10-26 | 2021-10-04 | ClinicalTrials.gov |
| NCT03890666 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose … | Phase4 | Asthma | Completed | 2020-10-26 | 2021-10-04 | ClinicalTrials.gov |
| NCT03890666 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose … | Phase4 | Asthma | Completed | 2020-10-26 | 2021-10-04 | ClinicalTrials.gov |
| NCT04447729 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cyst… | Phase2 | Interstitial Cystitis | Withdrawn | 2020-10-15 | 2022-02-10 | ClinicalTrials.gov |
| NCT04447729 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cyst… | Phase2 | Interstitial Cystitis | Withdrawn | 2020-10-15 | 2022-02-10 | ClinicalTrials.gov |
| NCT04447729 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cyst… | Phase2 | Interstitial Cystitis | Withdrawn | 2020-10-15 | 2022-02-10 | ClinicalTrials.gov |
| NCT04545385 | A Study to Test if TEV-48574 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2020-10-07 | 2022-01-17 | ClinicalTrials.gov |
| NCT04545385 | A Study to Test if TEV-48574 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2020-10-07 | 2022-01-17 | ClinicalTrials.gov |
| NCT04545385 | A Study to Test if TEV-48574 is Effective in Relieving Asthma | Phase2 | Asthma | Terminated | 2020-10-07 | 2022-01-17 | ClinicalTrials.gov |
| NCT04464707 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in … | Phase3 | Migraine | Completed | 2020-09-24 | 2024-11-29 | ClinicalTrials.gov |
| NCT04464707 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in … | Phase3 | Migraine | Completed | 2020-09-24 | 2024-11-29 | ClinicalTrials.gov |
| NCT04464707 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in … | Phase3 | Migraine | Completed | 2020-09-24 | 2024-11-29 | ClinicalTrials.gov |
| NCT04458857 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in… | Phase3 | Migraine | Completed | 2020-07-15 | 2024-03-13 | ClinicalTrials.gov |
| NCT04458857 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in… | Phase3 | Migraine | Completed | 2020-07-15 | 2024-03-13 | ClinicalTrials.gov |
| NCT04458857 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in… | Phase3 | Migraine | Completed | 2020-07-15 | 2024-03-13 | ClinicalTrials.gov |
| NCT04200352 | A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involu… | Phase3 | Cerebral Palsy, Dyskinetic | Terminated | 2020-02-04 | 2023-02-14 | ClinicalTrials.gov |
| NCT04200352 | A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involu… | Phase3 | Cerebral Palsy, Dyskinetic | Terminated | 2020-02-04 | 2023-02-14 | ClinicalTrials.gov |
| NCT04200352 | A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involu… | Phase3 | Cerebral Palsy, Dyskinetic | Terminated | 2020-02-04 | 2023-02-14 | ClinicalTrials.gov |
| NCT04088266 | An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationsh… | Phase4 | Evaluation of QTc Interval | Withdrawn | 2020-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT04088266 | An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationsh… | Phase4 | Evaluation of QTc Interval | Withdrawn | 2020-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT04088266 | An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationsh… | Phase4 | Evaluation of QTc Interval | Withdrawn | 2020-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT04041284 | A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Trea… | Phase4 | Migraine | Completed | 2019-09-13 | 2022-08-31 | ClinicalTrials.gov |
| NCT04041284 | A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Trea… | Phase4 | Migraine | Completed | 2019-09-13 | 2022-08-31 | ClinicalTrials.gov |
| NCT04041284 | A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Trea… | Phase4 | Migraine | Completed | 2019-09-13 | 2022-08-31 | ClinicalTrials.gov |
| NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cere… | Phase3 | Cerebral Palsy, Dyskinetic | Completed | 2019-08-06 | 2022-07-21 | ClinicalTrials.gov |
| NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cere… | Phase3 | Cerebral Palsy, Dyskinetic | Completed | 2019-08-06 | 2022-07-21 | ClinicalTrials.gov |
| NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cere… | Phase3 | Cerebral Palsy, Dyskinetic | Completed | 2019-08-06 | 2022-07-21 | ClinicalTrials.gov |
| NCT03965091 | A Study to Test the Effectiveness and Safety of Fremanezumab on Participants Wi… | Phase2 | Fibromyalgia | Terminated | 2019-07-31 | 2022-01-19 | ClinicalTrials.gov |
| NCT03965091 | A Study to Test the Effectiveness and Safety of Fremanezumab on Participants Wi… | Phase2 | Fibromyalgia | Terminated | 2019-07-31 | 2022-01-19 | ClinicalTrials.gov |
| NCT03965091 | A Study to Test the Effectiveness and Safety of Fremanezumab on Participants Wi… | Phase2 | Fibromyalgia | Terminated | 2019-07-31 | 2022-01-19 | ClinicalTrials.gov |
| NCT03893825 | A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia | Phase3 | Schizophrenia | Completed | 2019-04-17 | 2021-12-02 | ClinicalTrials.gov |
| NCT03893825 | A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia | Phase3 | Schizophrenia | Completed | 2019-04-17 | 2021-12-02 | ClinicalTrials.gov |
| NCT03893825 | A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia | Phase3 | Schizophrenia | Completed | 2019-04-17 | 2021-12-02 | ClinicalTrials.gov |
| NCT03954444 | A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" | Phase3 | Rosacea | Completed | 2019-04-15 | 2020-02-27 | ClinicalTrials.gov |
| NCT03954444 | A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" | Phase3 | Rosacea | Completed | 2019-04-15 | 2020-02-27 | ClinicalTrials.gov |
| NCT03954444 | A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" | Phase3 | Rosacea | Completed | 2019-04-15 | 2020-02-27 | ClinicalTrials.gov |
| NCT03879837 | Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… | Phase3 | Asthma | Completed | 2019-03-25 | 2021-07-09 | ClinicalTrials.gov |
| NCT03879837 | Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… | Phase3 | Asthma | Completed | 2019-03-25 | 2021-07-09 | ClinicalTrials.gov |
| NCT03879837 | Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inha… | Phase3 | Asthma | Completed | 2019-03-25 | 2021-07-09 | ClinicalTrials.gov |
| NCT03700658 | A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneou… | Phase1 | Contraception | Completed | 2019-01-15 | 2020-10-02 | ClinicalTrials.gov |
| NCT03700658 | A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneou… | Phase1 | Contraception | Completed | 2019-01-15 | 2020-10-02 | ClinicalTrials.gov |
| NCT03700658 | A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneou… | Phase1 | Contraception | Completed | 2019-01-15 | 2020-10-02 | ClinicalTrials.gov |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Phase2 | Hodgkin Lymphoma | Active_Not_Recruiting | 2018-12-12 | 2028-07-01 | ClinicalTrials.gov |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Phase2 | Hodgkin Lymphoma | Active_Not_Recruiting | 2018-12-12 | 2028-07-01 | ClinicalTrials.gov |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Phase2 | Hodgkin Lymphoma | Active_Not_Recruiting | 2018-12-12 | 2028-07-01 | ClinicalTrials.gov |
| NCT03756883 | Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… | Phase3 | Asthma | Completed | 2018-12-03 | 2019-11-10 | ClinicalTrials.gov |
| NCT03756883 | Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… | Phase3 | Asthma | Completed | 2018-12-03 | 2019-11-10 | ClinicalTrials.gov |
| NCT03756883 | Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salme… | Phase3 | Asthma | Completed | 2018-12-03 | 2019-11-10 | ClinicalTrials.gov |
| NCT03417583 | Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Hu… | Na | Huntington Disease | Completed | 2018-11-09 | 2023-10-10 | ClinicalTrials.gov |
| NCT03417583 | Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Hu… | Na | Huntington Disease | Completed | 2018-11-09 | 2023-10-10 | ClinicalTrials.gov |
| NCT03417583 | Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Hu… | Na | Huntington Disease | Completed | 2018-11-09 | 2023-10-10 | ClinicalTrials.gov |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Ly… | Phase1 | Multiple Myeloma | Completed | 2018-07-18 | 2024-11-06 | ClinicalTrials.gov |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Ly… | Phase1 | Multiple Myeloma | Completed | 2018-07-18 | 2024-11-06 | ClinicalTrials.gov |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Ly… | Phase1 | Multiple Myeloma | Completed | 2018-07-18 | 2024-11-06 | ClinicalTrials.gov |
| NCT03571256 | A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tou… | Phase3 | Tourette Syndrome | Completed | 2018-05-31 | 2019-12-09 | ClinicalTrials.gov |
| NCT03571256 | A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tou… | Phase3 | Tourette Syndrome | Completed | 2018-05-31 | 2019-12-09 | ClinicalTrials.gov |
| NCT03571256 | A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tou… | Phase3 | Tourette Syndrome | Completed | 2018-05-31 | 2019-12-09 | ClinicalTrials.gov |
| NCT03567291 | Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine)… | Phase3 | Tourette Syndrome | Terminated | 2018-05-25 | 2020-05-15 | ClinicalTrials.gov |
| NCT03567291 | Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine)… | Phase3 | Tourette Syndrome | Terminated | 2018-05-25 | 2020-05-15 | ClinicalTrials.gov |
| NCT03567291 | Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine)… | Phase3 | Tourette Syndrome | Terminated | 2018-05-25 | 2020-05-15 | ClinicalTrials.gov |
| NCT03503318 | Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Par… | Phase3 | Schizophrenia | Completed | 2018-04-27 | 2020-12-03 | ClinicalTrials.gov |
| NCT03503318 | Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Par… | Phase3 | Schizophrenia | Completed | 2018-04-27 | 2020-12-03 | ClinicalTrials.gov |
| NCT03503318 | Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Par… | Phase3 | Schizophrenia | Completed | 2018-04-27 | 2020-12-03 | ClinicalTrials.gov |
| NCT03452943 | Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 … | Phase2 | Tourette Syndrome | Completed | 2018-02-05 | 2019-11-12 | ClinicalTrials.gov |
| NCT03452943 | Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 … | Phase2 | Tourette Syndrome | Completed | 2018-02-05 | 2019-11-12 | ClinicalTrials.gov |
| NCT03452943 | Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 … | Phase2 | Tourette Syndrome | Completed | 2018-02-05 | 2019-11-12 | ClinicalTrials.gov |
| NCT03347188 | A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraum… | Phase2 | Post-Traumatic Headache | Completed | 2017-12-18 | 2020-06-03 | ClinicalTrials.gov |
| NCT03347188 | A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraum… | Phase2 | Post-Traumatic Headache | Completed | 2017-12-18 | 2020-06-03 | ClinicalTrials.gov |
| NCT03347188 | A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraum… | Phase2 | Post-Traumatic Headache | Completed | 2017-12-18 | 2020-06-03 | ClinicalTrials.gov |
| NCT03308968 | An Efficacy and Safety Study of Fremanezumab in Adults With Migraine | Phase3 | Migraine Prophylaxis | Completed | 2017-10-13 | 2019-05-29 | ClinicalTrials.gov |
| NCT03308968 | An Efficacy and Safety Study of Fremanezumab in Adults With Migraine | Phase3 | Migraine Prophylaxis | Completed | 2017-10-13 | 2019-05-29 | ClinicalTrials.gov |
| NCT03308968 | An Efficacy and Safety Study of Fremanezumab in Adults With Migraine | Phase3 | Migraine Prophylaxis | Completed | 2017-10-13 | 2019-05-29 | ClinicalTrials.gov |
| NCT03301649 | Clinical Endpoint Study of Ivermectin 0.5% Lotion | Phase3 | Head Lice | Completed | 2017-10-07 | 2018-03-12 | ClinicalTrials.gov |
| NCT03301649 | Clinical Endpoint Study of Ivermectin 0.5% Lotion | Phase3 | Head Lice | Completed | 2017-10-07 | 2018-03-12 | ClinicalTrials.gov |
| NCT03301649 | Clinical Endpoint Study of Ivermectin 0.5% Lotion | Phase3 | Head Lice | Completed | 2017-10-07 | 2018-03-12 | ClinicalTrials.gov |
| NCT03256695 | Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler… | Phase3 | Chronic Obstructive Pulmonary Disease | Completed | 2017-09-28 | 2018-04-17 | ClinicalTrials.gov |
| NCT03256695 | Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler… | Phase3 | Chronic Obstructive Pulmonary Disease | Completed | 2017-09-28 | 2018-04-17 | ClinicalTrials.gov |
| NCT03256695 | Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler… | Phase3 | Chronic Obstructive Pulmonary Disease | Completed | 2017-09-28 | 2018-04-17 | ClinicalTrials.gov |
| NCT02947945 | Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (E… | Phase2 | Asthma | Unknown | 2017-09-12 | 2018-12-01 | ClinicalTrials.gov |
| NCT02947945 | Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (E… | Phase2 | Asthma | Unknown | 2017-09-12 | 2018-12-01 | ClinicalTrials.gov |
| NCT02947945 | Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (E… | Phase2 | Asthma | Unknown | 2017-09-12 | 2018-12-01 | ClinicalTrials.gov |
| NCT03029000 | Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mo… | Phase3 | Healthy Participants | Terminated | 2017-08-02 | 2017-10-30 | ClinicalTrials.gov |
| NCT03029000 | Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mo… | Phase3 | Healthy Participants | Terminated | 2017-08-02 | 2017-10-30 | ClinicalTrials.gov |
| NCT03029000 | Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mo… | Phase3 | Healthy Participants | Terminated | 2017-08-02 | 2017-10-30 | ClinicalTrials.gov |
| NCT02937168 | An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizu… | Phase4 | Asthma | Terminated | 2017-05-08 | 2017-05-24 | ClinicalTrials.gov |
| NCT02937168 | An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizu… | Phase4 | Asthma | Terminated | 2017-05-08 | 2017-05-24 | ClinicalTrials.gov |
| NCT02937168 | An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizu… | Phase4 | Asthma | Terminated | 2017-05-08 | 2017-05-24 | ClinicalTrials.gov |
| NCT03107052 | A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125… | Phase3 | Cluster Headache | Terminated | 2017-04-27 | 2019-06-11 | ClinicalTrials.gov |
| NCT03107052 | A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125… | Phase3 | Cluster Headache | Terminated | 2017-04-27 | 2019-06-11 | ClinicalTrials.gov |
| NCT03107052 | A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125… | Phase3 | Cluster Headache | Terminated | 2017-04-27 | 2019-06-11 | ClinicalTrials.gov |
| NCT03074942 | Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab | Phase2 | Severe Asthma | Completed | 2017-04-20 | 2018-04-30 | ClinicalTrials.gov |
| NCT03074942 | Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab | Phase2 | Severe Asthma | Completed | 2017-04-20 | 2018-04-30 | ClinicalTrials.gov |
| NCT03074942 | Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab | Phase2 | Severe Asthma | Completed | 2017-04-20 | 2018-04-30 | ClinicalTrials.gov |
| NCT03052725 | A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinop… | Phase3 | Eosinophils, Asthma | Terminated | 2017-03-10 | 2018-02-22 | ClinicalTrials.gov |
| NCT03052725 | A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinop… | Phase3 | Eosinophils, Asthma | Terminated | 2017-03-10 | 2018-02-22 | ClinicalTrials.gov |
| NCT03052725 | A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinop… | Phase3 | Eosinophils, Asthma | Terminated | 2017-03-10 | 2018-02-22 | ClinicalTrials.gov |
| NCT03087136 | A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in B… | — | Multiple Sclerosis | Unknown | 2017-03-01 | 2025-03-31 | ClinicalTrials.gov |
| NCT03087136 | A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in B… | — | Multiple Sclerosis | Unknown | 2017-03-01 | 2025-03-31 | ClinicalTrials.gov |
| NCT03087136 | A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in B… | — | Multiple Sclerosis | Unknown | 2017-03-01 | 2025-03-31 | ClinicalTrials.gov |
| NCT02969408 | A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Pow… | Phase3 | Asthma | Completed | 2017-02-13 | 2018-02-02 | ClinicalTrials.gov |
| NCT02969408 | A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Pow… | Phase3 | Asthma | Completed | 2017-02-13 | 2018-02-02 | ClinicalTrials.gov |
| NCT02969408 | A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Pow… | Phase3 | Asthma | Completed | 2017-02-13 | 2018-02-02 | ClinicalTrials.gov |
| NCT02945046 | A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the… | Phase3 | Episodic Cluster Headache | Terminated | 2017-01-19 | 2019-05-13 | ClinicalTrials.gov |
| NCT02945046 | A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the… | Phase3 | Episodic Cluster Headache | Terminated | 2017-01-19 | 2019-05-13 | ClinicalTrials.gov |
| NCT02945046 | A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the… | Phase3 | Episodic Cluster Headache | Terminated | 2017-01-19 | 2019-05-13 | ClinicalTrials.gov |
| NCT02964338 | A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the P… | Phase3 | Chronic Cluster Headache | Terminated | 2017-01-17 | 2018-07-18 | ClinicalTrials.gov |
| NCT02964338 | A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the P… | Phase3 | Chronic Cluster Headache | Terminated | 2017-01-17 | 2018-07-18 | ClinicalTrials.gov |
| NCT02964338 | A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the P… | Phase3 | Chronic Cluster Headache | Terminated | 2017-01-17 | 2018-07-18 | ClinicalTrials.gov |
| NCT02495168 | Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… | Phase3 | Asthma | Completed | 2017-01-13 | 2018-05-31 | ClinicalTrials.gov |
| NCT02495168 | Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… | Phase3 | Asthma | Completed | 2017-01-13 | 2018-05-31 | ClinicalTrials.gov |
| NCT02495168 | Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/F… | Phase3 | Asthma | Completed | 2017-01-13 | 2018-05-31 | ClinicalTrials.gov |
| NCT02980133 | Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Flut… | Phase3 | Asthma | Completed | 2016-12-28 | 2019-04-13 | ClinicalTrials.gov |
| NCT02980133 | Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Flut… | Phase3 | Asthma | Completed | 2016-12-28 | 2019-04-13 | ClinicalTrials.gov |
| NCT02980133 | Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Flut… | Phase3 | Asthma | Completed | 2016-12-28 | 2019-04-13 | ClinicalTrials.gov |
| NCT02867917 | Comparison of Taste and Palatability in Fiber Supplements | Na | Constipation | Completed | 2016-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02867917 | Comparison of Taste and Palatability in Fiber Supplements | Na | Constipation | Completed | 2016-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02867917 | Comparison of Taste and Palatability in Fiber Supplements | Na | Constipation | Completed | 2016-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02817464 | Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyproge… | Phase1 | Pregnancy | Completed | 2016-10-26 | 2018-12-03 | ClinicalTrials.gov |
| NCT02817464 | Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyproge… | Phase1 | Pregnancy | Completed | 2016-10-26 | 2018-12-03 | ClinicalTrials.gov |
| NCT02817464 | Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyproge… | Phase1 | Pregnancy | Completed | 2016-10-26 | 2018-12-03 | ClinicalTrials.gov |
| NCT02869360 | Correlation Between PET and Advanced MRI in Multiple Sclerosis | — | Multiple Sclerosis | Completed | 2016-10-01 | 2019-10-02 | ClinicalTrials.gov |
| NCT02869360 | Correlation Between PET and Advanced MRI in Multiple Sclerosis | — | Multiple Sclerosis | Completed | 2016-10-01 | 2019-10-02 | ClinicalTrials.gov |
| NCT02869360 | Correlation Between PET and Advanced MRI in Multiple Sclerosis | — | Multiple Sclerosis | Completed | 2016-10-01 | 2019-10-02 | ClinicalTrials.gov |
| NCT02769091 | A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type … | Phase2 | Nonalcoholic Steatohepatitis | Withdrawn | 2016-09-30 | 2018-02-28 | ClinicalTrials.gov |
| NCT02769091 | A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type … | Phase2 | Nonalcoholic Steatohepatitis | Withdrawn | 2016-09-30 | 2018-02-28 | ClinicalTrials.gov |
| NCT02769091 | A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type … | Phase2 | Nonalcoholic Steatohepatitis | Withdrawn | 2016-09-30 | 2018-02-28 | ClinicalTrials.gov |
| NCT02833727 | Airway Inflammation and Disease Burden in Asthmatic Smokers | — | Asthma | Unknown | 2016-09-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT02833727 | Airway Inflammation and Disease Burden in Asthmatic Smokers | — | Asthma | Unknown | 2016-09-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT02833727 | Airway Inflammation and Disease Burden in Asthmatic Smokers | — | Asthma | Unknown | 2016-09-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT02772211 | D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatmen… | Phase4 | Treatment Resistant Depression | Unknown | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02772211 | D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatmen… | Phase4 | Treatment Resistant Depression | Unknown | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02772211 | D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatmen… | Phase4 | Treatment Resistant Depression | Unknown | 2016-06-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT03294538 | Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… | Phase3 | Atrophic Vaginitis | Completed | 2016-05-18 | 2017-02-15 | ClinicalTrials.gov |
| NCT03294538 | Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… | Phase3 | Atrophic Vaginitis | Completed | 2016-05-18 | 2017-02-15 | ClinicalTrials.gov |
| NCT03294538 | Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Crea… | Phase3 | Atrophic Vaginitis | Completed | 2016-05-18 | 2017-02-15 | ClinicalTrials.gov |
| NCT02680561 | A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Yea… | Phase1 | Asthma | Completed | 2016-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02877108 | Naturalistic Adasuve Clinical Trial Study | — | Agitation | Unknown | 2016-04-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02680561 | A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Yea… | Phase1 | Asthma | Completed | 2016-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02680561 | A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Yea… | Phase1 | Asthma | Completed | 2016-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02877108 | Naturalistic Adasuve Clinical Trial Study | — | Agitation | Unknown | 2016-04-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02877108 | Naturalistic Adasuve Clinical Trial Study | — | Agitation | Unknown | 2016-04-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT02673567 | To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese an… | Phase1 | Pharmacokinetics | Completed | 2016-03-31 | 2017-02-10 | ClinicalTrials.gov |
| NCT02673567 | To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese an… | Phase1 | Pharmacokinetics | Completed | 2016-03-31 | 2017-02-10 | ClinicalTrials.gov |
| NCT02673567 | To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese an… | Phase1 | Pharmacokinetics | Completed | 2016-03-31 | 2017-02-10 | ClinicalTrials.gov |
| NCT02629861 | Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Prev… | Phase3 | Migraine | Completed | 2016-03-23 | 2017-04-10 | ClinicalTrials.gov |
| NCT02629861 | Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Prev… | Phase3 | Migraine | Completed | 2016-03-23 | 2017-04-10 | ClinicalTrials.gov |
| NCT02629861 | Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Prev… | Phase3 | Migraine | Completed | 2016-03-23 | 2017-04-10 | ClinicalTrials.gov |
| NCT02621931 | Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration… | Phase3 | Migraine | Completed | 2016-03-22 | 2017-04-11 | ClinicalTrials.gov |
| NCT02621931 | Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration… | Phase3 | Migraine | Completed | 2016-03-22 | 2017-04-11 | ClinicalTrials.gov |
| NCT02621931 | Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration… | Phase3 | Migraine | Completed | 2016-03-22 | 2017-04-11 | ClinicalTrials.gov |
| NCT02638103 | Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) … | Phase3 | Migraine | Completed | 2016-02-26 | 2018-12-08 | ClinicalTrials.gov |
| NCT02638103 | Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) … | Phase3 | Migraine | Completed | 2016-02-26 | 2018-12-08 | ClinicalTrials.gov |
| NCT02638103 | Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) … | Phase3 | Migraine | Completed | 2016-02-26 | 2018-12-08 | ClinicalTrials.gov |
| NCT02519231 | Copper IUD Treatment Observation Study | Phase4 | Menorrhagia | Completed | 2016-02-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02519231 | Copper IUD Treatment Observation Study | Phase4 | Menorrhagia | Completed | 2016-02-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02519231 | Copper IUD Treatment Observation Study | Phase4 | Menorrhagia | Completed | 2016-02-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02559791 | Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosi… | Phase2 | Severe Persistent Asthma | Completed | 2015-10-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02611804 | A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Stu… | Phase3 | Actinic Keratosis | Completed | 2015-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02938858 | French Registry of First-line Treatment of Acute Promyelocytic Leukemia | — | Acute Promyelocytic Leukemia | Active_Not_Recruiting | 2015-10-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT02611804 | A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Stu… | Phase3 | Actinic Keratosis | Completed | 2015-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02559791 | Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosi… | Phase2 | Severe Persistent Asthma | Completed | 2015-10-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02559791 | Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosi… | Phase2 | Severe Persistent Asthma | Completed | 2015-10-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02611804 | A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Stu… | Phase3 | Actinic Keratosis | Completed | 2015-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02938858 | French Registry of First-line Treatment of Acute Promyelocytic Leukemia | — | Acute Promyelocytic Leukemia | Active_Not_Recruiting | 2015-10-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT02938858 | French Registry of First-line Treatment of Acute Promyelocytic Leukemia | — | Acute Promyelocytic Leukemia | Active_Not_Recruiting | 2015-10-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT02513160 | Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adole… | Phase3 | Persistent Asthma | Completed | 2015-09-30 | 2016-03-31 | ClinicalTrials.gov |
| NCT02513160 | Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adole… | Phase3 | Persistent Asthma | Completed | 2015-09-30 | 2016-03-31 | ClinicalTrials.gov |
| NCT02513160 | Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adole… | Phase3 | Persistent Asthma | Completed | 2015-09-30 | 2016-03-31 | ClinicalTrials.gov |
| NCT02501629 | An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral C… | Phase3 | Asthma | Completed | 2015-09-29 | 2017-12-04 | ClinicalTrials.gov |
| NCT02501629 | An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral C… | Phase3 | Asthma | Completed | 2015-09-29 | 2017-12-04 | ClinicalTrials.gov |
| NCT02501629 | An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral C… | Phase3 | Asthma | Completed | 2015-09-29 | 2017-12-04 | ClinicalTrials.gov |
| NCT02452190 | Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood… | Phase3 | Asthma | Completed | 2015-09-28 | 2018-01-31 | ClinicalTrials.gov |
| NCT02452190 | Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood… | Phase3 | Asthma | Completed | 2015-09-28 | 2018-01-31 | ClinicalTrials.gov |
| NCT02452190 | Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood… | Phase3 | Asthma | Completed | 2015-09-28 | 2018-01-31 | ClinicalTrials.gov |
| NCT02487108 | Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/A… | Phase3 | Pain | Completed | 2015-08-11 | 2016-03-30 | ClinicalTrials.gov |
| NCT02487108 | Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/A… | Phase3 | Pain | Completed | 2015-08-11 | 2016-03-30 | ClinicalTrials.gov |
| NCT02487108 | Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/A… | Phase3 | Pain | Completed | 2015-08-11 | 2016-03-30 | ClinicalTrials.gov |
| NCT02499900 | Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Mu… | Phase4 | Multiple Sclerosis | Completed | 2015-08-10 | 2017-06-02 | ClinicalTrials.gov |
| NCT02499900 | Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Mu… | Phase4 | Multiple Sclerosis | Completed | 2015-08-10 | 2017-06-02 | ClinicalTrials.gov |
| NCT02499900 | Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Mu… | Phase4 | Multiple Sclerosis | Completed | 2015-08-10 | 2017-06-02 | ClinicalTrials.gov |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubici… | Phase1 | Acute Myeloid Leukemia | Terminated | 2015-06-05 | 2018-11-30 | ClinicalTrials.gov |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubici… | Phase1 | Acute Myeloid Leukemia | Terminated | 2015-06-05 | 2018-11-30 | ClinicalTrials.gov |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubici… | Phase1 | Acute Myeloid Leukemia | Terminated | 2015-06-05 | 2018-11-30 | ClinicalTrials.gov |
| NCT02159872 | Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syn… | Phase2 | Leukemia | Completed | 2015-05-18 | 2020-04-14 | ClinicalTrials.gov |
| NCT02159872 | Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syn… | Phase2 | Leukemia | Completed | 2015-05-18 | 2020-04-14 | ClinicalTrials.gov |
| NCT02159872 | Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syn… | Phase2 | Leukemia | Completed | 2015-05-18 | 2020-04-14 | ClinicalTrials.gov |
| NCT02190721 | A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents… | Phase2 | Neutropenia | Completed | 2015-05-12 | 2017-04-04 | ClinicalTrials.gov |
| NCT02190721 | A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents… | Phase2 | Neutropenia | Completed | 2015-05-12 | 2017-04-04 | ClinicalTrials.gov |
| NCT02190721 | A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents… | Phase2 | Neutropenia | Completed | 2015-05-12 | 2017-04-04 | ClinicalTrials.gov |
| NCT02141477 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplas… | Phase1 | Leukemia | Terminated | 2015-05-06 | 2017-06-22 | ClinicalTrials.gov |
| NCT02141477 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplas… | Phase1 | Leukemia | Terminated | 2015-05-06 | 2017-06-22 | ClinicalTrials.gov |
| NCT02141477 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplas… | Phase1 | Leukemia | Terminated | 2015-05-06 | 2017-06-22 | ClinicalTrials.gov |
| NCT02437604 | Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propion… | Phase1 | Asthma | Completed | 2015-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02437604 | Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propion… | Phase1 | Asthma | Completed | 2015-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02437604 | Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propion… | Phase1 | Asthma | Completed | 2015-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02410343 | Study of TV-1106 in Growth Hormone-Deficient Adults | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2015-12-31 | ClinicalTrials.gov |
| NCT02410356 | Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficienc… | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2016-04-30 | ClinicalTrials.gov |
| NCT02410343 | Study of TV-1106 in Growth Hormone-Deficient Adults | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2015-12-31 | ClinicalTrials.gov |
| NCT02410356 | Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficienc… | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2016-04-30 | ClinicalTrials.gov |
| NCT02410343 | Study of TV-1106 in Growth Hormone-Deficient Adults | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2015-12-31 | ClinicalTrials.gov |
| NCT02410356 | Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficienc… | Phase3 | Growth Hormone Deficiency | Terminated | 2015-04-30 | 2016-04-30 | ClinicalTrials.gov |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2015-04-27 | 2021-04-21 | ClinicalTrials.gov |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2015-04-27 | 2021-04-21 | ClinicalTrials.gov |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | Phase2 | Multiple Myeloma | Completed | 2015-04-27 | 2021-04-21 | ClinicalTrials.gov |
| NCT02315144 | An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COP… | Phase1 | Chronic Obstructive Pulmonary Disease | Terminated | 2015-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02315144 | An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COP… | Phase1 | Chronic Obstructive Pulmonary Disease | Terminated | 2015-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02315144 | An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COP… | Phase1 | Chronic Obstructive Pulmonary Disease | Terminated | 2015-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02315131 | Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safe… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD | Terminated | 2015-03-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02315131 | Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safe… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD | Terminated | 2015-03-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02315131 | Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safe… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD | Terminated | 2015-03-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02365636 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointm… | Phase2 | Postherpetic Neuralgia | Completed | 2015-02-26 | 2017-05-09 | ClinicalTrials.gov |
| NCT02365636 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointm… | Phase2 | Postherpetic Neuralgia | Completed | 2015-02-26 | 2017-05-09 | ClinicalTrials.gov |
| NCT02365636 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointm… | Phase2 | Postherpetic Neuralgia | Completed | 2015-02-26 | 2017-05-09 | ClinicalTrials.gov |
| NCT02284568 | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosi… | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2015-01-12 | 2017-10-01 | ClinicalTrials.gov |
| NCT02284568 | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosi… | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2015-01-12 | 2017-10-01 | ClinicalTrials.gov |
| NCT02284568 | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosi… | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2015-01-12 | 2017-10-01 | ClinicalTrials.gov |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC an… | Phase3 | Tubular Breast Cancer Stage II | Completed | 2014-12-01 | 2017-01-30 | ClinicalTrials.gov |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC an… | Phase3 | Tubular Breast Cancer Stage II | Completed | 2014-12-01 | 2017-01-30 | ClinicalTrials.gov |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC an… | Phase3 | Tubular Breast Cancer Stage II | Completed | 2014-12-01 | 2017-01-30 | ClinicalTrials.gov |
| NCT02215616 | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Effic… | Phase2 | Huntington's Disease | Completed | 2014-10-28 | 2018-06-19 | ClinicalTrials.gov |
| NCT02215616 | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Effic… | Phase2 | Huntington's Disease | Completed | 2014-10-28 | 2018-06-19 | ClinicalTrials.gov |
| NCT02215616 | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Effic… | Phase2 | Huntington's Disease | Completed | 2014-10-28 | 2018-06-19 | ClinicalTrials.gov |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Gi… | Phase1 | Chronic Myeloid Leukemia | Terminated | 2014-10-09 | 2017-11-27 | ClinicalTrials.gov |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Gi… | Phase1 | Chronic Myeloid Leukemia | Terminated | 2014-10-09 | 2017-11-27 | ClinicalTrials.gov |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Gi… | Phase1 | Chronic Myeloid Leukemia | Terminated | 2014-10-09 | 2017-11-27 | ClinicalTrials.gov |
| NCT02266121 | Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis | Na | Relapsing Remitting Multiple Sclerosis | Terminated | 2014-10-01 | 2023-05-08 | ClinicalTrials.gov |
| NCT02266121 | Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis | Na | Relapsing Remitting Multiple Sclerosis | Terminated | 2014-10-01 | 2023-05-08 | ClinicalTrials.gov |
| NCT02266121 | Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis | Na | Relapsing Remitting Multiple Sclerosis | Terminated | 2014-10-01 | 2023-05-08 | ClinicalTrials.gov |
| NCT01940601 | Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pedia… | Phase2 | Solid Tumors | Withdrawn | 2014-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01940601 | Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pedia… | Phase2 | Solid Tumors | Withdrawn | 2014-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01940601 | Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pedia… | Phase2 | Solid Tumors | Withdrawn | 2014-09-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02203474 | A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler… | Phase2 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2014-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02215941 | Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in H… | Phase1 | Pharmacokinetics | Completed | 2014-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02249663 | Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 13… | Phase3 | Seasonal Allergic Rhinitis | Unknown | 2014-08-01 | — | ClinicalTrials.gov |
| NCT02203474 | A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler… | Phase2 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2014-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02215941 | Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in H… | Phase1 | Pharmacokinetics | Completed | 2014-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02249663 | Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 13… | Phase3 | Seasonal Allergic Rhinitis | Unknown | 2014-08-01 | — | ClinicalTrials.gov |
| NCT02215941 | Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in H… | Phase1 | Pharmacokinetics | Completed | 2014-08-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02249663 | Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 13… | Phase3 | Seasonal Allergic Rhinitis | Unknown | 2014-08-01 | — | ClinicalTrials.gov |
| NCT02203474 | A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler… | Phase2 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2014-08-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02570425 | Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healt… | Na | Asthma | Completed | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02308670 | Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Aceta… | — | Multiple Sclerosis | Completed | 2014-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02214381 | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optim… | Phase3 | Early Primary Breast Cancer | Completed | 2014-07-01 | 2025-01-15 | ClinicalTrials.gov |
| NCT02184767 | Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5,… | Phase1 | BiPolar | Completed | 2014-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02175771 | Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inha… | Phase3 | Persistent Asthma | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02175771 | Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inha… | Phase3 | Persistent Asthma | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02184767 | Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5,… | Phase1 | BiPolar | Completed | 2014-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02214381 | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optim… | Phase3 | Early Primary Breast Cancer | Completed | 2014-07-01 | 2025-01-15 | ClinicalTrials.gov |
| NCT02308670 | Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Aceta… | — | Multiple Sclerosis | Completed | 2014-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02570425 | Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healt… | Na | Asthma | Completed | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02175771 | Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inha… | Phase3 | Persistent Asthma | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02184767 | Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5,… | Phase1 | BiPolar | Completed | 2014-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02214381 | A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optim… | Phase3 | Early Primary Breast Cancer | Completed | 2014-07-01 | 2025-01-15 | ClinicalTrials.gov |
| NCT02308670 | Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Aceta… | — | Multiple Sclerosis | Completed | 2014-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02570425 | Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healt… | Na | Asthma | Completed | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02141854 | Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Ad… | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02141854 | Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Ad… | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02141854 | Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Ad… | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02139644 | Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI … | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02139644 | Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI … | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02139644 | Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI … | Phase3 | Asthma | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02062463 | Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (B… | Phase3 | Asthma | Completed | 2014-05-28 | 2015-03-13 | ClinicalTrials.gov |
| NCT02062463 | Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (B… | Phase3 | Asthma | Completed | 2014-05-28 | 2015-03-13 | ClinicalTrials.gov |
| NCT02062463 | Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (B… | Phase3 | Asthma | Completed | 2014-05-28 | 2015-03-13 | ClinicalTrials.gov |
| NCT01856114 | Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea | Phase2 | Advanced Cancers | Completed | 2014-05-27 | 2019-12-04 | ClinicalTrials.gov |
| NCT01856114 | Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea | Phase2 | Advanced Cancers | Completed | 2014-05-27 | 2019-12-04 | ClinicalTrials.gov |
| NCT01856114 | Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea | Phase2 | Advanced Cancers | Completed | 2014-05-27 | 2019-12-04 | ClinicalTrials.gov |
| NCT02126839 | A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inh… | Phase3 | Asthma | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02126839 | A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inh… | Phase3 | Asthma | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02126839 | A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inh… | Phase3 | Asthma | Completed | 2014-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02068599 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Oint… | Phase2 | Osteoarthritis of the Knee | Completed | 2014-04-14 | 2015-05-04 | ClinicalTrials.gov |
| NCT02068599 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Oint… | Phase2 | Osteoarthritis of the Knee | Completed | 2014-04-14 | 2015-05-04 | ClinicalTrials.gov |
| NCT02068599 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Oint… | Phase2 | Osteoarthritis of the Knee | Completed | 2014-04-14 | 2015-05-04 | ClinicalTrials.gov |
| NCT02044276 | A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to … | Phase3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | Completed | 2014-03-31 | 2018-04-24 | ClinicalTrials.gov |
| NCT02044276 | A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to … | Phase3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | Completed | 2014-03-31 | 2018-04-24 | ClinicalTrials.gov |
| NCT02044276 | A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to … | Phase3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | Completed | 2014-03-31 | 2018-04-24 | ClinicalTrials.gov |
| NCT02246920 | Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuat… | Phase3 | Seasonal Allergic Rhinitis | Terminated | 2014-03-01 | 2014-07-14 | ClinicalTrials.gov |
| NCT02246920 | Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuat… | Phase3 | Seasonal Allergic Rhinitis | Terminated | 2014-03-01 | 2014-07-14 | ClinicalTrials.gov |
| NCT02246920 | Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuat… | Phase3 | Seasonal Allergic Rhinitis | Terminated | 2014-03-01 | 2014-07-14 | ClinicalTrials.gov |
| NCT02092571 | A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vagina… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02092571 | A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vagina… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02085863 | A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02085863 | A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02017808 | Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Ove… | — | Multiple Sclerosis | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02017808 | Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Ove… | — | Multiple Sclerosis | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02085863 | A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02017808 | Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Ove… | — | Multiple Sclerosis | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02092571 | A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vagina… | Phase1 | Pharmacokinetics | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02021773 | Assessment of LBR-101 In Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT02021773 | Assessment of LBR-101 In Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT02021773 | Assessment of LBR-101 In Chronic Migraine | Phase2 | Chronic Migraine | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT02025556 | A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine | Phase2 | Episodic Migraine Headache | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT02025556 | A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine | Phase2 | Episodic Migraine Headache | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT02025556 | A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine | Phase2 | Episodic Migraine Headache | Completed | 2014-01-31 | 2015-03-31 | ClinicalTrials.gov |
| NCT01975298 | A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to In… | Phase3 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01975298 | A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to In… | Phase3 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01975298 | A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to In… | Phase3 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2014-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02040779 | A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 … | Phase3 | Persistent Asthma | Completed | 2013-12-26 | 2014-12-24 | ClinicalTrials.gov |
| NCT02040779 | A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 … | Phase3 | Persistent Asthma | Completed | 2013-12-26 | 2014-12-24 | ClinicalTrials.gov |
| NCT02040779 | A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 … | Phase3 | Persistent Asthma | Completed | 2013-12-26 | 2014-12-24 | ClinicalTrials.gov |
| NCT02040766 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02030457 | A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Diprop… | Phase1 | Pharmacokinetics | Completed | 2013-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02030457 | A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Diprop… | Phase1 | Pharmacokinetics | Completed | 2013-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02031640 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02030457 | A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Diprop… | Phase1 | Pharmacokinetics | Completed | 2013-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02040766 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02031640 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02024672 | Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed… | — | Contraception | Completed | 2013-12-01 | 2017-09-15 | ClinicalTrials.gov |
| NCT02024672 | Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed… | — | Contraception | Completed | 2013-12-01 | 2017-09-15 | ClinicalTrials.gov |
| NCT02040766 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02024672 | Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed… | — | Contraception | Completed | 2013-12-01 | 2017-09-15 | ClinicalTrials.gov |
| NCT02031640 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath… | Phase3 | Asthma | Completed | 2013-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01894048 | Targeted Small Airways Therapy in Persistent Asthma | Phase4 | Asthma | Completed | 2013-10-28 | 2018-06-25 | ClinicalTrials.gov |
| NCT01894048 | Targeted Small Airways Therapy in Persistent Asthma | Phase4 | Asthma | Completed | 2013-10-28 | 2018-06-25 | ClinicalTrials.gov |
| NCT01894048 | Targeted Small Airways Therapy in Persistent Asthma | Phase4 | Asthma | Completed | 2013-10-28 | 2018-06-25 | ClinicalTrials.gov |
| NCT02207387 | Ambulosono Rasagiline Musical Walking Study | Na | Parkinson's Disease | Unknown | 2013-10-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01848652 | Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and … | Phase2 | Cerebral Lymphoma B Cell Refractory | Terminated | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02207387 | Ambulosono Rasagiline Musical Walking Study | Na | Parkinson's Disease | Unknown | 2013-10-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01991509 | Safety and Bioavailability of IV and SC LBR-101 | Phase1 | Bioavailability and Pharmacokinetics | Completed | 2013-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01848652 | Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and … | Phase2 | Cerebral Lymphoma B Cell Refractory | Terminated | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01848652 | Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and … | Phase2 | Cerebral Lymphoma B Cell Refractory | Terminated | 2013-10-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01991509 | Safety and Bioavailability of IV and SC LBR-101 | Phase1 | Bioavailability and Pharmacokinetics | Completed | 2013-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01991509 | Safety and Bioavailability of IV and SC LBR-101 | Phase1 | Bioavailability and Pharmacokinetics | Completed | 2013-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02207387 | Ambulosono Rasagiline Musical Walking Study | Na | Parkinson's Disease | Unknown | 2013-10-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01795859 | First Time Use of SD-809 in Huntington Disease | Phase3 | Chorea | Completed | 2013-08-05 | 2014-12-05 | ClinicalTrials.gov |
| NCT01795859 | First Time Use of SD-809 in Huntington Disease | Phase3 | Chorea | Completed | 2013-08-05 | 2014-12-05 | ClinicalTrials.gov |
| NCT01795859 | First Time Use of SD-809 in Huntington Disease | Phase3 | Chorea | Completed | 2013-08-05 | 2014-12-05 | ClinicalTrials.gov |
| NCT01907334 | Dose-Response of Salmeterol in Children | Phase4 | Asthma | Completed | 2013-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01900509 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Pati… | Phase1 | Hodgkin Lymphoma | Completed | 2013-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01903824 | Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects | Phase1 | Cognitive Impairment | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01907334 | Dose-Response of Salmeterol in Children | Phase4 | Asthma | Completed | 2013-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01903824 | Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects | Phase1 | Cognitive Impairment | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01900509 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Pati… | Phase1 | Hodgkin Lymphoma | Completed | 2013-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01907334 | Dose-Response of Salmeterol in Children | Phase4 | Asthma | Completed | 2013-08-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01903824 | Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects | Phase1 | Cognitive Impairment | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01900509 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Pati… | Phase1 | Hodgkin Lymphoma | Completed | 2013-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01803555 | Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Po… | Phase3 | Asthma | Completed | 2013-07-04 | 2014-03-20 | ClinicalTrials.gov |
| NCT01803555 | Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Po… | Phase3 | Asthma | Completed | 2013-07-04 | 2014-03-20 | ClinicalTrials.gov |
| NCT01803555 | Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Po… | Phase3 | Asthma | Completed | 2013-07-04 | 2014-03-20 | ClinicalTrials.gov |
| NCT01922752 | To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Adva… | Phase1 | Solid Tumors | Completed | 2013-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01922752 | To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Adva… | Phase1 | Solid Tumors | Completed | 2013-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01922739 | Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Ex… | Phase3 | Low Back Pain | Completed | 2013-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01899144 | Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroal… | Phase2 | Asthma | Completed | 2013-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01844869 | An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesucc… | Phase1 | Hematologic Malignancies | Completed | 2013-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01710228 | Alternative Treatment Paradigm for Natalizumab Trial | Phase2 | Multiple Sclerosis (MS) | Withdrawn | 2013-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01710228 | Alternative Treatment Paradigm for Natalizumab Trial | Phase2 | Multiple Sclerosis (MS) | Withdrawn | 2013-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01844869 | An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesucc… | Phase1 | Hematologic Malignancies | Completed | 2013-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01899144 | Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroal… | Phase2 | Asthma | Completed | 2013-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01922739 | Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Ex… | Phase3 | Low Back Pain | Completed | 2013-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01922752 | To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Adva… | Phase1 | Solid Tumors | Completed | 2013-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01922739 | Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Ex… | Phase3 | Low Back Pain | Completed | 2013-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01899144 | Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroal… | Phase2 | Asthma | Completed | 2013-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01844869 | An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesucc… | Phase1 | Hematologic Malignancies | Completed | 2013-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01710228 | Alternative Treatment Paradigm for Natalizumab Trial | Phase2 | Multiple Sclerosis (MS) | Withdrawn | 2013-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01879748 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and … | Phase1 | Parkinson's Disease | Completed | 2013-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01990443 | Absolute Bioavailability of Reslizumab in Healthy Subjects | Phase1 | Absolute Bioavailability | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01879748 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and … | Phase1 | Parkinson's Disease | Completed | 2013-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01887366 | Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in C… | Phase2 | Cocaine Addiction | Completed | 2013-06-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01990443 | Absolute Bioavailability of Reslizumab in Healthy Subjects | Phase1 | Absolute Bioavailability | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01874145 | Safety and Tolerability of Glatiramer Acetate | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01874145 | Safety and Tolerability of Glatiramer Acetate | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01887366 | Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in C… | Phase2 | Cocaine Addiction | Completed | 2013-06-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01874145 | Safety and Tolerability of Glatiramer Acetate | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01990443 | Absolute Bioavailability of Reslizumab in Healthy Subjects | Phase1 | Absolute Bioavailability | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01879748 | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and … | Phase1 | Parkinson's Disease | Completed | 2013-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01887366 | Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in C… | Phase2 | Cocaine Addiction | Completed | 2013-06-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase2 | Acute Myelogenous Leukemia (AML) | Terminated | 2013-05-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT01857323 | Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI) | Phase3 | Asthma | Completed | 2013-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase2 | Acute Myelogenous Leukemia (AML) | Terminated | 2013-05-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT01874561 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirs… | Phase1 | Cardiac Conduction and Repolarization | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01857323 | Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI) | Phase3 | Asthma | Completed | 2013-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01857323 | Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI) | Phase3 | Asthma | Completed | 2013-05-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01874561 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirs… | Phase1 | Cardiac Conduction and Repolarization | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01874561 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirs… | Phase1 | Cardiac Conduction and Repolarization | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase2 | Acute Myelogenous Leukemia (AML) | Terminated | 2013-05-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT01844401 | Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir®… | Phase1 | Asthma | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT02190695 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | Phase2 | Acute Myeloid Leukemia | Completed | 2013-04-01 | 2020-04-16 | ClinicalTrials.gov |
| NCT02190695 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | Phase2 | Acute Myeloid Leukemia | Completed | 2013-04-01 | 2020-04-16 | ClinicalTrials.gov |
| NCT01844401 | Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir®… | Phase1 | Asthma | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT02190695 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | Phase2 | Acute Myeloid Leukemia | Completed | 2013-04-01 | 2020-04-16 | ClinicalTrials.gov |
| NCT01844401 | Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir®… | Phase1 | Asthma | Completed | 2013-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01811576 | Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormo… | Phase2 | Growth Hormone Deficiency | Completed | 2013-03-31 | 2013-08-05 | ClinicalTrials.gov |
| NCT01811576 | Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormo… | Phase2 | Growth Hormone Deficiency | Completed | 2013-03-31 | 2013-08-05 | ClinicalTrials.gov |
| NCT01811576 | Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormo… | Phase2 | Growth Hormone Deficiency | Completed | 2013-03-31 | 2013-08-05 | ClinicalTrials.gov |
| NCT01791972 | Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-… | Phase3 | Exercise-Induced Bronchoconstriction (EIB) | Completed | 2013-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01789970 | Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Mode… | Phase3 | Low Back Pain | Completed | 2013-03-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT04635852 | Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Pati… | Phase2 | Cancer | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01789970 | Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Mode… | Phase3 | Low Back Pain | Completed | 2013-03-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01791972 | Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-… | Phase3 | Exercise-Induced Bronchoconstriction (EIB) | Completed | 2013-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01791972 | Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-… | Phase3 | Exercise-Induced Bronchoconstriction (EIB) | Completed | 2013-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT04635852 | Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Pati… | Phase2 | Cancer | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT04635852 | Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Pati… | Phase2 | Cancer | Completed | 2013-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01789970 | Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Mode… | Phase3 | Low Back Pain | Completed | 2013-03-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01707992 | The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relap… | Phase3 | Multiple Sclerosis | Completed | 2013-02-20 | 2017-07-04 | ClinicalTrials.gov |
| NCT01707992 | The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relap… | Phase3 | Multiple Sclerosis | Completed | 2013-02-20 | 2017-07-04 | ClinicalTrials.gov |
| NCT01707992 | The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relap… | Phase3 | Multiple Sclerosis | Completed | 2013-02-20 | 2017-07-04 | ClinicalTrials.gov |
| NCT02140541 | The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils | — | Asthma | Unknown | 2013-02-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02140541 | The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils | — | Asthma | Unknown | 2013-02-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02140541 | The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils | — | Asthma | Unknown | 2013-02-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01772368 | Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiro… | Phase2 | Asthma | Completed | 2013-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01783548 | Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11)… | Phase3 | Allergic Rhinitis | Completed | 2013-01-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01769677 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2013-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01769677 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2013-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01772368 | Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiro… | Phase2 | Asthma | Completed | 2013-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01783548 | Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11)… | Phase3 | Allergic Rhinitis | Completed | 2013-01-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01769677 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2013-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01785433 | To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstruct… | Phase1 | COPD | Completed | 2013-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01772368 | Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiro… | Phase2 | Asthma | Completed | 2013-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01783548 | Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11)… | Phase3 | Allergic Rhinitis | Completed | 2013-01-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01785433 | To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstruct… | Phase1 | COPD | Completed | 2013-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01785433 | To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstruct… | Phase1 | COPD | Completed | 2013-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01424813 | A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versu… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01758978 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2012-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01747629 | Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01424813 | A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versu… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01424813 | A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versu… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01747629 | Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01758978 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2012-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01758978 | A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extend… | Phase1 | Pain | Completed | 2012-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01747629 | Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With… | Phase3 | Asthma | Completed | 2012-12-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01723228 | Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patient… | Phase4 | Parkinson's Disease | Completed | 2012-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01723228 | Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patient… | Phase4 | Parkinson's Disease | Completed | 2012-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01723228 | Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patient… | Phase4 | Parkinson's Disease | Completed | 2012-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01697956 | Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Pere… | Phase3 | Allergic Rhinitis | Completed | 2012-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01697956 | Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Pere… | Phase3 | Allergic Rhinitis | Completed | 2012-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01698320 | Safety Study of Albuterol Spiromax® in Subjects With Asthma | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01698320 | Safety Study of Albuterol Spiromax® in Subjects With Asthma | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01697956 | Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Pere… | Phase3 | Allergic Rhinitis | Completed | 2012-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01698320 | Safety Study of Albuterol Spiromax® in Subjects With Asthma | Phase3 | Asthma | Completed | 2012-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01686152 | Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in … | Phase3 | Actinic Keratosis | Completed | 2012-09-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01686152 | Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in … | Phase3 | Actinic Keratosis | Completed | 2012-09-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01686152 | Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in … | Phase3 | Actinic Keratosis | Completed | 2012-09-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01596621 | A Study of Bendamustine in the Treatment of Chinese Participants With Indolent … | Phase3 | Non-Hodgkin Lymphoma | Completed | 2012-08-06 | 2017-04-24 | ClinicalTrials.gov |
| NCT01596621 | A Study of Bendamustine in the Treatment of Chinese Participants With Indolent … | Phase3 | Non-Hodgkin Lymphoma | Completed | 2012-08-06 | 2017-04-24 | ClinicalTrials.gov |
| NCT01596621 | A Study of Bendamustine in the Treatment of Chinese Participants With Indolent … | Phase3 | Non-Hodgkin Lymphoma | Completed | 2012-08-06 | 2017-04-24 | ClinicalTrials.gov |
| NCT01632540 | Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allerg… | — | Perennial Allergic Rhinitis (PAR) | Completed | 2012-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01632540 | Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allerg… | — | Perennial Allergic Rhinitis (PAR) | Completed | 2012-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01624480 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodaf… | Phase1 | Narcolepsy | Completed | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01632540 | Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allerg… | — | Perennial Allergic Rhinitis (PAR) | Completed | 2012-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01624480 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodaf… | Phase1 | Narcolepsy | Completed | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01624480 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodaf… | Phase1 | Narcolepsy | Completed | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Cust… | Phase1 | Cancer | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01576718 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01576718 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Cust… | Phase1 | Cancer | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01576718 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Cust… | Phase1 | Cancer | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01404117 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled S… | Phase2 | Relapsing Multiple Sclerosis | Withdrawn | 2012-03-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01578785 | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2012-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01404117 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled S… | Phase2 | Relapsing Multiple Sclerosis | Withdrawn | 2012-03-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01578785 | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2012-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01404117 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled S… | Phase2 | Relapsing Multiple Sclerosis | Withdrawn | 2012-03-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01578785 | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2012-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01508936 | Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients W… | Phase3 | Eosinophilic Asthma | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01340781 | Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patie… | — | Obstructive Sleep Apnea | Completed | 2012-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01340781 | Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patie… | — | Obstructive Sleep Apnea | Completed | 2012-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01508936 | Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients W… | Phase3 | Eosinophilic Asthma | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01508936 | Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients W… | Phase3 | Eosinophilic Asthma | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01340781 | Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patie… | — | Obstructive Sleep Apnea | Completed | 2012-02-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01497652 | A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognit… | Phase4 | Parkinson's Disease | Completed | 2012-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01497652 | A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognit… | Phase4 | Parkinson's Disease | Completed | 2012-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01479621 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01479621 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01497652 | A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognit… | Phase4 | Parkinson's Disease | Completed | 2012-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01479621 | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propi… | Phase2 | Asthma | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01584037 | Adenovirus Vaccine Pregnancy Registry | — | Adenovirus | Withdrawn | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01584037 | Adenovirus Vaccine Pregnancy Registry | — | Adenovirus | Withdrawn | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01523236 | Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation | Phase1 | Seasonal Allergic Rhinitis | Completed | 2011-12-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01523236 | Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation | Phase1 | Seasonal Allergic Rhinitis | Completed | 2011-12-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01523236 | Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation | Phase1 | Seasonal Allergic Rhinitis | Completed | 2011-12-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01584037 | Adenovirus Vaccine Pregnancy Registry | — | Adenovirus | Withdrawn | 2011-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01396213 | A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the … | Phase2 | Celiac Disease | Completed | 2011-11-07 | 2013-08-20 | ClinicalTrials.gov |
| NCT01396213 | A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the … | Phase2 | Celiac Disease | Completed | 2011-11-07 | 2013-08-20 | ClinicalTrials.gov |
| NCT01396213 | A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the … | Phase2 | Celiac Disease | Completed | 2011-11-07 | 2013-08-20 | ClinicalTrials.gov |
| NCT01729351 | Qvar Therapy in Smoking Asthmatics | — | Asthma | Completed | 2011-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01729351 | Qvar Therapy in Smoking Asthmatics | — | Asthma | Completed | 2011-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01729351 | Qvar Therapy in Smoking Asthmatics | — | Asthma | Completed | 2011-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01388491 | A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on… | Phase2 | Hemostasis | Completed | 2011-10-31 | 2012-09-30 | ClinicalTrials.gov |
| NCT01388491 | A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on… | Phase2 | Hemostasis | Completed | 2011-10-31 | 2012-09-30 | ClinicalTrials.gov |
| NCT01388491 | A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on… | Phase2 | Hemostasis | Completed | 2011-10-31 | 2012-09-30 | ClinicalTrials.gov |
| NCT01460628 | Effect of Nuvigil on Fatigue | Phase4 | Menopause | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01460628 | Effect of Nuvigil on Fatigue | Phase4 | Menopause | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01442610 | Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease | Phase4 | Sleep Disturbances | Completed | 2011-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01460628 | Effect of Nuvigil on Fatigue | Phase4 | Menopause | Completed | 2011-10-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01442610 | Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease | Phase4 | Sleep Disturbances | Completed | 2011-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01442610 | Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease | Phase4 | Sleep Disturbances | Completed | 2011-10-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01397734 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemi… | Phase1 | Chronic Myelogenous Leukemia | Terminated | 2011-09-01 | 2018-08-06 | ClinicalTrials.gov |
| NCT01456416 | Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities | — | Relapsing Remitting Multiple Sclerosis | Completed | 2011-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01397734 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemi… | Phase1 | Chronic Myelogenous Leukemia | Terminated | 2011-09-01 | 2018-08-06 | ClinicalTrials.gov |
| NCT01456416 | Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities | — | Relapsing Remitting Multiple Sclerosis | Completed | 2011-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01456416 | Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities | — | Relapsing Remitting Multiple Sclerosis | Completed | 2011-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01397734 | Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemi… | Phase1 | Chronic Myelogenous Leukemia | Terminated | 2011-09-01 | 2018-08-06 | ClinicalTrials.gov |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Re… | Phase1 | Multiple Myeloma | Completed | 2011-08-03 | 2013-03-14 | ClinicalTrials.gov |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Re… | Phase1 | Multiple Myeloma | Completed | 2011-08-03 | 2013-03-14 | ClinicalTrials.gov |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Re… | Phase1 | Multiple Myeloma | Completed | 2011-08-03 | 2013-03-14 | ClinicalTrials.gov |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-pos… | Phase2 | Tubular Breast Cancer Stage II | Completed | 2011-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | Phase2 | Lung Cancer | Completed | 2011-08-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | Phase2 | Lung Cancer | Completed | 2011-08-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | Phase2 | Lung Cancer | Completed | 2011-08-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-pos… | Phase2 | Tubular Breast Cancer Stage II | Completed | 2011-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-pos… | Phase2 | Tubular Breast Cancer Stage II | Completed | 2011-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01290887 | Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Res… | Phase3 | Eosinophilic Asthma | Terminated | 2011-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01290887 | Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Res… | Phase3 | Eosinophilic Asthma | Terminated | 2011-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01382342 | The Effect of Rasagiline on Cognition in Parkinson's Disease | Phase4 | Parkinson's Disease | Completed | 2011-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01290887 | Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Res… | Phase3 | Eosinophilic Asthma | Terminated | 2011-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01382342 | The Effect of Rasagiline on Cognition in Parkinson's Disease | Phase4 | Parkinson's Disease | Completed | 2011-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01382342 | The Effect of Rasagiline on Cognition in Parkinson's Disease | Phase4 | Parkinson's Disease | Completed | 2011-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in… | Phase1 | Solid Tumors | Terminated | 2011-05-02 | 2013-10-16 | ClinicalTrials.gov |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in… | Phase1 | Solid Tumors | Terminated | 2011-05-02 | 2013-10-16 | ClinicalTrials.gov |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in… | Phase1 | Solid Tumors | Terminated | 2011-05-02 | 2013-10-16 | ClinicalTrials.gov |
| NCT01419301 | Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) | Na | Multiple Sclerosis | Completed | 2011-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01419301 | Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) | Na | Multiple Sclerosis | Completed | 2011-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01419301 | Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) | Na | Multiple Sclerosis | Completed | 2011-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01287039 | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Re… | Phase3 | Eosinophilic Asthma | Completed | 2011-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01287039 | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Re… | Phase3 | Eosinophilic Asthma | Completed | 2011-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01287039 | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Re… | Phase3 | Eosinophilic Asthma | Completed | 2011-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01302587 | A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalka… | — | Asthma | Completed | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01285323 | A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosi… | Phase3 | Eosinophilic Asthma | Completed | 2011-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01285323 | A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosi… | Phase3 | Eosinophilic Asthma | Completed | 2011-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01302587 | A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalka… | — | Asthma | Completed | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01307319 | Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children … | Phase3 | Seasonal Allergic Rhinitis | Completed | 2011-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01307319 | Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children … | Phase3 | Seasonal Allergic Rhinitis | Completed | 2011-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01302587 | A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalka… | — | Asthma | Completed | 2011-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01285323 | A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosi… | Phase3 | Eosinophilic Asthma | Completed | 2011-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01307319 | Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children … | Phase3 | Seasonal Allergic Rhinitis | Completed | 2011-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01270464 | A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as… | Phase3 | Eosinophilic Asthma | Completed | 2011-02-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01270464 | A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as… | Phase3 | Eosinophilic Asthma | Completed | 2011-02-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01877954 | Qvar vs FP in Pediatrics | — | Asthma | Completed | 2011-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01877954 | Qvar vs FP in Pediatrics | — | Asthma | Completed | 2011-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01877954 | Qvar vs FP in Pediatrics | — | Asthma | Completed | 2011-02-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01270464 | A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as… | Phase3 | Eosinophilic Asthma | Completed | 2011-02-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01291004 | A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 C… | Phase1 | Follicle Development | Completed | 2011-01-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT01291004 | A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 C… | Phase1 | Follicle Development | Completed | 2011-01-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT01291004 | A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 C… | Phase1 | Follicle Development | Completed | 2011-01-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT01454791 | Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients T… | Phase4 | Multiple Sclerosis | Completed | 2011-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01454791 | Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients T… | Phase4 | Multiple Sclerosis | Completed | 2011-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01454791 | Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients T… | Phase4 | Multiple Sclerosis | Completed | 2011-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Canc… | Phase3 | Squamous Cell Carcinoma of the Oral Cavity | Completed | 2010-12-01 | 2020-12-04 | ClinicalTrials.gov |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Canc… | Phase3 | Squamous Cell Carcinoma of the Oral Cavity | Completed | 2010-12-01 | 2020-12-04 | ClinicalTrials.gov |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Canc… | Phase3 | Squamous Cell Carcinoma of the Oral Cavity | Completed | 2010-12-01 | 2020-12-04 | ClinicalTrials.gov |
| NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With … | Phase3 | Prostate Cancer | Completed | 2010-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01240863 | Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Re… | Phase3 | Chronic Pain | Completed | 2010-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01240863 | Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Re… | Phase3 | Chronic Pain | Completed | 2010-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With … | Phase3 | Prostate Cancer | Completed | 2010-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01240863 | Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Re… | Phase3 | Chronic Pain | Completed | 2010-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With … | Phase3 | Prostate Cancer | Completed | 2010-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01085084 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Arthritis | Completed | 2010-10-04 | 2012-11-12 | ClinicalTrials.gov |
| NCT01085084 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Arthritis | Completed | 2010-10-04 | 2012-11-12 | ClinicalTrials.gov |
| NCT01085084 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Arthritis | Completed | 2010-10-04 | 2012-11-12 | ClinicalTrials.gov |
| NCT01223365 | Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Relea… | Phase3 | Chronic Pain | Completed | 2010-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01223365 | Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Relea… | Phase3 | Chronic Pain | Completed | 2010-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01218009 | A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a … | Phase3 | Asthma | Terminated | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01218009 | A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a … | Phase3 | Asthma | Terminated | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01223365 | Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Relea… | Phase3 | Chronic Pain | Completed | 2010-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01218009 | A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a … | Phase3 | Asthma | Terminated | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01085097 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Nephritis | Completed | 2010-09-01 | 2012-10-24 | ClinicalTrials.gov |
| NCT01085097 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Nephritis | Completed | 2010-09-01 | 2012-10-24 | ClinicalTrials.gov |
| NCT01192503 | Safety and Efficacy of Rasagiline in Restless Legs Syndrome | Phase2 | Restless Legs Syndrome | Terminated | 2010-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non… | Phase1 | DLBCL | Completed | 2010-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non… | Phase1 | DLBCL | Completed | 2010-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01192503 | Safety and Efficacy of Rasagiline in Restless Legs Syndrome | Phase2 | Restless Legs Syndrome | Terminated | 2010-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01192503 | Safety and Efficacy of Rasagiline in Restless Legs Syndrome | Phase2 | Restless Legs Syndrome | Terminated | 2010-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non… | Phase1 | DLBCL | Completed | 2010-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01085097 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) A… | Phase2 | Lupus Nephritis | Completed | 2010-09-01 | 2012-10-24 | ClinicalTrials.gov |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients Wit… | Phase1 | Leukemia | Completed | 2010-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01178125 | A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pre… | Phase3 | Contraception | Completed | 2010-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients Wit… | Phase1 | Leukemia | Completed | 2010-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01178125 | A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pre… | Phase3 | Contraception | Completed | 2010-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients Wit… | Phase1 | Leukemia | Completed | 2010-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01178125 | A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pre… | Phase3 | Contraception | Completed | 2010-08-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01151787 | Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the T… | Phase3 | Chronic Migraine | Terminated | 2010-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01167426 | Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting M… | Phase3 | Multiple Sclerosis | Completed | 2010-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01151787 | Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the T… | Phase3 | Chronic Migraine | Terminated | 2010-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01167426 | Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting M… | Phase3 | Multiple Sclerosis | Completed | 2010-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01167426 | Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting M… | Phase3 | Multiple Sclerosis | Completed | 2010-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01151787 | Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the T… | Phase3 | Chronic Migraine | Terminated | 2010-07-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01126190 | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel | Phase3 | Chemotherapy-induced Neutropenia | Completed | 2010-06-30 | 2012-02-29 | ClinicalTrials.gov |
| NCT01126190 | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel | Phase3 | Chemotherapy-induced Neutropenia | Completed | 2010-06-30 | 2012-02-29 | ClinicalTrials.gov |
| NCT01126190 | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel | Phase3 | Chemotherapy-induced Neutropenia | Completed | 2010-06-30 | 2012-02-29 | ClinicalTrials.gov |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Asses… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2010-06-22 | 2017-05-12 | ClinicalTrials.gov |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Asses… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2010-06-22 | 2017-05-12 | ClinicalTrials.gov |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Asses… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2010-06-22 | 2017-05-12 | ClinicalTrials.gov |
| NCT01133626 | Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subject… | Phase3 | Perennial Allergic Rhinitis | Completed | 2010-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01133626 | Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subject… | Phase3 | Perennial Allergic Rhinitis | Completed | 2010-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01133626 | Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subject… | Phase3 | Perennial Allergic Rhinitis | Completed | 2010-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01047319 | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2010-05-27 | 2017-06-30 | ClinicalTrials.gov |
| NCT01047319 | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2010-05-27 | 2017-06-30 | ClinicalTrials.gov |
| NCT01047319 | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2010-05-27 | 2017-06-30 | ClinicalTrials.gov |
| NCT00737932 | Laquinimod Phase IIa Study in Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00737932 | Laquinimod Phase IIa Study in Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01134705 | Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis) | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01202786 | Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Pr… | — | Neoplasms, Unknown Primary | Completed | 2010-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01134705 | Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis) | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01202786 | Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Pr… | — | Neoplasms, Unknown Primary | Completed | 2010-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00737932 | Laquinimod Phase IIa Study in Active Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01134705 | Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis) | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2010-05-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01202786 | Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Pr… | — | Neoplasms, Unknown Primary | Completed | 2010-05-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01055379 | Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-imp… | Phase4 | Depressive Symptoms | Completed | 2010-03-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel… | Phase3 | Castrate-Resistant Prostate Cancer | Terminated | 2010-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01055379 | Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-imp… | Phase4 | Depressive Symptoms | Completed | 2010-03-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel… | Phase3 | Castrate-Resistant Prostate Cancer | Terminated | 2010-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01055379 | Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-imp… | Phase4 | Depressive Symptoms | Completed | 2010-03-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel… | Phase3 | Castrate-Resistant Prostate Cancer | Terminated | 2010-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01058863 | A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ag… | Phase2 | Asthma | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00988988 | The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glat… | Phase4 | Multiple Sclerosis | Withdrawn | 2010-02-01 | 2012-08-03 | ClinicalTrials.gov |
| NCT00988988 | The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glat… | Phase4 | Multiple Sclerosis | Withdrawn | 2010-02-01 | 2012-08-03 | ClinicalTrials.gov |
| NCT01058863 | A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ag… | Phase2 | Asthma | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01058863 | A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ag… | Phase2 | Asthma | Completed | 2010-02-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00988988 | The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glat… | Phase4 | Multiple Sclerosis | Withdrawn | 2010-02-01 | 2012-08-03 | ClinicalTrials.gov |
| NCT01056159 | A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a D… | Phase1 | Asthma | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01046214 | Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Depressive Disorder | Terminated | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01046214 | Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Depressive Disorder | Terminated | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01187888 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supra… | Phase3 | Progressive Supranuclear Palsy | Terminated | 2010-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01056159 | A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a D… | Phase1 | Asthma | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01187888 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supra… | Phase3 | Progressive Supranuclear Palsy | Terminated | 2010-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01056159 | A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a D… | Phase1 | Asthma | Completed | 2010-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01187888 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supra… | Phase3 | Progressive Supranuclear Palsy | Terminated | 2010-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01046214 | Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Depressive Disorder | Terminated | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01024608 | Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | Phase3 | Seasonal Allergic Rhinitis | Completed | 2009-12-31 | 2010-02-28 | ClinicalTrials.gov |
| NCT01024608 | Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | Phase3 | Seasonal Allergic Rhinitis | Completed | 2009-12-31 | 2010-02-28 | ClinicalTrials.gov |
| NCT01024608 | Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | Phase3 | Seasonal Allergic Rhinitis | Completed | 2009-12-31 | 2010-02-28 | ClinicalTrials.gov |
| NCT00977665 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesyl… | Phase2 | Multiple System Atrophy | Completed | 2009-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01032486 | Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease | — | Parkinson's Disease | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01049984 | Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disea… | Phase4 | Parkinson's Disease | Completed | 2009-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01049984 | Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disea… | Phase4 | Parkinson's Disease | Completed | 2009-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01032486 | Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease | — | Parkinson's Disease | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00977665 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesyl… | Phase2 | Multiple System Atrophy | Completed | 2009-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01032486 | Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease | — | Parkinson's Disease | Completed | 2009-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00977665 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesyl… | Phase2 | Multiple System Atrophy | Completed | 2009-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01049984 | Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disea… | Phase4 | Parkinson's Disease | Completed | 2009-12-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00988052 | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Co… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2009-11-10 | 2017-07-01 | ClinicalTrials.gov |
| NCT00988052 | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Co… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2009-11-10 | 2017-07-01 | ClinicalTrials.gov |
| NCT00988052 | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Co… | Phase3 | Relapsing Multiple Sclerosis | Terminated | 2009-11-10 | 2017-07-01 | ClinicalTrials.gov |
| NCT01007630 | A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's … | Phase4 | Parkinson's Disease | Unknown | 2009-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01007630 | A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's … | Phase4 | Parkinson's Disease | Unknown | 2009-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01007630 | A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's … | Phase4 | Parkinson's Disease | Unknown | 2009-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00988247 | Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluor… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2009-10-31 | 2011-02-28 | ClinicalTrials.gov |
| NCT00988247 | Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluor… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2009-10-31 | 2011-02-28 | ClinicalTrials.gov |
| NCT00988247 | Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluor… | Phase3 | Rhinitis, Allergic, Perennial | Completed | 2009-10-31 | 2011-02-28 | ClinicalTrials.gov |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Primary Hepatocellular Carcinoma | Terminated | 2009-10-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Primary Hepatocellular Carcinoma | Terminated | 2009-10-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00964730 | A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm | Phase1 | Healthy | Completed | 2009-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00964730 | A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm | Phase1 | Healthy | Completed | 2009-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Primary Hepatocellular Carcinoma | Terminated | 2009-10-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00964730 | A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm | Phase1 | Healthy | Completed | 2009-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00982150 | Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2009-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00990340 | Comparison of a Needle-free Injection Method With a Needle-syringe Injection Me… | Phase4 | Growth Hormone Deficiency | Completed | 2009-09-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00982150 | Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2009-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00962936 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Chronic Hepatitis C | Terminated | 2009-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00982150 | Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2009-09-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00962936 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Chronic Hepatitis C | Terminated | 2009-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00990340 | Comparison of a Needle-free Injection Method With a Needle-syringe Injection Me… | Phase4 | Growth Hormone Deficiency | Completed | 2009-09-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00962936 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients Wit… | Phase1 | Chronic Hepatitis C | Terminated | 2009-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00990340 | Comparison of a Needle-free Injection Method With a Needle-syringe Injection Me… | Phase4 | Growth Hormone Deficiency | Completed | 2009-09-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00991510 | Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Pati… | Phase4 | Stable Renal Transplant Recipients | Terminated | 2009-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00991510 | Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Pati… | Phase4 | Stable Renal Transplant Recipients | Terminated | 2009-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00991510 | Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Pati… | Phase4 | Stable Renal Transplant Recipients | Terminated | 2009-08-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00936676 | ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Pa… | — | Parkinson's Disease | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00947752 | Safety of New Formulation of Glatiramer Acetate | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00955604 | Azilect + Antidepressant Chart Review | — | Serotonin Syndrome | Completed | 2009-07-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00936676 | ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Pa… | — | Parkinson's Disease | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00947752 | Safety of New Formulation of Glatiramer Acetate | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00955604 | Azilect + Antidepressant Chart Review | — | Serotonin Syndrome | Completed | 2009-07-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00936676 | ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Pa… | — | Parkinson's Disease | Completed | 2009-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00947752 | Safety of New Formulation of Glatiramer Acetate | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00955604 | Azilect + Antidepressant Chart Review | — | Serotonin Syndrome | Completed | 2009-07-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00972062 | Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis | Na | Multiple Sclerosis | Completed | 2009-06-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00972062 | Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis | Na | Multiple Sclerosis | Completed | 2009-06-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00932581 | Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychom… | — | Parkinson's Disease | Completed | 2009-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00972062 | Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis | Na | Multiple Sclerosis | Completed | 2009-06-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00932581 | Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychom… | — | Parkinson's Disease | Completed | 2009-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00932581 | Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychom… | — | Parkinson's Disease | Completed | 2009-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00868361 | A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel | Phase1 | Healthy | Terminated | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00868361 | A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel | Phase1 | Healthy | Terminated | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00868361 | A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel | Phase1 | Healthy | Terminated | 2009-05-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2009-04-30 | 2012-03-31 | ClinicalTrials.gov |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2009-04-30 | 2012-03-31 | ClinicalTrials.gov |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R… | Phase3 | Non-Hodgkin's Lymphoma | Completed | 2009-04-30 | 2012-03-31 | ClinicalTrials.gov |
| NCT00250302 | Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal T… | Phase1 | Tibial Fracture | Completed | 2009-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00250302 | Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal T… | Phase1 | Tibial Fracture | Completed | 2009-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00250302 | Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal T… | Phase1 | Tibial Fracture | Completed | 2009-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00854360 | Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01537692 | Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aer… | Phase1 | Allergic Rhinitis | Completed | 2009-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT01006655 | The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivi… | Phase2 | Asthma | Completed | 2009-03-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00854360 | Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01537692 | Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aer… | Phase1 | Allergic Rhinitis | Completed | 2009-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00854360 | Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2009-03-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01006655 | The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivi… | Phase2 | Asthma | Completed | 2009-03-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01006655 | The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivi… | Phase2 | Asthma | Completed | 2009-03-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01537692 | Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aer… | Phase1 | Allergic Rhinitis | Completed | 2009-03-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00856635 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effect… | Phase3 | Optic Neuritis | Completed | 2009-02-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00830154 | A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stutteri… | Phase2 | Stuttering | Completed | 2009-02-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00830154 | A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stutteri… | Phase2 | Stuttering | Completed | 2009-02-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00856635 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effect… | Phase3 | Optic Neuritis | Completed | 2009-02-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00856635 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effect… | Phase3 | Optic Neuritis | Completed | 2009-02-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00830154 | A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stutteri… | Phase2 | Stuttering | Completed | 2009-02-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00819000 | Therapy Optimization in Multiple Sclerosis (MS) | — | Multiple Sclerosis | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00819195 | Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) T… | — | Multiple Sclerosis | Completed | 2008-12-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00819000 | Therapy Optimization in Multiple Sclerosis (MS) | — | Multiple Sclerosis | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00819195 | Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) T… | — | Multiple Sclerosis | Completed | 2008-12-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00819195 | Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) T… | — | Multiple Sclerosis | Completed | 2008-12-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00819000 | Therapy Optimization in Multiple Sclerosis (MS) | — | Multiple Sclerosis | Completed | 2008-12-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00724048 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntingto… | Phase2 | Huntington Disease | Completed | 2008-10-24 | 2010-07-26 | ClinicalTrials.gov |
| NCT00724048 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntingto… | Phase2 | Huntington Disease | Completed | 2008-10-24 | 2010-07-26 | ClinicalTrials.gov |
| NCT00724048 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntingto… | Phase2 | Huntington Disease | Completed | 2008-10-24 | 2010-07-26 | ClinicalTrials.gov |
| NCT00731172 | A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Effi… | Phase2 | Crohns Disease | Unknown | 2008-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00696332 | Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | ALS | Completed | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00696332 | Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | ALS | Completed | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00731172 | A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Effi… | Phase2 | Crohns Disease | Unknown | 2008-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00731172 | A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Effi… | Phase2 | Crohns Disease | Unknown | 2008-09-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00696332 | Talampanel for Amyotrophic Lateral Sclerosis (ALS) | Phase2 | ALS | Completed | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00837265 | Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Doc… | Phase2 | Chemotherapy-induced Neutropenia | Completed | 2008-08-21 | 2009-06-26 | ClinicalTrials.gov |
| NCT00837265 | Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Doc… | Phase2 | Chemotherapy-induced Neutropenia | Completed | 2008-08-21 | 2009-06-26 | ClinicalTrials.gov |
| NCT00837265 | Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Doc… | Phase2 | Chemotherapy-induced Neutropenia | Completed | 2008-08-21 | 2009-06-26 | ClinicalTrials.gov |
| NCT01344369 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted… | Phase1 | Healthy | Completed | 2008-08-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01344369 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted… | Phase1 | Healthy | Completed | 2008-08-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT01344369 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted… | Phase1 | Healthy | Completed | 2008-08-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00605215 | BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants W… | Phase3 | Multiple Sclerosis | Completed | 2008-04-24 | 2011-06-10 | ClinicalTrials.gov |
| NCT00665223 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's… | Phase3 | Huntington's Disease | Completed | 2008-04-24 | 2010-06-14 | ClinicalTrials.gov |
| NCT00665223 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's… | Phase3 | Huntington's Disease | Completed | 2008-04-24 | 2010-06-14 | ClinicalTrials.gov |
| NCT00665223 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's… | Phase3 | Huntington's Disease | Completed | 2008-04-24 | 2010-06-14 | ClinicalTrials.gov |
| NCT00605215 | BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants W… | Phase3 | Multiple Sclerosis | Completed | 2008-04-24 | 2011-06-10 | ClinicalTrials.gov |
| NCT00605215 | BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants W… | Phase3 | Multiple Sclerosis | Completed | 2008-04-24 | 2011-06-10 | ClinicalTrials.gov |
| NCT00643578 | Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay | Na | Asthma | Completed | 2008-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00643578 | Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay | Na | Asthma | Completed | 2008-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00643578 | Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay | Na | Asthma | Completed | 2008-03-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT01896128 | Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recover… | Phase2 | Stroke | Completed | 2008-01-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01896128 | Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recover… | Phase2 | Stroke | Completed | 2008-01-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01896128 | Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recover… | Phase2 | Stroke | Completed | 2008-01-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT00509145 | Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatm… | Phase3 | Multiple Sclerosis | Completed | 2007-11-13 | 2010-11-08 | ClinicalTrials.gov |
| NCT00509145 | Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatm… | Phase3 | Multiple Sclerosis | Completed | 2007-11-13 | 2010-11-08 | ClinicalTrials.gov |
| NCT00509145 | Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatm… | Phase3 | Multiple Sclerosis | Completed | 2007-11-13 | 2010-11-08 | ClinicalTrials.gov |
| NCT00544882 | A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-10… | Phase3 | Healthy | Completed | 2007-10-31 | 2008-03-31 | ClinicalTrials.gov |
| NCT00544882 | A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-10… | Phase3 | Healthy | Completed | 2007-10-31 | 2008-03-31 | ClinicalTrials.gov |
| NCT00544882 | A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-10… | Phase3 | Healthy | Completed | 2007-10-31 | 2008-03-31 | ClinicalTrials.gov |
| NCT00937157 | Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) | Na | Multiple Sclerosis | Completed | 2007-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00937157 | Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) | Na | Multiple Sclerosis | Completed | 2007-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00937157 | Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) | Na | Multiple Sclerosis | Completed | 2007-09-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01157169 | Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-08-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00577655 | Albuterol HFA MDI in Pediatric Participants With Asthma | Phase3 | Asthma | Completed | 2007-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00577655 | Albuterol HFA MDI in Pediatric Participants With Asthma | Phase3 | Asthma | Completed | 2007-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00577655 | Albuterol HFA MDI in Pediatric Participants With Asthma | Phase3 | Asthma | Completed | 2007-08-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT01157169 | Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-08-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT01157169 | Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-08-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00530062 | Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Alb… | Phase4 | Asthma | Completed | 2007-07-25 | 2008-10-24 | ClinicalTrials.gov |
| NCT00530062 | Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Alb… | Phase4 | Asthma | Completed | 2007-07-25 | 2008-10-24 | ClinicalTrials.gov |
| NCT00530062 | Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Alb… | Phase4 | Asthma | Completed | 2007-07-25 | 2008-10-24 | ClinicalTrials.gov |
| NCT01182636 | Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris | Phase1 | Acne Vulgaris | Completed | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01182636 | Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris | Phase1 | Acne Vulgaris | Completed | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT01182636 | Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris | Phase1 | Acne Vulgaris | Completed | 2007-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00483275 | Fall Prevention by Alfacalcidol and Training | Phase4 | Accidental Falls | Withdrawn | 2007-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00483275 | Fall Prevention by Alfacalcidol and Training | Phase4 | Accidental Falls | Withdrawn | 2007-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01439243 | Donepezil 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01439230 | Donepezil 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT01439230 | Donepezil 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT01439243 | Donepezil 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00483275 | Fall Prevention by Alfacalcidol and Training | Phase4 | Accidental Falls | Withdrawn | 2007-06-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01439243 | Donepezil 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01439230 | Donepezil 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00455260 | A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDe… | Phase1 | Growth Hormone Deficiency | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00455260 | A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDe… | Phase1 | Growth Hormone Deficiency | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00455260 | A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDe… | Phase1 | Growth Hormone Deficiency | Completed | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) … | Phase2 | Chronic Myeloid Leukemia | Completed | 2007-03-07 | 2013-06-27 | ClinicalTrials.gov |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) … | Phase2 | Chronic Myeloid Leukemia | Completed | 2007-03-07 | 2013-06-27 | ClinicalTrials.gov |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) … | Phase2 | Chronic Myeloid Leukemia | Completed | 2007-03-07 | 2013-06-27 | ClinicalTrials.gov |
| NCT01157182 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01157182 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT01157182 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00859430 | Levetiracetam 1000 mg Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01181726 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00859430 | Levetiracetam 1000 mg Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00859521 | Levetiracetam 1000 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00859521 | Levetiracetam 1000 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00859521 | Levetiracetam 1000 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00859430 | Levetiracetam 1000 mg Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01181726 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT01181726 | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions | Phase1 | Healthy | Completed | 2007-01-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT01340625 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Co… | Phase1 | Bioequivalence | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00036296 | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Phase1 | Dyskinesias | Completed | 2006-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00909610 | Ursodiol Tablets 500 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00036296 | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Phase1 | Dyskinesias | Completed | 2006-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00036296 | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Phase1 | Dyskinesias | Completed | 2006-12-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00909610 | Ursodiol Tablets 500 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01340625 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Co… | Phase1 | Bioequivalence | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00909610 | Ursodiol Tablets 500 mg Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT01340625 | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Co… | Phase1 | Bioequivalence | Completed | 2006-12-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00829764 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00829790 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00399477 | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone… | Phase4 | Parkinson's Disease | Completed | 2006-10-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00974012 | Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00974012 | Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00911274 | Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00910663 | Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00911274 | Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00910663 | Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00829790 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00829764 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00910663 | Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00399477 | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone… | Phase4 | Parkinson's Disease | Completed | 2006-10-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00911274 | Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00974012 | Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00829790 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00829764 | Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-10-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00399477 | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone… | Phase4 | Parkinson's Disease | Completed | 2006-10-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic… | Phase2 | Chronic Myeloid Leukemia | Completed | 2006-09-20 | 2013-06-28 | ClinicalTrials.gov |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic… | Phase2 | Chronic Myeloid Leukemia | Completed | 2006-09-20 | 2013-06-28 | ClinicalTrials.gov |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic… | Phase2 | Chronic Myeloid Leukemia | Completed | 2006-09-20 | 2013-06-28 | ClinicalTrials.gov |
| NCT00909753 | Ursodiol 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00909753 | Ursodiol 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00909753 | Ursodiol 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-09-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00337779 | Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (R… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2006-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00908128 | Mycophenolate Mofetil Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00974441 | Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00908128 | Mycophenolate Mofetil Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00337779 | Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (R… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2006-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00974441 | Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00337779 | Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (R… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2006-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00974441 | Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00908128 | Mycophenolate Mofetil Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2006-08-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00336557 | Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of M… | — | Multiple Sclerosis | Completed | 2006-07-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01182207 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditi… | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00907907 | Mycophenolate Mofetil Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00907907 | Mycophenolate Mofetil Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01182207 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditi… | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00336557 | Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of M… | — | Multiple Sclerosis | Completed | 2006-07-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00336557 | Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of M… | — | Multiple Sclerosis | Completed | 2006-07-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01182207 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditi… | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00907907 | Mycophenolate Mofetil Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2006-07-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00308685 | Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthma… | Phase3 | Asthma | Completed | 2006-06-10 | 2006-12-04 | ClinicalTrials.gov |
| NCT00308685 | Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthma… | Phase3 | Asthma | Completed | 2006-06-10 | 2006-12-04 | ClinicalTrials.gov |
| NCT00308685 | Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthma… | Phase3 | Asthma | Completed | 2006-06-10 | 2006-12-04 | ClinicalTrials.gov |
| NCT01182194 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions. | Phase1 | Healthy | Completed | 2006-06-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01182194 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions. | Phase1 | Healthy | Completed | 2006-06-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01182194 | Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions. | Phase1 | Healthy | Completed | 2006-06-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01260922 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Condi… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01260922 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Condi… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01260922 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Condi… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01260948 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting C… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01260948 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting C… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT01260948 | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting C… | Phase1 | Healthy | Completed | 2006-04-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00240006 | A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Soluti… | Phase4 | Multiple Sclerosis | Completed | 2006-01-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00830206 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2006-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00830206 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2006-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00830206 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2006-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00240006 | A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Soluti… | Phase4 | Multiple Sclerosis | Completed | 2006-01-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00240006 | A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Soluti… | Phase4 | Multiple Sclerosis | Completed | 2006-01-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme | Completed | 2005-12-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme | Completed | 2005-12-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme | Completed | 2005-12-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00285051 | Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From… | Phase2 | Cancer | Terminated | 2005-11-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00285051 | Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From… | Phase2 | Cancer | Terminated | 2005-11-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00256204 | A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease … | Phase3 | Parkinson's Disease | Completed | 2005-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00849485 | Levetiracetam 750 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00849485 | Levetiracetam 750 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00285051 | Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From… | Phase2 | Cancer | Terminated | 2005-11-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00256204 | A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease … | Phase3 | Parkinson's Disease | Completed | 2005-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00849485 | Levetiracetam 750 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00256204 | A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease … | Phase3 | Parkinson's Disease | Completed | 2005-11-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00203086 | A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therap… | — | Relapsing Remitting Multiple Sclerosis | Completed | 2005-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00830336 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00232999 | Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild… | Phase2 | Asthma | Completed | 2005-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00830336 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00203086 | A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therap… | — | Relapsing Remitting Multiple Sclerosis | Completed | 2005-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00849862 | Levetiracetam 750 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00849862 | Levetiracetam 750 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00232999 | Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild… | Phase2 | Asthma | Completed | 2005-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00232999 | Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild… | Phase2 | Asthma | Completed | 2005-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00849862 | Levetiracetam 750 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00830336 | A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Und… | Phase1 | Healthy | Completed | 2005-10-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00203086 | A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therap… | — | Relapsing Remitting Multiple Sclerosis | Completed | 2005-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00250341 | Non-invasive Measures of Distal Lung Disease in Asthmatics | Phase4 | Asthma | Completed | 2005-09-30 | 2007-09-30 | ClinicalTrials.gov |
| NCT00250341 | Non-invasive Measures of Distal Lung Disease in Asthmatics | Phase4 | Asthma | Completed | 2005-09-30 | 2007-09-30 | ClinicalTrials.gov |
| NCT00250341 | Non-invasive Measures of Distal Lung Disease in Asthmatics | Phase4 | Asthma | Completed | 2005-09-30 | 2007-09-30 | ClinicalTrials.gov |
| NCT00834717 | Granisetron 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00834717 | Granisetron 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT01183390 | Anastrozole 1 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT01183390 | Anastrozole 1 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT01183390 | Anastrozole 1 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00834717 | Granisetron 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-09-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT01182181 | Anastrozole 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00239993 | A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections… | Phase4 | Multiple Sclerosis | Completed | 2005-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00239993 | A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections… | Phase4 | Multiple Sclerosis | Completed | 2005-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT01182181 | Anastrozole 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT01182181 | Anastrozole 1 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00239993 | A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections… | Phase4 | Multiple Sclerosis | Completed | 2005-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00834535 | Cefdinir Capsules 300 mg, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00835484 | Cefdinir Capsules 300 mg, Fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00834535 | Cefdinir Capsules 300 mg, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00834522 | Granisetron 1 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00203151 | A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in t… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2005-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00203151 | A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in t… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2005-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00834522 | Granisetron 1 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00834535 | Cefdinir Capsules 300 mg, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00835484 | Cefdinir Capsules 300 mg, Fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00849797 | Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00849797 | Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00835484 | Cefdinir Capsules 300 mg, Fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00834522 | Granisetron 1 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00203151 | A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in t… | Phase2 | Systemic Lupus Erythematosus | Terminated | 2005-07-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00849797 | Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-07-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00112411 | Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics | Phase2 | Asthma | Completed | 2005-06-30 | 2005-09-30 | ClinicalTrials.gov |
| NCT00112411 | Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics | Phase2 | Asthma | Completed | 2005-06-30 | 2005-09-30 | ClinicalTrials.gov |
| NCT00112411 | Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics | Phase2 | Asthma | Completed | 2005-06-30 | 2005-09-30 | ClinicalTrials.gov |
| NCT00830024 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting … | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00829426 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Cond… | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00829426 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Cond… | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00830024 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting … | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00829426 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Cond… | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00830024 | Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting … | Phase1 | Healthy | Completed | 2005-06-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00830258 | Pravastatin Sodium 80 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00850174 | Oxcarbazepine 600 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00850174 | Oxcarbazepine 600 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00850174 | Oxcarbazepine 600 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00830258 | Pravastatin Sodium 80 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00830258 | Pravastatin Sodium 80 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-04-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00349193 | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2005-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00829309 | Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00829309 | Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00829309 | Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00349193 | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2005-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00835549 | Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00835549 | Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00835549 | Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting | Phase1 | Healthy | Completed | 2005-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00349193 | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2005-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT01074463 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00834574 | Cefdinir for Oral Suspension 250 mg/5mL, Fasting | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01074450 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01074463 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00834574 | Cefdinir for Oral Suspension 250 mg/5mL, Fasting | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00834574 | Cefdinir for Oral Suspension 250 mg/5mL, Fasting | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01074450 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01074463 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01074450 | Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-02-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT01149499 | Valacyclovir 1000 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00203047 | Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Tre… | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2005-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01149499 | Valacyclovir 1000 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00203047 | Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Tre… | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2005-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00203047 | Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Tre… | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2005-01-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01149499 | Valacyclovir 1000 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2005-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT01149746 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-12-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00203099 | Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetyl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT01149746 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-12-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Glioblastoma Multiforme | Completed | 2004-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00203099 | Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetyl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00203099 | Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetyl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Glioblastoma Multiforme | Completed | 2004-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Glioblastoma Multiforme | Completed | 2004-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT01149746 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-12-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00830219 | The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed … | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT01149733 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT01149733 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00830219 | The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed … | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT01149733 | Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00830219 | The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed … | Phase1 | Healthy | Completed | 2004-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00094016 | Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in… | Phase3 | Asthma | Completed | 2004-10-31 | 2006-06-30 | ClinicalTrials.gov |
| NCT00094016 | Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in… | Phase3 | Asthma | Completed | 2004-10-31 | 2006-06-30 | ClinicalTrials.gov |
| NCT00094016 | Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in… | Phase3 | Asthma | Completed | 2004-10-31 | 2006-06-30 | ClinicalTrials.gov |
| NCT00840073 | Trandolapril 4 mg Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00840073 | Trandolapril 4 mg Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00840632 | Trandolapril 4 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00829504 | Ropinirole 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00240032 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an … | Phase4 | Multiple Sclerosis | Completed | 2004-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00829504 | Ropinirole 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00840073 | Trandolapril 4 mg Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00240032 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an … | Phase4 | Multiple Sclerosis | Completed | 2004-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00840632 | Trandolapril 4 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00829504 | Ropinirole 0.25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00840632 | Trandolapril 4 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-10-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00240032 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an … | Phase4 | Multiple Sclerosis | Completed | 2004-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT01149460 | Valacyclovir 1000 mg Tablet Under Fed Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00834275 | Cefadroxil 500 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT01149460 | Valacyclovir 1000 mg Tablet Under Fed Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00834275 | Cefadroxil 500 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00835081 | Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjec… | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00835081 | Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjec… | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT01149460 | Valacyclovir 1000 mg Tablet Under Fed Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00835081 | Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjec… | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00834275 | Cefadroxil 500 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-09-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00829452 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00829452 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00834431 | Famciclovir 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00834444 | Famciclovir 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00220922 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alco… | Phase4 | Multiple Sclerosis | Completed | 2004-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00104273 | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to … | Phase2 | Dementia | Completed | 2004-08-01 | — | ClinicalTrials.gov |
| NCT00834444 | Famciclovir 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00834431 | Famciclovir 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00829530 | Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00829452 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00828321 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00220922 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alco… | Phase4 | Multiple Sclerosis | Completed | 2004-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00829530 | Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00828321 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00846885 | Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00834431 | Famciclovir 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00834444 | Famciclovir 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00104273 | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to … | Phase2 | Dementia | Completed | 2004-08-01 | — | ClinicalTrials.gov |
| NCT00828321 | Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00829530 | Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00104273 | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to … | Phase2 | Dementia | Completed | 2004-08-01 | — | ClinicalTrials.gov |
| NCT00846885 | Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00220922 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alco… | Phase4 | Multiple Sclerosis | Completed | 2004-08-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00846885 | Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-08-01 | 2004-10-01 | ClinicalTrials.gov |
| NCT00109668 | Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered D… | Phase3 | Asthma | Completed | 2004-07-31 | 2006-09-30 | ClinicalTrials.gov |
| NCT00109668 | Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered D… | Phase3 | Asthma | Completed | 2004-07-31 | 2006-09-30 | ClinicalTrials.gov |
| NCT00109668 | Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered D… | Phase3 | Asthma | Completed | 2004-07-31 | 2006-09-30 | ClinicalTrials.gov |
| NCT00202995 | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA … | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2004-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00202995 | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA … | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2004-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00202995 | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA … | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2004-07-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00085774 | Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exerci… | Phase3 | Exercise-induced Bronchospasm | Completed | 2004-06-30 | 2004-09-30 | ClinicalTrials.gov |
| NCT00085774 | Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exerci… | Phase3 | Exercise-induced Bronchospasm | Completed | 2004-06-30 | 2004-09-30 | ClinicalTrials.gov |
| NCT00085774 | Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exerci… | Phase3 | Exercise-induced Bronchospasm | Completed | 2004-06-30 | 2004-09-30 | ClinicalTrials.gov |
| NCT00203112 | Safety and Efficacy Study of Copaxone Administered in Combination With Minocycl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-06-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00835497 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00829712 | Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00203138 | Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With… | Phase3 | Parkinson's Disease | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00834587 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00829673 | Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00829673 | Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00835497 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00203138 | Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With… | Phase3 | Parkinson's Disease | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00834587 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00829673 | Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00203138 | Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With… | Phase3 | Parkinson's Disease | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00203112 | Safety and Efficacy Study of Copaxone Administered in Combination With Minocycl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-06-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00835497 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00203112 | Safety and Efficacy Study of Copaxone Administered in Combination With Minocycl… | Phase2 | Relapse Remitting Multiple Sclerosis | Completed | 2004-06-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00829712 | Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00829712 | Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00834587 | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2004-06-01 | 2004-06-01 | ClinicalTrials.gov |
| NCT00835354 | Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting | Phase1 | Healthy | Completed | 2004-05-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT01045967 | Lansoprazole 30 mg DR Capsule Fasting Study | Phase1 | Healthy | Completed | 2004-05-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00835354 | Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting | Phase1 | Healthy | Completed | 2004-05-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT01045967 | Lansoprazole 30 mg DR Capsule Fasting Study | Phase1 | Healthy | Completed | 2004-05-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00835354 | Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting | Phase1 | Healthy | Completed | 2004-05-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT01045967 | Lansoprazole 30 mg DR Capsule Fasting Study | Phase1 | Healthy | Completed | 2004-05-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00834977 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Cond… | Phase1 | Healthy | Completed | 2004-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00835614 | Cefprozil for Oral Suspension 250 mg/5 mL, Fasting | Phase1 | Healthy | Completed | 2004-04-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00834977 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Cond… | Phase1 | Healthy | Completed | 2004-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00835614 | Cefprozil for Oral Suspension 250 mg/5 mL, Fasting | Phase1 | Healthy | Completed | 2004-04-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00835614 | Cefprozil for Oral Suspension 250 mg/5 mL, Fasting | Phase1 | Healthy | Completed | 2004-04-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00834977 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Cond… | Phase1 | Healthy | Completed | 2004-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT01149473 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT01149473 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00835367 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditio… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT01149473 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00835367 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditio… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00835367 | Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditio… | Phase1 | Healthy | Completed | 2004-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00829998 | Zaleplon 10mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00829868 | Zaleplon 10 mg Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00839930 | Cilostazol 50 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840476 | Meloxicam 15 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840879 | Meloxicam 15 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840476 | Meloxicam 15 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00839930 | Cilostazol 50 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00839930 | Cilostazol 50 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00829998 | Zaleplon 10mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00829868 | Zaleplon 10 mg Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00829998 | Zaleplon 10mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840476 | Meloxicam 15 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840879 | Meloxicam 15 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00840879 | Meloxicam 15 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00829868 | Zaleplon 10 mg Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2004-02-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00071552 | Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthma… | Phase4 | Asthma | Terminated | 2004-01-31 | 2006-07-31 | ClinicalTrials.gov |
| NCT00071552 | Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthma… | Phase4 | Asthma | Terminated | 2004-01-31 | 2006-07-31 | ClinicalTrials.gov |
| NCT00071552 | Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthma… | Phase4 | Asthma | Terminated | 2004-01-31 | 2006-07-31 | ClinicalTrials.gov |
| NCT01149486 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-01-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00666224 | Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinicall… | Phase3 | Multiple Sclerosis | Completed | 2004-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00666224 | Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinicall… | Phase3 | Multiple Sclerosis | Completed | 2004-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00666224 | Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinicall… | Phase3 | Multiple Sclerosis | Completed | 2004-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01149486 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-01-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00114712 | The Ribavirin Pregnancy Registry | — | Birth Defects | Terminated | 2004-01-01 | 2020-11-02 | ClinicalTrials.gov |
| NCT00114712 | The Ribavirin Pregnancy Registry | — | Birth Defects | Terminated | 2004-01-01 | 2020-11-02 | ClinicalTrials.gov |
| NCT01287351 | Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study | — | Asthma | Completed | 2004-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01046253 | Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study | Phase1 | Healthy | Completed | 2004-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT01149486 | Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Un… | Phase1 | Healthy | Completed | 2004-01-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT01287351 | Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study | — | Asthma | Completed | 2004-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00114712 | The Ribavirin Pregnancy Registry | — | Birth Defects | Terminated | 2004-01-01 | 2020-11-02 | ClinicalTrials.gov |
| NCT01046253 | Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study | Phase1 | Healthy | Completed | 2004-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT01287351 | Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study | — | Asthma | Completed | 2004-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01046253 | Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study | Phase1 | Healthy | Completed | 2004-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00835393 | Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00835588 | Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00835588 | Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00835393 | Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00835588 | Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00835393 | Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-12-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00838630 | Cilostazol 100 mg Tablet Formulations Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836056 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00838630 | Cilostazol 100 mg Tablet Formulations Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836004 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836056 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836004 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836004 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00838630 | Cilostazol 100 mg Tablet Formulations Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00836056 | Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-11-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01124162 | Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Recurrent Glioblastoma Multiforme | Completed | 2003-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Recurrent Glioblastoma Multiforme | Completed | 2003-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT00834067 | Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00835042 | Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00834067 | Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00835042 | Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01124162 | Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01124175 | Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00835042 | Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00834067 | Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Phase2 | Recurrent Glioblastoma Multiforme | Completed | 2003-10-01 | 2006-07-01 | ClinicalTrials.gov |
| NCT01124175 | Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01124162 | Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT01124175 | Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-10-01 | 2003-11-01 | ClinicalTrials.gov |
| NCT00834990 | Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835146 | Ribavirin 200 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00972855 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840866 | Cefprozil 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840866 | Cefprozil 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00836901 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Con… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835146 | Ribavirin 200 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00834990 | Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835146 | Ribavirin 200 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00834639 | Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00836901 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Con… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840281 | Cefprozil 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834990 | Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00973050 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Condit… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840866 | Cefprozil 500 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840281 | Cefprozil 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00972855 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00972855 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00973050 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Condit… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835705 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00973050 | Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Condit… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835705 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834639 | Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835536 | Ribavirin 200 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00835536 | Ribavirin 200 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00836901 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Con… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00840281 | Cefprozil 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00835536 | Ribavirin 200 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00835705 | Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834639 | Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-09-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834743 | Metformin ER 750 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00834743 | Metformin ER 750 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT01046084 | Lansoprazole 30 mg DR Capsule Replicate Food Study | Phase1 | Healthy | Completed | 2003-08-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834743 | Metformin ER 750 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00202982 | A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copax… | Phase2 | Relapse-Remitting Multiple Sclerosis | Completed | 2003-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00834613 | Metformin ER 750 mg Tablets, Fed | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00202982 | A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copax… | Phase2 | Relapse-Remitting Multiple Sclerosis | Completed | 2003-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT01046084 | Lansoprazole 30 mg DR Capsule Replicate Food Study | Phase1 | Healthy | Completed | 2003-08-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834613 | Metformin ER 750 mg Tablets, Fed | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT01046084 | Lansoprazole 30 mg DR Capsule Replicate Food Study | Phase1 | Healthy | Completed | 2003-08-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834613 | Metformin ER 750 mg Tablets, Fed | Phase1 | Healthy | Completed | 2003-08-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00202982 | A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copax… | Phase2 | Relapse-Remitting Multiple Sclerosis | Completed | 2003-08-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Phase2 | Glioblastoma Multiforme | Terminated | 2003-07-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00834197 | 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00835575 | 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00835211 | Desmopressin Acetate 0.2 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Phase2 | Glioblastoma Multiforme | Terminated | 2003-07-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00835211 | Desmopressin Acetate 0.2 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00835211 | Desmopressin Acetate 0.2 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00835575 | 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Phase2 | Glioblastoma Multiforme | Terminated | 2003-07-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00835575 | 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00834197 | 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00834197 | 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2003-07-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00203073 | A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed… | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2003-06-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00203073 | A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed… | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2003-06-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00203073 | A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed… | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2003-06-01 | 2005-04-01 | ClinicalTrials.gov |
| NCT00238654 | A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Cop… | — | Multiple Sclerosis | Completed | 2003-05-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00840203 | Mesalamine 4 gm/60 mL Rectal Enema | Phase1 | Healthy | Completed | 2003-05-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00840203 | Mesalamine 4 gm/60 mL Rectal Enema | Phase1 | Healthy | Completed | 2003-05-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00238654 | A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Cop… | — | Multiple Sclerosis | Completed | 2003-05-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00840203 | Mesalamine 4 gm/60 mL Rectal Enema | Phase1 | Healthy | Completed | 2003-05-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00238654 | A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Cop… | — | Multiple Sclerosis | Completed | 2003-05-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00836472 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting | Phase1 | Healthy | Completed | 2003-04-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00841815 | Amlodipine 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00841542 | Amlodipine 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00841542 | Amlodipine 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00836472 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting | Phase1 | Healthy | Completed | 2003-04-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00841815 | Amlodipine 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00836472 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting | Phase1 | Healthy | Completed | 2003-04-01 | 2003-04-01 | ClinicalTrials.gov |
| NCT00841542 | Amlodipine 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00841815 | Amlodipine 10 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2003-04-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00054964 | Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Pati… | Phase2 | Asthma | Completed | 2003-03-31 | 2003-08-31 | ClinicalTrials.gov |
| NCT00054964 | Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Pati… | Phase2 | Asthma | Completed | 2003-03-31 | 2003-08-31 | ClinicalTrials.gov |
| NCT00054964 | Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Pati… | Phase2 | Asthma | Completed | 2003-03-31 | 2003-08-31 | ClinicalTrials.gov |
| NCT00847405 | Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835172 | Glimepiride 4 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835172 | Glimepiride 4 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00847405 | Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835172 | Glimepiride 4 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00847405 | Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-03-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT01282814 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00834340 | Glimepiride 4 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00934921 | Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00934921 | Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00835991 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT01282814 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835991 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00934921 | Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00834340 | Glimepiride 4 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT01282814 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00834340 | Glimepiride 4 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2003-02-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835991 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed | Phase1 | Healthy | Completed | 2003-02-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00203008 | A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Highe… | — | Parkinson's Disease | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00203008 | A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Highe… | — | Parkinson's Disease | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00203008 | A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Highe… | — | Parkinson's Disease | Completed | 2003-01-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00834249 | Venlafaxine 25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00834964 | Venlafaxine 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00934180 | Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00834249 | Venlafaxine 25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00834964 | Venlafaxine 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00934180 | Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00834249 | Venlafaxine 25 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00934180 | Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00834964 | Venlafaxine 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-12-01 | 2002-12-01 | ClinicalTrials.gov |
| NCT00841698 | Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-10-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00841698 | Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-10-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00841698 | Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-10-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00840411 | Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01282801 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01282801 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01260896 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Condit… | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01260896 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Condit… | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01282801 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00835692 | Clarithromycin 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00835692 | Clarithromycin 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00840411 | Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00840411 | Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT01260896 | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Condit… | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00834756 | Azithromycin 600 Mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00834756 | Azithromycin 600 Mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00834756 | Azithromycin 600 Mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-09-01 | 2002-10-01 | ClinicalTrials.gov |
| NCT00835692 | Clarithromycin 500 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-09-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00841659 | Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840099 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fastin… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840216 | Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions. | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840099 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fastin… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00841659 | Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840216 | Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions. | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840840 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Co… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840216 | Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions. | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840099 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fastin… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840840 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Co… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00841659 | Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00840840 | 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Co… | Phase1 | Healthy | Completed | 2002-08-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00836706 | Clarithromycin 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-07-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00836706 | Clarithromycin 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-07-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00834132 | Azithromycin 600 Mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-07-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00834132 | Azithromycin 600 Mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-07-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00834132 | Azithromycin 600 Mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-07-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT00836706 | Clarithromycin 500 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-07-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00835666 | Finasteride 5 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00835796 | Finasteride 5 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00905164 | Topiramate 25 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00834418 | Leflunomide 20 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00905346 | Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00835666 | Finasteride 5 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00834418 | Leflunomide 20 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00904943 | Topiramate 25 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00835796 | Finasteride 5 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00835796 | Finasteride 5 mg Tablets, Non-fasting | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00904943 | Topiramate 25 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00904943 | Topiramate 25 mg Capsules Under Fed Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00905164 | Topiramate 25 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00905346 | Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00905164 | Topiramate 25 mg Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00834418 | Leflunomide 20 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00905346 | Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00835666 | Finasteride 5 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-06-01 | 2002-06-01 | ClinicalTrials.gov |
| NCT00203164 | Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkins… | Phase3 | Parkinson's Disease | Completed | 2002-05-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00203164 | Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkins… | Phase3 | Parkinson's Disease | Completed | 2002-05-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00203164 | Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkins… | Phase3 | Parkinson's Disease | Completed | 2002-05-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00830414 | Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women | Phase1 | Healthy | Completed | 2002-04-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00834405 | Leflunomide 20 mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-04-01 | 2002-05-01 | ClinicalTrials.gov |
| NCT00834405 | Leflunomide 20 mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-04-01 | 2002-05-01 | ClinicalTrials.gov |
| NCT00834405 | Leflunomide 20 mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-04-01 | 2002-05-01 | ClinicalTrials.gov |
| NCT00830414 | Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women | Phase1 | Healthy | Completed | 2002-04-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00830414 | Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women | Phase1 | Healthy | Completed | 2002-04-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT00836849 | Sertraline Hydrochloride 100 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00836849 | Sertraline Hydrochloride 100 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00833937 | Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00835276 | Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00836667 | Sertraline Hydrochloride 100 mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00836667 | Sertraline Hydrochloride 100 mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00836849 | Sertraline Hydrochloride 100 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00835276 | Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00833937 | Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00833937 | Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00836667 | Sertraline Hydrochloride 100 mg Tablets, Fed | Phase1 | Healthy | Completed | 2002-03-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00835276 | Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-03-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00838136 | Lamotrigine 25 mg Chewable Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00833521 | Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-02-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00838279 | Lamotrigine 25 mg Chewable Tablets, Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00838136 | Lamotrigine 25 mg Chewable Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00833521 | Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-02-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00833521 | Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-02-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00838136 | Lamotrigine 25 mg Chewable Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00838279 | Lamotrigine 25 mg Chewable Tablets, Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00838279 | Lamotrigine 25 mg Chewable Tablets, Fasting | Phase1 | Healthy | Completed | 2002-02-01 | 2002-03-01 | ClinicalTrials.gov |
| NCT00035503 | Multicenter Trial For Patients With Acute Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2002-01-31 | 2004-01-31 | ClinicalTrials.gov |
| NCT00035503 | Multicenter Trial For Patients With Acute Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2002-01-31 | 2004-01-31 | ClinicalTrials.gov |
| NCT00035503 | Multicenter Trial For Patients With Acute Crohn's Disease | Phase2 | Crohn's Disease | Completed | 2002-01-31 | 2004-01-31 | ClinicalTrials.gov |
| NCT00833664 | Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00835640 | Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00835640 | Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00034814 | Multicenter Trial for Adults With Partial Seizures | Phase2 | Epilepsy | Completed | 2002-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00835263 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00834561 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00834561 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT01020396 | Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vagino… | Phase1 | Bacterial Vaginosis | Completed | 2002-01-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT01020396 | Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vagino… | Phase1 | Bacterial Vaginosis | Completed | 2002-01-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00835263 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00834561 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT01020396 | Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vagino… | Phase1 | Bacterial Vaginosis | Completed | 2002-01-01 | 2003-03-01 | ClinicalTrials.gov |
| NCT00034814 | Multicenter Trial for Adults With Partial Seizures | Phase2 | Epilepsy | Completed | 2002-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00835640 | Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00835263 | Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-02-01 | ClinicalTrials.gov |
| NCT00833664 | Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00034814 | Multicenter Trial for Adults With Partial Seizures | Phase2 | Epilepsy | Completed | 2002-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00833664 | Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00833586 | Terbinafine HCl 250 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00833586 | Terbinafine HCl 250 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00833586 | Terbinafine HCl 250 mg Tablet Under Fasting Conditions | Phase1 | Healthy | Completed | 2002-01-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00834873 | Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00840398 | Buspirone Hydrochloride 30mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00840606 | Buspirone Hydrochloride 30mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00834873 | Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00834795 | Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00840398 | Buspirone Hydrochloride 30mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00840606 | Buspirone Hydrochloride 30mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00840398 | Buspirone Hydrochloride 30mg Tablets, Non-Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00840606 | Buspirone Hydrochloride 30mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-12-01 | 2002-04-01 | ClinicalTrials.gov |
| NCT00834873 | Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00834795 | Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT00834795 | Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects | Phase1 | Healthy | Completed | 2001-12-01 | 2001-12-01 | ClinicalTrials.gov |
| NCT01020877 | Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects | Phase1 | Healthy | Completed | 2001-11-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT01020877 | Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects | Phase1 | Healthy | Completed | 2001-11-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT01020877 | Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects | Phase1 | Healthy | Completed | 2001-11-01 | 2002-01-01 | ClinicalTrials.gov |
| NCT00203177 | Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Tre… | Phase3 | Parkinson's Disease | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00203177 | Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Tre… | Phase3 | Parkinson's Disease | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00203177 | Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Tre… | Phase3 | Parkinson's Disease | Completed | 2001-10-01 | — | ClinicalTrials.gov |
| NCT00829894 | Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00905567 | Topiramate 25 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00905606 | Topiramate 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00905606 | Topiramate 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00829894 | Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00905606 | Topiramate 25 mg Tablets Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00830349 | Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00905567 | Topiramate 25 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00905567 | Topiramate 25 mg Tablets Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-06-01 | ClinicalTrials.gov |
| NCT00830349 | Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00829894 | Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00830349 | Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-06-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT01247272 | 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01247285 | 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01247285 | 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01247285 | 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01247272 | 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT01247272 | 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions | Phase1 | Healthy | Completed | 2001-05-01 | 2001-07-01 | ClinicalTrials.gov |
| NCT00836537 | Benazepril HCl 40 mg Tablets, Fed | Phase1 | Healthy | Completed | 2001-03-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00836537 | Benazepril HCl 40 mg Tablets, Fed | Phase1 | Healthy | Completed | 2001-03-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00836537 | Benazepril HCl 40 mg Tablets, Fed | Phase1 | Healthy | Completed | 2001-03-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00836576 | Benazepril HCl 40 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-02-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00836576 | Benazepril HCl 40 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-02-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT00836576 | Benazepril HCl 40 mg Tablets, Fasting | Phase1 | Healthy | Completed | 2001-02-01 | 2001-03-01 | ClinicalTrials.gov |
| NCT01141439 | Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticostero… | — | Asthma | Completed | 2001-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01141439 | Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticostero… | — | Asthma | Completed | 2001-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01141439 | Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticostero… | — | Asthma | Completed | 2001-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01141452 | Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the… | — | Chronic Obstructive Pulmonary Disease | Completed | 2001-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01141452 | Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the… | — | Chronic Obstructive Pulmonary Disease | Completed | 2001-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT01141452 | Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the… | — | Chronic Obstructive Pulmonary Disease | Completed | 2001-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00203125 | A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PREST… | Phase3 | Parkinson's Disease | Completed | 2000-10-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00203125 | A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PREST… | Phase3 | Parkinson's Disease | Completed | 2000-10-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00203125 | A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PREST… | Phase3 | Parkinson's Disease | Completed | 2000-10-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00834379 | Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2000-09-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00834379 | Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2000-09-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00834379 | Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditi… | Phase1 | Healthy | Completed | 2000-09-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00834847 | Pravastatin Sodium 40 mg Tablets Food Challenge Study | Phase1 | Healthy | Completed | 2000-08-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00834847 | Pravastatin Sodium 40 mg Tablets Food Challenge Study | Phase1 | Healthy | Completed | 2000-08-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00834847 | Pravastatin Sodium 40 mg Tablets Food Challenge Study | Phase1 | Healthy | Completed | 2000-08-01 | 2000-09-01 | ClinicalTrials.gov |
| NCT00835406 | Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions. | Phase1 | Healthy | Completed | 2000-06-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00835406 | Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions. | Phase1 | Healthy | Completed | 2000-06-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00835406 | Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions. | Phase1 | Healthy | Completed | 2000-06-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00203034 | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa … | Phase3 | Parkinson's Disease | Completed | 2000-05-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00203034 | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa … | Phase3 | Parkinson's Disease | Completed | 2000-05-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00203034 | Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa … | Phase3 | Parkinson's Disease | Completed | 2000-05-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00203060 | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disea… | Phase3 | Parkinson's Disease | Completed | 1997-07-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00203060 | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disea… | Phase3 | Parkinson's Disease | Completed | 1997-07-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00203060 | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disea… | Phase3 | Parkinson's Disease | Completed | 1997-07-01 | 2000-07-01 | ClinicalTrials.gov |
| NCT00203021 | Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Orig… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 1994-03-26 | 2018-02-28 | ClinicalTrials.gov |
| NCT00203021 | Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Orig… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 1994-03-26 | 2018-02-28 | ClinicalTrials.gov |
| NCT00203021 | Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Orig… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 1994-03-26 | 2018-02-28 | ClinicalTrials.gov |
| NCT01400217 | Qvar Versus Clenil, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01313585 | Device Mixing in Asthma, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01313585 | Device Mixing in Asthma, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01697722 | Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared W… | — | Asthma | Completed | 1991-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01400217 | Qvar Versus Clenil, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01697722 | Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared W… | — | Asthma | Completed | 1991-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01400217 | Qvar Versus Clenil, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01697722 | Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared W… | — | Asthma | Completed | 1991-01-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01313585 | Device Mixing in Asthma, a General Practice Research Database Study | — | Asthma | Completed | 1991-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00404989 | Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… | — | HIV Infections | Recruiting | 1989-01-01 | 2099-01-01 | ClinicalTrials.gov |
| NCT00404989 | Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… | — | HIV Infections | Recruiting | 1989-01-01 | 2099-01-01 | ClinicalTrials.gov |
| NCT00404989 | Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… | — | HIV Infections | Recruiting | 1989-01-01 | 2099-01-01 | ClinicalTrials.gov |
Total clinical trials: 1479
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| [14C]-TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| Deutetrabenazine | Other | Phase PHASE2 | Huntington Disease | ACTIVE_NOT_RECRUITING | NCT04713982 |
| Fp MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| TEV-56248 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| Deutetrabenazine Oral Capsule | Other | Phase PHASE4 | Tardive Dyskinesia | RECRUITING | NCT06997198 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04458857 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04458857 |
| Radiotherapy | Drug | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Quality of Life Measurements | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| DTIC | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Cyclophosphamide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Filgrastim | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Prednisone | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vinblastine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vincristine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Bleomycin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Doxorubicin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Etoposide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| bendamustine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Talampanel (non-radiolabeled), [14C] Talampanel | Other | Phase PHASE1 | Healthy | TERMINATED | NCT00868361 |
| Tamsulosin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149746 |
| Rebif | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Betaseron | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Glatiramer Acetate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Rebif | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Betaseron | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Glatiramer Acetate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00202995 |
| Anastrozole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01183390 |
| Anastrozole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01183390 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046253 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046084 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046084 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046084 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01046084 |
| Prevacid® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01045967 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01045967 |
| Placebo | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT00034814 |
| Talampanel | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT00034814 |
| PROTONIX® 40 mg delayed-release tablets. | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| Pantoprazole Sodium 40 mg delayed-release tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| PROTONIX® 40 mg delayed-release tablets. | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| Pantoprazole Sodium 40 mg delayed-release tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| PROTONIX® 40 mg delayed-release tablets. | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| Pantoprazole Sodium 40 mg delayed-release tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835393 |
| Fosamax® Tablets 70mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835406 |
| Alendronate Sodium Tablets 70mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835406 |
| Rasagiline | Other | Phase PHASE2 | Dementia | COMPLETED | NCT00104273 |
| Rasagiline | Other | Phase PHASE2 | Dementia | COMPLETED | NCT00104273 |
| ALLEGRA® 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835640 |
| Fexofenadine 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835640 |
| ALLEGRA® 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835640 |
| Fexofenadine 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835640 |
| ALLEGRA® 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835276 |
| Fexofenadine 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835276 |
| ALLEGRA® 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835276 |
| Fexofenadine 180 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835276 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834990 |
| divalproex sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834990 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834990 |
| divalproex sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834990 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834639 |
| divalproex sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834639 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834639 |
| divalproex sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834639 |
| Casodex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00973050 |
| Bicalutamide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00973050 |
| Casodex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00973050 |
| Bicalutamide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00973050 |
| Casodex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00972855 |
| Bicalutamide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00972855 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Divalproex Sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Divalproex Sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Divalproex Sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974441 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974012 |
| Divalproex Sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974012 |
| Depakote® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974012 |
| Divalproex Sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00974012 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849862 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849485 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849485 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849485 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849485 |
| Imitrex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Sumatriptan Succinate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Imitrex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Sumatriptan Succinate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Imitrex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Sumatriptan Succinate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00847405 |
| Imitrex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00846885 |
| Sumatriptan Succinate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00846885 |
| Imitrex® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00846885 |
| Sumatriptan Succinate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00846885 |
| DDAVP® 0.2 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835211 |
| Desmopressin Acetate 0.2 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835211 |
| DDAVP® 0.2 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835211 |
| Desmopressin Acetate 0.2 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835211 |
| Requip® 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829504 |
| Ropinirole HCl 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829504 |
| Requip® 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829504 |
| Ropinirole HCl 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829504 |
| 5 mg/500 mg METAGLIP™ Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835497 |
| 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835497 |
| 5 mg/500 mg METAGLIP™ Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835497 |
| 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835497 |
| 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834587 |
| 5 mg/500 mg METAGLIP™ Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834587 |
| 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834587 |
| 5 mg/500 mg METAGLIP™ Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834587 |
| Requip® 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830219 |
| Ropinirole HCl 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830219 |
| Requip® 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830219 |
| Ropinirole HCl 0.25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830219 |
| Topamax® Tablet 2 x 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905567 |
| Topiramate 2 x 25 mg tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905567 |
| Topamax® Tablet 2 x 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905567 |
| Topiramate 2 x 25 mg tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905567 |
| glatiramer acetate 40 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| glatiramer acetate 20 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| glatiramer acetate 40 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| glatiramer acetate 20 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| glatiramer acetate 40 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| glatiramer acetate 20 mg | Other | Phase PHASE2 | Relapse-Remitting Multiple Sclerosis | COMPLETED | NCT00202982 |
| rasagiline mesylate 1.0 mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203177 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203177 |
| rasagiline mesylate 1.0 mg | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203177 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203177 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203164 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203164 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| 1.0 mg rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| 1.0 mg rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203034 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Talampanel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Talampanel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00964730 |
| Pramipexole Dihydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01074463 |
| Pramipexole Dihydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01074450 |
| Pramipexole Dihydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01074450 |
| Pramipexole Dihydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01074450 |
| Valacyclovir | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149499 |
| Valacyclovir | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149499 |
| Valacyclovir | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149499 |
| Metronidazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01020877 |
| Metronidazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01020877 |
| Anastrozole (Arimidex®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182181 |
| Anastrozole (Teva Pharmaceuticals USA) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182181 |
| Anastrozole (Arimidex®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182181 |
| Anastrozole (Teva Pharmaceuticals USA) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182181 |
| Placebo | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01182636 |
| Differin® | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01182636 |
| Adapalene | Other | Phase PHASE1 | Acne Vulgaris | COMPLETED | NCT01182636 |
| YAZ® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182207 |
| Drospirenone/Ethinyl Estradiol (Gianvi®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182207 |
| YAZ® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182207 |
| Drospirenone/Ethinyl Estradiol (Gianvi®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182207 |
| YAZ® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182194 |
| Drospirenone/Ethinyl Estradiol (Gianvi®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182194 |
| YAZ® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182194 |
| Drospirenone/Ethinyl Estradiol (Gianvi®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01182194 |
| Activella® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01181726 |
| Estradiol/Norethindrone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01181726 |
| Activella® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01181726 |
| Estradiol/Norethindrone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01181726 |
| Hyzaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149486 |
| Losartan potassium/Hydrochlorothiazide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149486 |
| Hyzaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149486 |
| Losartan potassium/Hydrochlorothiazide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149486 |
| Cozaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124162 |
| Losartan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124162 |
| Cozaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124162 |
| Losartan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124162 |
| Activella® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157182 |
| Estradiol/Norethindrone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157182 |
| Activella® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157182 |
| Estradiol/Norethindrone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157182 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260948 |
| Donepezil Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260948 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260948 |
| Donepezil Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260948 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Donepezil Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Donepezil Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Donepezil Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260922 |
| Effexor® XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| Venlafaxine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| Effexor® XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| Venlafaxine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| Effexor® XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| Venlafaxine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01260896 |
| PROZAC WEEKLY® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| Fluoxetine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| PROZAC WEEKLY® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| Fluoxetine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| PROZAC WEEKLY® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| Fluoxetine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247285 |
| PROZAC WEEKLY® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247272 |
| Fluoxetine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247272 |
| PROZAC WEEKLY® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247272 |
| Fluoxetine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01247272 |
| Effexor® XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01282814 |
| Venlafaxine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01282814 |
| Effexor® XR | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01282801 |
| Venlafaxine Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01282801 |
| Chlorofluorocarbon beclomethasone dipropionate | Other | Preclinical | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01141452 |
| Hydrofluoroalkane beclomethasone metred dose inhaler | Other | Preclinical | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01141452 |
| Fluticasone propionate metred dose inhaler | Other | Preclinical | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01141452 |
| Chlorofluorocarbon beclomethasone metered dose inhaler | Other | Preclinical | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01141452 |
| Extra-fine hydrofluoroalkane beclomethasone MDI | Other | Preclinical | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01141452 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device | Device | Preclinical | Asthma | COMPLETED | NCT01313585 |
| Placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| laquinimod 0.6 | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| laquinimod 0.3 | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| Placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| laquinimod 0.6 | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| laquinimod 0.3 | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00349193 |
| Alcohol Wipes vs. No Alcohol Wipes | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00220922 |
| Alcohol Wipes vs. No Alcohol Wipes | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00220922 |
| glatiramer acetate with placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00240032 |
| glatiramer acetate injection with oral cetirizine hydrochloride | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00240032 |
| Shared Solutions® plus MS Center v. Shared Solutions® | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00240006 |
| Shared Solutions® plus MS Center v. Shared Solutions® | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00240006 |
| Rasagiline mesylate with Requip | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| Rasagiline mesylate with Levodopa | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| Rasagiline mesylate plus Mirapex | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| rasagiline mesylate | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| Rasagiline mesylate with Requip | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| Rasagiline mesylate with Levodopa | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| Rasagiline mesylate plus Mirapex | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| rasagiline mesylate | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT00399477 |
| edratide | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT00203151 |
| edratide | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT00203151 |
| edratide | Other | Phase PHASE2 | Systemic Lupus Erythematosus | TERMINATED | NCT00203151 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203138 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203138 |
| tyramine | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203125 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203125 |
| tyramine | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203125 |
| rasagiline mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203125 |
| Glatiramer acetate with placebo | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203112 |
| glatiramer acetate with minocycline | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203112 |
| Glatiramer acetate with placebo | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203112 |
| glatiramer acetate with minocycline | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203112 |
| placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203060 |
| Rasagiline Mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203060 |
| placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203060 |
| Rasagiline Mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00203060 |
| talampanel | Other | Phase PHASE1 | Dyskinesias | COMPLETED | NCT00036296 |
| talampanel | Other | Phase PHASE1 | Dyskinesias | COMPLETED | NCT00036296 |
| glatiramer acetate 20 mg, with mitoxantrone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00203073 |
| glatiramer acetate 20 mg | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00203073 |
| glatiramer acetate 20 mg, with mitoxantrone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00203073 |
| glatiramer acetate 20 mg | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00203073 |
| autologous mesenchymal stem cells implantation | Other | Phase PHASE1 | Tibial Fracture | COMPLETED | NCT00250302 |
| autologous mesenchymal stem cells implantation | Other | Phase PHASE1 | Tibial Fracture | COMPLETED | NCT00250302 |
| autologous mesenchymal stem cells implantation | Other | Phase PHASE1 | Tibial Fracture | COMPLETED | NCT00250302 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439243 |
| Donepezil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439243 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439243 |
| Donepezil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439243 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Donepezil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Donepezil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Aricept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Donepezil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01439230 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00256204 |
| Rasagiline Mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00256204 |
| Placebo | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00256204 |
| Rasagiline Mesylate | Other | Phase PHASE3 | Parkinson's Disease | COMPLETED | NCT00256204 |
| TP-38 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00104091 |
| Talampanel | Other | Phase PHASE2 | Glioblastoma Multiforme | TERMINATED | NCT00062504 |
| Talampanel | Other | Phase PHASE2 | Glioblastoma Multiforme | TERMINATED | NCT00062504 |
| Ovcon® 35 Fe | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT01340625 |
| Norethindrone/Ethinyl Estradiol | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT01340625 |
| Ovcon® 35 Fe | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT01340625 |
| Norethindrone/Ethinyl Estradiol | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT01340625 |
| FEMCON® Fe | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| Norethindrone/Ethinyl Estradiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| FEMCON® Fe | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| Norethindrone/Ethinyl Estradiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| FEMCON® Fe | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| Norethindrone/Ethinyl Estradiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01344369 |
| Patient education | Other | Phase PHASE4 | Accidental Falls | WITHDRAWN | NCT00483275 |
| Balance, gait and strength training | Other | Phase PHASE4 | Accidental Falls | WITHDRAWN | NCT00483275 |
| Alfacalcidol | Other | Phase PHASE4 | Accidental Falls | WITHDRAWN | NCT00483275 |
| TevTropin® needle-syringe injection method | Other | Phase PHASE4 | Growth Hormone Deficiency | COMPLETED | NCT00990340 |
| T-jet® containing TevTropin® | Other | Phase PHASE4 | Growth Hormone Deficiency | COMPLETED | NCT00990340 |
| TevTropin® needle-syringe injection method | Other | Phase PHASE4 | Growth Hormone Deficiency | COMPLETED | NCT00990340 |
| T-jet® containing TevTropin® | Other | Phase PHASE4 | Growth Hormone Deficiency | COMPLETED | NCT00990340 |
| glatiramer acetate 20 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| Glatiramer Acetate (GA) 40 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| glatiramer acetate 20 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| Glatiramer Acetate (GA) 40 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| glatiramer acetate 20 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| Glatiramer Acetate (GA) 40 mg | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00337779 |
| placebo | Other | Phase PHASE2 | ALS | COMPLETED | NCT00696332 |
| Talampanel | Other | Phase PHASE2 | ALS | COMPLETED | NCT00696332 |
| Dry Powder Inhaler (Twisthaler) | Other | Approved | Asthma | COMPLETED | NCT00643578 |
| formoterol | Other | Approved | Asthma | COMPLETED | NCT00643578 |
| TP38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| TP-38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| TP38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| TP-38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| TP38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| TP-38 | Other | Phase PHASE2 | Recurrent Glioblastoma Multiforme | COMPLETED | NCT00071539 |
| Placebo | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01523236 |
| Nasonex® | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01523236 |
| Mometasone furoate | Other | Phase PHASE1 | Seasonal Allergic Rhinitis | COMPLETED | NCT01523236 |
| Glatiramer Acetate (OL) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| Glatiramer Acetate (DB) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| Glatiramer Acetate (OL) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| Glatiramer Acetate (DB) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00666224 |
| BDP HFA Inhalation Aerosol (QVAR) | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT01537692 |
| BDP HFA Nasal Aerosol | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT01537692 |
| Placebo Cream | Other | Approved | Multiple Sclerosis | COMPLETED | NCT00972062 |
| Bach's Rescue Remedy Cream | Other | Approved | Multiple Sclerosis | COMPLETED | NCT00972062 |
| Glatiramer Acetate, N-Acetylcysteine | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203099 |
| Glatiramer Acetate, N-Acetylcysteine | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203099 |
| Glatiramer Acetate, N-Acetylcysteine | Other | Phase PHASE2 | Relapse Remitting Multiple Sclerosis | COMPLETED | NCT00203099 |
| Placebo | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00854360 |
| Beclomethasone dipropionate HFA Nasal Aerosol | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00854360 |
| Placebo | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00854360 |
| Beclomethasone dipropionate HFA Nasal Aerosol | Other | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00854360 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT01134705 |
| Albuterol | Other | Preclinical | Asthma | COMPLETED | NCT01302587 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Placebo Prednisone Capsules | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Prednisone capsules | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Placebo Prednisone Capsules | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Prednisone capsules | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Perennial Allergic Rhinitis | COMPLETED | NCT01133626 |
| placebo | Other | Phase PHASE2 | Stuttering | COMPLETED | NCT00830154 |
| pagoclone | Other | Phase PHASE2 | Stuttering | COMPLETED | NCT00830154 |
| placebo | Other | Phase PHASE2 | Stuttering | COMPLETED | NCT00830154 |
| pagoclone | Other | Phase PHASE2 | Stuttering | COMPLETED | NCT00830154 |
| ICS / LABA via separate pMDI and / or BAI inhalers | Other | Preclinical | Asthma | COMPLETED | NCT01697722 |
| Extra-fine hydrofluoroalkane-beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01697722 |
| ICS / LABA via separate pMDI and / or BAI inhalers | Other | Preclinical | Asthma | COMPLETED | NCT01697722 |
| Extra-fine hydrofluoroalkane-beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01697722 |
| CT-011 | Other | Phase PHASE1 | Primary Hepatocellular Carcinoma | TERMINATED | NCT00966251 |
| CT-011 | Other | Phase PHASE1 | Primary Hepatocellular Carcinoma | TERMINATED | NCT00966251 |
| standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler | Other | Preclinical | Asthma | COMPLETED | NCT01400217 |
| extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler | Other | Preclinical | Asthma | COMPLETED | NCT01400217 |
| Chlorofluorocarbon beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Extra-fine hydrofluoroalkane-beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Chlorofluorocarbon beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Extra-fine hydrofluoroalkane-beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Chlorofluorocarbon beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Extra-fine hydrofluoroalkane-beclomethasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01141439 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01879748 |
| Rasagiline | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01879748 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01879748 |
| Rasagiline | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT01879748 |
| Albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Methacholine Chloride | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Flovent Diskus 100 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Advair Diskus100/50 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Methacholine Chloride | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Flovent Diskus 100 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Advair Diskus100/50 µg | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01907334 |
| Cozaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124175 |
| Losartan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124175 |
| Cozaar® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124175 |
| Losartan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01124175 |
| Metronidazole | Other | Phase PHASE1 | Bacterial Vaginosis | COMPLETED | NCT01020396 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00911274 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00911274 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00911274 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00911274 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00910663 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00910663 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00910663 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00910663 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909753 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| Urso Forte™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| Ursodiol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00909610 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00908128 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00908128 |
| CellCept® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00908128 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00908128 |
| CellCept® Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00907907 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00907907 |
| Topamax® Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905606 |
| Topiramate Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905606 |
| Topamax® Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905606 |
| Topiramate Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905606 |
| Trileptal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00850174 |
| Oxcarbazepine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00850174 |
| Trileptal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849797 |
| Oxcarbazepine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849797 |
| Trileptal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849797 |
| Oxcarbazepine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00849797 |
| Paxil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841698 |
| Paroxetine HCl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841698 |
| Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00819000 |
| Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00819000 |
| placebo (sugar pill) | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT01192503 |
| rasagiline | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT01192503 |
| placebo (sugar pill) | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT01192503 |
| rasagiline | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT01192503 |
| 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B). | Drug | Phase PHASE1 | Pain | COMPLETED | NCT01769677 |
| a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B). | Drug | Phase PHASE1 | Pain | COMPLETED | NCT01758978 |
| a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B). | Drug | Phase PHASE1 | Pain | COMPLETED | NCT01758978 |
| a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B). | Drug | Phase PHASE1 | Pain | COMPLETED | NCT01758978 |
| Sugar pill | Other | Phase PHASE3 | Progressive Supranuclear Palsy | TERMINATED | NCT01187888 |
| Rasagiline | Other | Phase PHASE3 | Progressive Supranuclear Palsy | TERMINATED | NCT01187888 |
| Sugar pill | Other | Phase PHASE3 | Progressive Supranuclear Palsy | TERMINATED | NCT01187888 |
| Rasagiline | Other | Phase PHASE3 | Progressive Supranuclear Palsy | TERMINATED | NCT01187888 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01877954 |
| Extra-fine hydrofluoroalkane beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01877954 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01877954 |
| Extra-fine hydrofluoroalkane beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01877954 |
| Polysomnogram | Other | Preclinical | Obstructive Sleep Apnea | COMPLETED | NCT01340781 |
| Polysomnogram | Other | Preclinical | Obstructive Sleep Apnea | COMPLETED | NCT01340781 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| extra-fine hydrofluoroalkane beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| extra-fine hydrofluoroalkane beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| Fluticasone propionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| extra-fine hydrofluoroalkane beclometasone dipropionate | Other | Preclinical | Asthma | COMPLETED | NCT01287351 |
| Talampanel | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT00982150 |
| Talampanel | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT00982150 |
| Talampanel | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT00982150 |
| Glatiramer Acetate or interferon-beta+ Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Laquinimod 1.2 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Laquinimod 0.6 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Glatiramer Acetate or interferon-beta+ Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Laquinimod 1.2 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Laquinimod 0.6 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT01404117 |
| Rasagiline mesylate | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01032486 |
| Rasagiline mesylate | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT01032486 |
| hGH-ViaDerm™ System | Other | Phase PHASE1 | Growth Hormone Deficiency | COMPLETED | NCT00455260 |
| hGH-ViaDerm™ System (hGH or somatropin) | Other | Phase PHASE1 | Growth Hormone Deficiency | COMPLETED | NCT00455260 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00819195 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00819195 |
| Glatiramer acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Glatiramer Acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Glatiramer acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Glatiramer Acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Glatiramer acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Glatiramer Acetate 20 mg/0.5 mL | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01167426 |
| Rituximab | Other | Phase PHASE1 | DLBCL | COMPLETED | NCT01205737 |
| TL011 | Other | Phase PHASE1 | DLBCL | COMPLETED | NCT01205737 |
| NAbs testing | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00336557 |
| NAbs testing | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00336557 |
| ProAir® HFA | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01844401 |
| Albuterol Spiromax® | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01844401 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | UNKNOWN | NCT01007630 |
| Prednisone | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Glatiramer Acetate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Prednisone | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Glatiramer Acetate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00203047 |
| Reslizumab SC | Other | Phase PHASE1 | Absolute Bioavailability | COMPLETED | NCT01990443 |
| Reslizumab IV | Other | Phase PHASE1 | Absolute Bioavailability | COMPLETED | NCT01990443 |
| Reslizumab SC | Other | Phase PHASE1 | Absolute Bioavailability | COMPLETED | NCT01990443 |
| Reslizumab IV | Other | Phase PHASE1 | Absolute Bioavailability | COMPLETED | NCT01990443 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01578785 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01578785 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01578785 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01578785 |
| Placebo | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT01903824 |
| modafinil | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT01903824 |
| donepezil hydrochloride | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT01903824 |
| CEP-26401 | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT01903824 |
| placebo | Other | Phase PHASE3 | Chronic Migraine | TERMINATED | NCT01151787 |
| cyclobenzaprine hydrochloride | Other | Phase PHASE3 | Chronic Migraine | TERMINATED | NCT01151787 |
| placebo | Other | Phase PHASE3 | Chronic Migraine | TERMINATED | NCT01151787 |
| cyclobenzaprine hydrochloride | Other | Phase PHASE3 | Chronic Migraine | TERMINATED | NCT01151787 |
| Spiriva® Respimat® 5 mcg/day | Other | Phase PHASE1 | COPD | COMPLETED | NCT01785433 |
| SPIRIVA® HandiHaler® 18 mcg/day | Other | Phase PHASE1 | COPD | COMPLETED | NCT01785433 |
| Tiotropium HFA BAI 9.0 mcg | Other | Phase PHASE1 | COPD | COMPLETED | NCT01785433 |
| Tiotropium HFA BAI 4.5 mcg | Other | Phase PHASE1 | COPD | COMPLETED | NCT01785433 |
| CT-011 | Other | Phase PHASE1 | Chronic Hepatitis C | TERMINATED | NCT00962936 |
| CT-011 | Other | Phase PHASE1 | Chronic Hepatitis C | TERMINATED | NCT00962936 |
| CT-011 | Other | Phase PHASE1 | Chronic Hepatitis C | TERMINATED | NCT00962936 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | UNKNOWN | NCT02249663 |
| Dymista™ | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | UNKNOWN | NCT02249663 |
| Azelastine hydrochloride and Fluticasone propionate | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | UNKNOWN | NCT02249663 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01697956 |
| BDP | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01697956 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01697956 |
| BDP | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01697956 |
| Dexamethasone | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide phosphate | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Clofarabine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Bendamustine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Dexamethasone | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide phosphate | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Clofarabine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Bendamustine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Placebo | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT01240863 |
| Hydrocodone ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT01240863 |
| Placebo | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT01240863 |
| Hydrocodone ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT01240863 |
| Decitabine | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02141477 |
| Omacetaxine | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02141477 |
| mycophenolate mofetil (Cellcept) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| mycophenolate mofetil (Myfenax) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| mycophenolate mofetil (Cellcept) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| mycophenolate mofetil (Myfenax) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| Placebo | Other | Phase PHASE3 | Tourette Syndrome | COMPLETED | NCT03571256 |
| TEV-50717 | Other | Phase PHASE3 | Tourette Syndrome | COMPLETED | NCT03571256 |
| Placebo | Other | Phase PHASE3 | Tourette Syndrome | COMPLETED | NCT03571256 |
| TEV-50717 | Other | Phase PHASE3 | Tourette Syndrome | COMPLETED | NCT03571256 |
| Placebo | Other | Phase PHASE3 | Tourette Syndrome | TERMINATED | NCT03567291 |
| TEV-50717 | Other | Phase PHASE3 | Tourette Syndrome | TERMINATED | NCT03567291 |
| Placebo | Other | Phase PHASE2 | Tourette Syndrome | COMPLETED | NCT03452943 |
| TEV-50717 | Other | Phase PHASE2 | Tourette Syndrome | COMPLETED | NCT03452943 |
| Placebo | Other | Phase PHASE3 | Migraine Prophylaxis | COMPLETED | NCT03308968 |
| Fremanezumab | Other | Phase PHASE3 | Migraine Prophylaxis | COMPLETED | NCT03308968 |
| Placebo | Other | Phase PHASE3 | Migraine Prophylaxis | COMPLETED | NCT03308968 |
| Fremanezumab | Other | Phase PHASE3 | Migraine Prophylaxis | COMPLETED | NCT03308968 |
| Albuterol sulfate (ABS) | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03256695 |
| Albuterol sulfate (ABS) | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03256695 |
| Albuterol sulfate (ABS) | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03256695 |
| Fremanezumab | Other | Phase PHASE3 | Cluster Headache | TERMINATED | NCT03107052 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Fluticasone Propionate/Salmeterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Fluticasone Propionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Fluticasone Propionate/Salmeterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Fluticasone Propionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02980133 |
| Albuterol Sulfate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02969408 |
| Albuterol Sulfate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02969408 |
| Albuterol Sulfate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02969408 |
| Placebo | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Fremanezumab | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Placebo | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Fremanezumab | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Placebo | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Fremanezumab | Other | Phase PHASE3 | Chronic Cluster Headache | TERMINATED | NCT02964338 |
| Placebo | Other | Phase PHASE3 | Episodic Cluster Headache | TERMINATED | NCT02945046 |
| Fremanezumab | Other | Phase PHASE3 | Episodic Cluster Headache | TERMINATED | NCT02945046 |
| Placebo | Other | Phase PHASE4 | Asthma | TERMINATED | NCT02937168 |
| Fludeoxyglucose F 18 (FDG) | Other | Phase PHASE4 | Asthma | TERMINATED | NCT02937168 |
| Reslizumab | Other | Phase PHASE4 | Asthma | TERMINATED | NCT02937168 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | WITHDRAWN | NCT02769091 |
| TEV-45478 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | WITHDRAWN | NCT02769091 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | WITHDRAWN | NCT02769091 |
| TEV-45478 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | WITHDRAWN | NCT02769091 |
| Fluticasone propionate/salmeterol | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Fluticasone Propionate/Salmeterol MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Fluticasone Propionate MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Fluticasone propionate/salmeterol | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Fluticasone Propionate/Salmeterol MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Fluticasone Propionate MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT02680561 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04545385 |
| TEV-48574 | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04545385 |
| Paxil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Paroxetine HCl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Paxil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Paroxetine HCl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Paxil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Paroxetine HCl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841659 |
| Mobic® 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840879 |
| Meloxicam 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840879 |
| Mobic® 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840879 |
| Meloxicam 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840879 |
| Buspirone Hydrochloride 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840606 |
| BUSPAR® 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840606 |
| Buspirone Hydrochloride 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840606 |
| BUSPAR® 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840606 |
| Mobic® 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840476 |
| Meloxicam 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840476 |
| Mobic® 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840476 |
| Meloxicam 15 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840476 |
| BIAXIN® XL 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840411 |
| Clarithromycin ER 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840411 |
| BIAXIN® XL 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840411 |
| Clarithromycin ER 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840411 |
| Buspirone Hydrochloride 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840398 |
| BUSPAR® 30 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840398 |
| BIAXIN® XL 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840216 |
| Clarithromycin ER 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840216 |
| Mesalamine 4 gm/60 mL Rectal Enema | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840203 |
| Rowasa® 4 gm/60 mL Rectal Enema | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840203 |
| Mesalamine 4 gm/60 mL Rectal Enema | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840203 |
| Rowasa® 4 gm/60 mL Rectal Enema | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840203 |
| Pletal® 100 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838630 |
| Cilostazol 100 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838630 |
| Pletal® 100 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838630 |
| Cilostazol 100 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838630 |
| Lamictal® 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamotrigine 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamictal® 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamotrigine 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamictal® 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamotrigine 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838279 |
| Lamictal® 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838136 |
| Lamotrigine 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838136 |
| Lamictal® 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838136 |
| Lamotrigine 25 mg Chewable Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00838136 |
| Sertraline hydrochloride 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836849 |
| Zoloft® 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836849 |
| Sertraline hydrochloride 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836849 |
| Zoloft® 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836849 |
| Sertraline hydrochloride 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836667 |
| Zoloft® 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836667 |
| Sertraline hydrochloride 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836667 |
| Zoloft® 100 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836667 |
| Lotensin® 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836576 |
| Benazepril HCl 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836576 |
| Lotensin® 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836576 |
| Benazepril HCl 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836576 |
| Glucovance® 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836472 |
| Glyburide/Metformin 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836472 |
| Glucovance® 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836472 |
| Glyburide/Metformin 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836472 |
| Cleocin HCl 300 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836056 |
| Clindamycin 300 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836056 |
| Cleocin HCl 300 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836056 |
| Clindamycin 300 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836056 |
| Cleocin HCl 300 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836004 |
| Clindamycin 300 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836004 |
| Cleocin HCl 300 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836004 |
| Clindamycin 300 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836004 |
| Glucovance® 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835991 |
| Glyburide/Metformin 5 mg/500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835991 |
| PROSCAR® 5mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835796 |
| Finasteride 5 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835796 |
| Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| Mavik® 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840073 |
| Trandolapril 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840073 |
| Pletal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00839930 |
| Cilostazol 50 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00839930 |
| Pletal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00839930 |
| Cilostazol 50 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00839930 |
| BIAXIN® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836706 |
| clarithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836706 |
| BIAXIN® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836706 |
| clarithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836706 |
| Augmentin® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835705 |
| amoxicillin-clavulanic acid | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835705 |
| Augmentin® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835705 |
| amoxicillin-clavulanic acid | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835705 |
| Biaxin® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835692 |
| Clarithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835692 |
| Biaxin® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835692 |
| Clarithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835692 |
| CEFZIL® for Oral Suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835614 |
| Cefprozil for oral suspension 250 mg/5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835614 |
| CEFZIL® for Oral Suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835614 |
| Cefprozil for oral suspension 250 mg/5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835614 |
| PROTONIX® 40 mg delayed-release tablets. | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835588 |
| Pantoprazole Sodium 40 mg delayed-release tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835588 |
| REMERON SolTab® 15 mg Orally Disintegrating Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835575 |
| Mirtazapine 15 mg (Orally Disintegrating) Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835575 |
| REMERON SolTab® 15 mg Orally Disintegrating Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835575 |
| Mirtazapine 15 mg (Orally Disintegrating) Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835575 |
| OMNICEF® for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835549 |
| Cefdinir for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835549 |
| OMNICEF® for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835549 |
| Cefdinir for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835549 |
| COPEGUS™ 200 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835536 |
| Ribavirin 200 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835536 |
| COPEGUS™ 200 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835536 |
| Ribavirin 200 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835536 |
| OMNICEF® 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835484 |
| Cefdinir Capsules 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835484 |
| OMNICEF® 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835484 |
| Cefdinir Capsules 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835484 |
| CEFZIL® for Oral Suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835354 |
| Cefprozil for oral suspension 250 mg/5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835354 |
| CEFZIL® for Oral Suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835354 |
| Cefprozil for oral suspension 250 mg/5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835354 |
| AMARYL® 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835172 |
| Glimepiride 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835172 |
| COPEGUS™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| Ribavirin 200 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| COPEGUS™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| Ribavirin 200 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| COPEGUS™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| Ribavirin 200 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835146 |
| UNIRETIC® 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835042 |
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835042 |
| Mindfulness based stress reduction (MBSR) | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01419301 |
| Mindfulness based stress reduction (MBSR) | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01419301 |
| Mindfulness based stress reduction (MBSR) | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01419301 |
| Filgrastim | Other | Phase PHASE2 | Solid Tumors | WITHDRAWN | NCT01940601 |
| Balugrastim | Other | Phase PHASE2 | Solid Tumors | WITHDRAWN | NCT01940601 |
| Filgrastim | Other | Phase PHASE2 | Solid Tumors | WITHDRAWN | NCT01940601 |
| Balugrastim | Other | Phase PHASE2 | Solid Tumors | WITHDRAWN | NCT01940601 |
| omacetaxine mepesuccinate | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT01844869 |
| omacetaxine mepesuccinate | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT01844869 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01382342 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01382342 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01382342 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01382342 |
| Placebo nasal aerosol | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| BDP HFA | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| Placebo nasal aerosol | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| BDP HFA | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| Placebo nasal aerosol | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| BDP HFA | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01307319 |
| LBR-101 SC | Other | Phase PHASE1 | Bioavailability and Pharmacokinetics | COMPLETED | NCT01991509 |
| LBR-101 IV | Other | Phase PHASE1 | Bioavailability and Pharmacokinetics | COMPLETED | NCT01991509 |
| LBR-101 SC | Other | Phase PHASE1 | Bioavailability and Pharmacokinetics | COMPLETED | NCT01991509 |
| LBR-101 IV | Other | Phase PHASE1 | Bioavailability and Pharmacokinetics | COMPLETED | NCT01991509 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01454791 |
| diclofenac sodium topical gel | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01454791 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01454791 |
| diclofenac sodium topical gel | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01454791 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| Laquinimod | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| Laquinimod | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| placebo | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| Laquinimod | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00737932 |
| Music | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02207387 |
| Exercise | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02207387 |
| Azilect | Other | Approved | Parkinson's Disease | UNKNOWN | NCT02207387 |
| Albuterol Spiromax | Other | Phase PHASE3 | Asthma | TERMINATED | NCT01218009 |
| Placebo Spiromax | Other | Phase PHASE3 | Asthma | TERMINATED | NCT01218009 |
| Albuterol Spiromax | Other | Phase PHASE3 | Asthma | TERMINATED | NCT01218009 |
| Placebo Spiromax | Other | Phase PHASE3 | Asthma | TERMINATED | NCT01218009 |
| Albuterol Spiromax® | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01857323 |
| Placebo Spiromax | Other | Phase PHASE3 | Exercise-Induced Bronchoconstriction (EIB) | COMPLETED | NCT01791972 |
| Albuterol Spiromax | Other | Phase PHASE3 | Exercise-Induced Bronchoconstriction (EIB) | COMPLETED | NCT01791972 |
| Placebo Spiromax | Other | Phase PHASE3 | Exercise-Induced Bronchoconstriction (EIB) | COMPLETED | NCT01791972 |
| Albuterol Spiromax | Other | Phase PHASE3 | Exercise-Induced Bronchoconstriction (EIB) | COMPLETED | NCT01791972 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01747629 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01747629 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01747629 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01747629 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01424813 |
| infusion of MYOCET | Other | Phase PHASE2 | Cerebral Lymphoma B Cell Refractory | TERMINATED | NCT01848652 |
| infusion of MYOCET | Other | Phase PHASE2 | Cerebral Lymphoma B Cell Refractory | TERMINATED | NCT01848652 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01698320 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01698320 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01698320 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01698320 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01783548 |
| BDP Nasal Aerosol | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01783548 |
| Placebo | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01783548 |
| BDP Nasal Aerosol | Other | Phase PHASE3 | Allergic Rhinitis | COMPLETED | NCT01783548 |
| Placebo | Other | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01887366 |
| TV-1380 300 mg | Other | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01887366 |
| TV-1380 150 mg | Other | Phase PHASE2 | Cocaine Addiction | COMPLETED | NCT01887366 |
| Bupropion HCl | Other | Phase PHASE1 | Depressive Disorder | TERMINATED | NCT01046214 |
| Bupropion HCl | Other | Phase PHASE1 | Depressive Disorder | TERMINATED | NCT01046214 |
| Bupropion HCl | Other | Phase PHASE1 | Depressive Disorder | TERMINATED | NCT01046214 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01006655 |
| Beclomethasone dipropionate HFA | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01006655 |
| placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01006655 |
| Beclomethasone dipropionate HFA | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01006655 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01497652 |
| Rasagiline/Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01497652 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01497652 |
| Rasagiline/Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01497652 |
| GA 40 mg/mL | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01874145 |
| GA 20 mg/mL | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01874145 |
| GA 40 mg/mL | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01874145 |
| GA 20 mg/mL | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01874145 |
| Placebo | Other | Phase PHASE4 | Sleep Disturbances | COMPLETED | NCT01442610 |
| Rasagiline | Other | Phase PHASE4 | Sleep Disturbances | COMPLETED | NCT01442610 |
| Placebo | Other | Phase PHASE4 | Sleep Disturbances | COMPLETED | NCT01442610 |
| Rasagiline | Other | Phase PHASE4 | Sleep Disturbances | COMPLETED | NCT01442610 |
| background treatment | Drug | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| Carboplatin | Other | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| background treatment | Drug | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| Carboplatin | Other | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| background treatment | Drug | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| Carboplatin | Other | Phase PHASE2 | Tubular Breast Cancer Stage II | COMPLETED | NCT01426880 |
| Placebo | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| D-cycloserine | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| Ketamine | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| Placebo | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| D-cycloserine | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| Ketamine | Other | Phase PHASE4 | Treatment Resistant Depression | UNKNOWN | NCT02772211 |
| adjuvant TMZ 200mg | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| temozolomide(TMZ) 75mg | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| Radiation Therapy (RT) 5 days a week + | Drug | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| Talampanel | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| adjuvant TMZ 200mg | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| temozolomide(TMZ) 75mg | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| Radiation Therapy (RT) 5 days a week + | Drug | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| Talampanel | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00267592 |
| Bendamustine | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT01088984 |
| Training on SYMBICORT Turbohaler followed by BF Spiromax | Other | Approved | Asthma | COMPLETED | NCT02570425 |
| Training on BF Spiromax followed by SYMBICORT Turbohaler | Other | Approved | Asthma | COMPLETED | NCT02570425 |
| Training on SYMBICORT Turbohaler followed by BF Spiromax | Other | Approved | Asthma | COMPLETED | NCT02570425 |
| Training on BF Spiromax followed by SYMBICORT Turbohaler | Other | Approved | Asthma | COMPLETED | NCT02570425 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | TERMINATED | NCT01290887 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | TERMINATED | NCT01290887 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01270464 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01270464 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01508936 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01508936 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01508936 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01508936 |
| methylprednisolone | Other | Phase PHASE2 | Multiple Sclerosis (MS) | WITHDRAWN | NCT01710228 |
| Group AD Anti-PD + Antidepressant | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Group R Rasagiline | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Group R+AD Rasagiline + Antidepressant | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Group AD Anti-PD + Antidepressant | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Group R Rasagiline | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Group R+AD Rasagiline + Antidepressant | Other | Preclinical | Serotonin Syndrome | COMPLETED | NCT00955604 |
| Warm compress prior to injection of glatiramer acetate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00239993 |
| glatiramer acetate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00239993 |
| Warm compress prior to injection of glatiramer acetate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00239993 |
| glatiramer acetate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00239993 |
| Experimental Glatiramer Acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00947752 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00947752 |
| Armodafinil | Other | Phase PHASE4 | Menopause | COMPLETED | NCT01460628 |
| Dexamethasone | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide phosphate | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Etoposide | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Clofarabine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Bendamustine | Other | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT01900509 |
| Placebo | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02611804 |
| Diclofenac sodium | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02611804 |
| Placebo | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02611804 |
| Diclofenac sodium | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT02611804 |
| Placebo | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01789970 |
| Hydrocodone ER | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01789970 |
| Placebo | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01789970 |
| Hydrocodone ER | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01789970 |
| Placebo MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| albuterol/salbutamol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Flovent Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Placebo MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| albuterol/salbutamol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Flovent Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01479621 |
| Hydrocodone ER | Other | Phase PHASE3 | Chronic Pain | COMPLETED | NCT01223365 |
| Albuterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Advair Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| FS MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Albuterol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Advair Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| FS MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01772368 |
| Reslizumab | Other | Phase PHASE2 | Asthma | UNKNOWN | NCT02947945 |
| Reslizumab | Other | Phase PHASE2 | Asthma | UNKNOWN | NCT02947945 |
| Placebo | Other | Phase PHASE3 | Chorea | COMPLETED | NCT01795859 |
| SD-809 | Other | Phase PHASE3 | Chorea | COMPLETED | NCT01795859 |
| Placebo | Other | Phase PHASE3 | Chorea | COMPLETED | NCT01795859 |
| SD-809 | Other | Phase PHASE3 | Chorea | COMPLETED | NCT01795859 |
| Immediate postpartum placement of IUD | Other | Preclinical | Contraception | COMPLETED | NCT02024672 |
| Immediate postpartum placement of IUD | Other | Preclinical | Contraception | COMPLETED | NCT02024672 |
| Immediate postpartum placement of IUD | Other | Preclinical | Contraception | COMPLETED | NCT02024672 |
| Psyllium Orange | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| Metamucil Orange | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| Volcolon sugar free | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| Psyllium Orange | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| Metamucil Orange | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| Volcolon sugar free | Other | Approved | Constipation | COMPLETED | NCT02867917 |
| doxorubicin | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| cyclophosphamide | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| prednisone | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| vincristine | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| rituximab | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| bendamustine | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| doxorubicin | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| cyclophosphamide | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| prednisone | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| vincristine | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| rituximab | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| bendamustine | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00877006 |
| placebo | Other | Phase PHASE3 | Optic Neuritis | COMPLETED | NCT00856635 |
| Glatiramer Acetate | Other | Phase PHASE3 | Optic Neuritis | COMPLETED | NCT00856635 |
| Decitabine | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02141477 |
| Omacetaxine | Other | Phase PHASE1 | Leukemia | TERMINATED | NCT02141477 |
| Placebo | Other | Phase PHASE2 | Severe Persistent Asthma | COMPLETED | NCT02559791 |
| Reslizumab | Other | Phase PHASE2 | Severe Persistent Asthma | COMPLETED | NCT02559791 |
| Placebo | Other | Phase PHASE2 | Severe Persistent Asthma | COMPLETED | NCT02559791 |
| Reslizumab | Other | Phase PHASE2 | Severe Persistent Asthma | COMPLETED | NCT02559791 |
| Smoking | Other | Preclinical | Asthma | UNKNOWN | NCT02833727 |
| Smoking | Other | Preclinical | Asthma | UNKNOWN | NCT02833727 |
| albuterol/salbutamol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Flovent Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Placebo MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| albuterol/salbutamol | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Flovent Diskus | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Placebo MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Fp MDPI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01576718 |
| Reslizumab | Other | Phase PHASE2 | Severe Asthma | COMPLETED | NCT03074942 |
| Arsenic trioxide | Other | Phase PHASE1 | Chronic Myelogenous Leukemia | TERMINATED | NCT01397734 |
| Arsenic trioxide | Other | Phase PHASE1 | Chronic Myelogenous Leukemia | TERMINATED | NCT01397734 |
| Arsenic trioxide | Other | Phase PHASE1 | Chronic Myelogenous Leukemia | TERMINATED | NCT01397734 |
| mycophenolate mofetil (Cellcept) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| mycophenolate mofetil (Myfenax) | Other | Phase PHASE4 | Stable Renal Transplant Recipients | TERMINATED | NCT00991510 |
| Qvar® (beclometasone dipropionate HFA) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT01894048 |
| Omacetaxine | Other | Phase PHASE2 | Acute Myelogenous Leukemia (AML) | TERMINATED | NCT01873495 |
| Placebo | Other | Phase PHASE2 | Stroke | COMPLETED | NCT01896128 |
| Armodafinil | Other | Phase PHASE2 | Stroke | COMPLETED | NCT01896128 |
| Vehicle Lotion | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Sklice® (Ivermectin) Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Generic Ivermectin Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Vehicle Lotion | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Sklice® (Ivermectin) Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Generic Ivermectin Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Vehicle Lotion | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Sklice® (Ivermectin) Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Generic Ivermectin Lotion 0.5% | Other | Phase PHASE3 | Head Lice | COMPLETED | NCT03301649 |
| Vehicle Vaginal Cream | Other | Phase PHASE3 | Atrophic Vaginitis | COMPLETED | NCT03294538 |
| Estrace® Vaginal Cream USP, 0.01% | Other | Phase PHASE3 | Atrophic Vaginitis | COMPLETED | NCT03294538 |
| Generic Estradiol Vaginal Cream USP, 0.01% | Other | Phase PHASE3 | Atrophic Vaginitis | COMPLETED | NCT03294538 |
| Pravachol® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834847 |
| pravastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834847 |
| Buprenorphine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157169 |
| Buprenorphine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01157169 |
| Glatiramer acetate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00203021 |
| Glatiramer acetate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00203021 |
| Placebo | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT02215616 |
| Laquinimod | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT02215616 |
| Placebo | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT02215616 |
| Laquinimod | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT02215616 |
| Questionnaires | Other | Phase PHASE2 | Advanced Cancers | COMPLETED | NCT01856114 |
| Placebo Buccal Tablet | Other | Phase PHASE2 | Advanced Cancers | COMPLETED | NCT01856114 |
| Fentanyl Buccal Tablet | Other | Phase PHASE2 | Advanced Cancers | COMPLETED | NCT01856114 |
| 16 mg buprenorphine with 4 mg naloxone sublingual film | Other | Phase PHASE4 | Evaluation of QTc Interval | WITHDRAWN | NCT04088266 |
| 16 mg buprenorphine with 4 mg naloxone sublingual film | Other | Phase PHASE4 | Evaluation of QTc Interval | WITHDRAWN | NCT04088266 |
| Pravachol® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834379 |
| pravastatin sodium | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834379 |
| Placebo | Other | Phase PHASE4 | Menorrhagia | COMPLETED | NCT02519231 |
| Naproxen | Other | Phase PHASE4 | Menorrhagia | COMPLETED | NCT02519231 |
| Placebo | Other | Phase PHASE4 | Menorrhagia | COMPLETED | NCT02519231 |
| Naproxen | Other | Phase PHASE4 | Menorrhagia | COMPLETED | NCT02519231 |
| Immediate release morphine | Other | Phase PHASE2 | Cancer | COMPLETED | NCT04635852 |
| Fentanyl | Other | Phase PHASE2 | Cancer | COMPLETED | NCT04635852 |
| Immediate release morphine | Other | Phase PHASE2 | Cancer | COMPLETED | NCT04635852 |
| Fentanyl | Other | Phase PHASE2 | Cancer | COMPLETED | NCT04635852 |
| Vehicle of Test Product | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| Zyclara® | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| Imiquimod Cream, 3.75% | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| Vehicle of Test Product | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| Zyclara® | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| Imiquimod Cream, 3.75% | Other | Phase PHASE3 | Actinic Keratosis | COMPLETED | NCT01686152 |
| inhaled delta-8-THC 300mcg or 600mcg per dose | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00285051 |
| inhaled delta-8-THC 300mcg or 600mcg per dose | Other | Phase PHASE2 | Cancer | TERMINATED | NCT00285051 |
| Arsenic Trioxide | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT01470248 |
| Arsenic Trioxide | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT01470248 |
| Arsenic Trioxide | Other | Phase PHASE2 | Lung Cancer | COMPLETED | NCT01470248 |
| Copaxone | Other | Approved | Multiple Sclerosis | COMPLETED | NCT00937157 |
| Arsenic trioxide | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02190695 |
| Carboplatin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02190695 |
| Decitabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02190695 |
| Omacetaxine | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT02159872 |
| Omacetaxine | Other | Phase PHASE2 | Leukemia | COMPLETED | NCT02159872 |
| Placebo | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Rhofade Cream, 1% | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Oxymetazoline Hydrochloride | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Placebo | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Rhofade Cream, 1% | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Oxymetazoline Hydrochloride | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Placebo | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Rhofade Cream, 1% | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Oxymetazoline Hydrochloride | Other | Phase PHASE3 | Rosacea | COMPLETED | NCT03954444 |
| Omacetaxine mepesuccinate | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02440568 |
| Idarubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02440568 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02440568 |
| Placebo | Other | Phase PHASE4 | Depressive Symptoms | COMPLETED | NCT01055379 |
| Rasagiline | Other | Phase PHASE4 | Depressive Symptoms | COMPLETED | NCT01055379 |
| Placebo | Other | Phase PHASE4 | Depressive Symptoms | COMPLETED | NCT01055379 |
| Rasagiline | Other | Phase PHASE4 | Depressive Symptoms | COMPLETED | NCT01055379 |
| Placebo pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Flovent HFA pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Fluticasone propionate pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Placebo pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Flovent HFA pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Fluticasone propionate pressurized metered dose inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03879837 |
| Placebo Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03756883 |
| Fluticasone Propionate and Salmeterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03756883 |
| Placebo Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03756883 |
| Fluticasone Propionate and Salmeterol Inhalation Powder | Other | Phase PHASE3 | Asthma | COMPLETED | NCT03756883 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00509145 |
| Laquinimod | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00509145 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00509145 |
| Laquinimod | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00509145 |
| fremanezumab | Other | Phase PHASE2 | Interstitial Cystitis | WITHDRAWN | NCT04447729 |
| fremanezumab | Other | Phase PHASE2 | Interstitial Cystitis | WITHDRAWN | NCT04447729 |
| fremanezumab | Other | Phase PHASE2 | Interstitial Cystitis | WITHDRAWN | NCT04447729 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02638103 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02638103 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02638103 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02638103 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02629861 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02629861 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02629861 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02629861 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT02621931 |
| Beclomethasone dipropionate via 320 mcg MDI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| albuterol/salbutamol | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone dipropionate via 320 mcg BAI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Placebo | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone Dipropionate 640 | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone dipropionate via 320 mcg MDI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| albuterol/salbutamol | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone dipropionate via 320 mcg BAI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Placebo | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone Dipropionate 640 | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone dipropionate via 320 mcg MDI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| albuterol/salbutamol | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone dipropionate via 320 mcg BAI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Placebo | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Beclomethasone Dipropionate 640 | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02513160 |
| Oral Corticosteroid (OCS) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Non-Oral Corticosteroid (non-OCS) Asthma Medication | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Reslizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Oral Corticosteroid (OCS) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Non-Oral Corticosteroid (non-OCS) Asthma Medication | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Reslizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Oral Corticosteroid (OCS) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Non-Oral Corticosteroid (non-OCS) Asthma Medication | Drug | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Reslizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02501629 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02452190 |
| Reslizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02452190 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02452190 |
| Reslizumab | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02452190 |
| Treatment D: Advair | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment C Flovent | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment B: FS MDPI | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment A: Fp MDPI | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment D: Advair | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment C Flovent | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment B: FS MDPI | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Treatment A: Fp MDPI | Drug | Phase PHASE1 | Asthma | COMPLETED | NCT02437604 |
| Placebo | Other | Phase PHASE2 | Postherpetic Neuralgia | COMPLETED | NCT02365636 |
| TV-45070 | Other | Phase PHASE2 | Postherpetic Neuralgia | COMPLETED | NCT02365636 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| TV48108 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| TV48108 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| TV48108 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | TERMINATED | NCT02315144 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD | TERMINATED | NCT02315131 |
| TV46017 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD | TERMINATED | NCT02315131 |
| Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD | TERMINATED | NCT02315131 |
| TV46017 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD | TERMINATED | NCT02315131 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02215941 |
| TV-45070 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02215941 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02215941 |
| TV-45070 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02215941 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| Tiotropium 18 mcg Capsule | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| Tiotropium HFA BAI 5 mcg | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| Tiotropium 18 mcg Capsule | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| Tiotropium HFA BAI 5 mcg | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | WITHDRAWN | NCT02203474 |
| albuterol/salbutamol HFA | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| ADVAIR DISKUS | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| FLOVENT HFA | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| FS MDPI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| Fp MDPI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| albuterol/salbutamol HFA | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| ADVAIR DISKUS | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| FLOVENT HFA | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| FS MDPI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| Fp MDPI | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02175771 |
| Albuterol/salmeterol HFA MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02141854 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02141854 |
| Fp MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02141854 |
| FS MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02141854 |
| ProAir HFA inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| ProAir HFA inhaler | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| Albuterol MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02126839 |
| Progesterone vaginal ring, | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02092571 |
| Progesterone vaginal ring, | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02092571 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02085863 |
| laquinimod | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02085863 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02085863 |
| laquinimod | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02085863 |
| Omacetaxine mepesuccinate | Other | Phase PHASE1 | Chronic Myeloid Leukemia | TERMINATED | NCT02078960 |
| Omacetaxine mepesuccinate | Other | Phase PHASE1 | Chronic Myeloid Leukemia | TERMINATED | NCT02078960 |
| Omacetaxine mepesuccinate | Other | Phase PHASE1 | Chronic Myeloid Leukemia | TERMINATED | NCT02078960 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis of the Knee | COMPLETED | NCT02068599 |
| TV-45070 | Other | Phase PHASE2 | Osteoarthritis of the Knee | COMPLETED | NCT02068599 |
| albuterol/salbutamol | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| Placebo breath-actuated inhaler | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| Beclomethasone dipropionate breath-actuated inhaler | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| albuterol/salbutamol | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| Placebo breath-actuated inhaler | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| Beclomethasone dipropionate breath-actuated inhaler | Other | Phase PHASE3 | Persistent Asthma | COMPLETED | NCT02040779 |
| Placebo MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| albuterol/salbutamol 90 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Placebo BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Placebo MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| albuterol/salbutamol 90 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Placebo BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Placebo MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate MDI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| albuterol/salbutamol 90 mcg | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Placebo BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Beclomethasone dipropionate BAI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02040766 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02031640 |
| Beclomethasone dipropionate MDI | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02030457 |
| Beclomethasone dipropionate BAI | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02030457 |
| Beclomethasone dipropionate MDI | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02030457 |
| Beclomethasone dipropionate BAI | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02030457 |
| Avonex® | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01975298 |
| Laquinimod | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01975298 |
| Placebo | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01922739 |
| Hydrocodone ER | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT01922739 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01723228 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01723228 |
| Placebo | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01723228 |
| Rasagiline | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01723228 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01707992 |
| Laquinimod | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01707992 |
| Armodafinil | Other | Phase PHASE1 | Narcolepsy | COMPLETED | NCT01624480 |
| Armodafinil | Other | Phase PHASE1 | Narcolepsy | COMPLETED | NCT01624480 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01287039 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01287039 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01287039 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01287039 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01285323 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01285323 |
| Placebo | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01285323 |
| Reslizumab | Other | Phase PHASE3 | Eosinophilic Asthma | COMPLETED | NCT01285323 |
| DR-102 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01178125 |
| DR-102 | Other | Phase PHASE3 | Contraception | COMPLETED | NCT01178125 |
| Placebo Inhaler | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01058863 |
| ProAir® HFA | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01058863 |
| Albuterol Spiromax® | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01058863 |
| ADASUVE® | Other | Phase PHASE1 | BiPolar | COMPLETED | NCT02184767 |
| ADASUVE® | Other | Phase PHASE1 | BiPolar | COMPLETED | NCT02184767 |
| ADASUVE® | Other | Phase PHASE1 | BiPolar | COMPLETED | NCT02184767 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| Fp MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| FS MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| albuterol/salbutamol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| Placebo MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| Fp MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| FS MDPI | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02139644 |
| CEP-37440 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01922752 |
| CEP-37440 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01922752 |
| Proventil® HFA | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Albuterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Proventil® HFA | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Albuterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00577655 |
| Nebulized IVX-0142 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00232999 |
| Nebulized IVX-0142 | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00232999 |
| Omacetaxine mepesuccinate | Other | Phase PHASE2 | Chronic Myeloid Leukemia | COMPLETED | NCT00375219 |
| Kariva® | Other | Phase PHASE3 | Healthy | COMPLETED | NCT00544882 |
| Mircette® | Other | Phase PHASE3 | Healthy | COMPLETED | NCT00544882 |
| DR-1021 | Other | Phase PHASE3 | Healthy | COMPLETED | NCT00544882 |
| beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00094016 |
| beclomethasone dipropionate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00094016 |
| placebo aerosol by HFA | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| albuterol aerosol by HFA BOI | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| albuterol aerosol by HFA MDI | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| placebo aerosol by HFA | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| albuterol aerosol by HFA BOI | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| albuterol aerosol by HFA MDI | Other | Phase PHASE3 | Exercise-induced Bronchospasm | COMPLETED | NCT00085774 |
| Flovent Diskus | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Qvar | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Flovent Diskus | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Qvar | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Flovent Diskus | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Qvar | Other | Phase PHASE4 | Asthma | TERMINATED | NCT00071552 |
| Albuterol HFA-MDI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00054964 |
| Albuterol HFA-BOI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00054964 |
| Albuterol HFA-MDI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00054964 |
| Albuterol HFA-BOI | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00054964 |
| Servent Diskus | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| Advair | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| QVAR | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| Servent Diskus | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| Advair | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| QVAR | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00250341 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01024608 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | COMPLETED | NCT01024608 |
| Placebo Nasal Aerosol | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00988247 |
| Beclomethasone dipropionate | Other | Phase PHASE3 | Rhinitis, Allergic, Perennial | COMPLETED | NCT00988247 |
| desogestrel/ethinyl estradiol | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT01388491 |
| desogestrel/ethinyl estradiol and ethinyl estradiol | Other | Phase PHASE2 | Hemostasis | COMPLETED | NCT01388491 |
| 28-day levonorgestrel oral contraceptive | Other | Phase PHASE1 | Follicle Development | COMPLETED | NCT01291004 |
| 28-day drospirenone oral contraceptive | Other | Phase PHASE1 | Follicle Development | COMPLETED | NCT01291004 |
| Desogestrel/ethinyl estradiol and ethinyl estradiol | Other | Phase PHASE1 | Follicle Development | COMPLETED | NCT01291004 |
| Bronchodilator | Other | Phase PHASE2 | Asthma | COMPLETED | NCT00112411 |
| beclomethasone dipropionate (QVAR) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00109668 |
| beclomethasone dipropionate (QVAR) | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00109668 |
| etiprednol dicloacetate | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00035503 |
| etiprednol dicloacetate | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00035503 |
| Copaxone® | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02499900 |
| Copaxone® | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02499900 |
| Placebo | Other | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT02021773 |
| LBR-101 Low Dose | Other | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT02021773 |
| LBR-101 High Dose | Other | Phase PHASE2 | Chronic Migraine | COMPLETED | NCT02021773 |
| Placebo | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01067521 |
| Glatiramer acetate (GA) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01067521 |
| Placebo | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01067521 |
| Glatiramer acetate (GA) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01067521 |
| Laquinimod | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | TERMINATED | NCT01047319 |
| Laquinimod | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | TERMINATED | NCT01047319 |
| Laquinimod | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | TERMINATED | NCT00988052 |
| Laquinimod | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | TERMINATED | NCT00988052 |
| dGH | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| TV-1106 | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| dGH | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| TV-1106 | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| dGH | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| TV-1106 | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410356 |
| tbo-filgrastim | Other | Phase PHASE2 | Neutropenia | COMPLETED | NCT02190721 |
| tbo-filgrastim | Other | Phase PHASE2 | Neutropenia | COMPLETED | NCT02190721 |
| tbo-filgrastim | Other | Phase PHASE2 | Neutropenia | COMPLETED | NCT02190721 |
| Recombinant human growth hormone | Other | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01811576 |
| TV-1106 | Other | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01811576 |
| Recombinant human growth hormone | Other | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01811576 |
| TV-1106 | Other | Phase PHASE2 | Growth Hormone Deficiency | COMPLETED | NCT01811576 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 3 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 2 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 1 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 3 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 2 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 1 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 3 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 2 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| TEV-48125 - 1 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02673567 |
| Omacetaxine mepesuccinate | Other | Phase PHASE2 | Chronic Myeloid Leukemia | COMPLETED | NCT00462943 |
| Omacetaxine mepesuccinate | Other | Phase PHASE2 | Chronic Myeloid Leukemia | COMPLETED | NCT00462943 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410343 |
| TV-1106 | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410343 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410343 |
| TV-1106 | Other | Phase PHASE3 | Growth Hormone Deficiency | TERMINATED | NCT02410343 |
| Placebo | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| LBR-101 Low Dose | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| LBR-101 High Dose | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| Placebo | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| LBR-101 Low Dose | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| LBR-101 High Dose | Other | Phase PHASE2 | Episodic Migraine Headache | COMPLETED | NCT02025556 |
| TV-46046 Placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| Depo-subQ 104 | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| TV-46046 | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| TV-46046 Placebo | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| Depo-subQ 104 | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| TV-46046 | Other | Phase PHASE1 | Contraception | COMPLETED | NCT03700658 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| ProAir HFA | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| Albuterol Spiromax | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| Placebo | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| ProAir HFA | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| Albuterol Spiromax | Other | Phase PHASE2 | Asthma | COMPLETED | NCT01899144 |
| Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01056159 |
| Albuterol dry powder inhaler | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01056159 |
| Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01056159 |
| Albuterol dry powder inhaler | Other | Phase PHASE1 | Asthma | COMPLETED | NCT01056159 |
| Methylprednisolone | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Prednisolone/Prednisone | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Laquinimod | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Methylprednisolone | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Prednisolone/Prednisone | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Laquinimod | Other | Phase PHASE2 | Lupus Nephritis | COMPLETED | NCT01085097 |
| Laquinimod | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02284568 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02284568 |
| Laquinimod | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02284568 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02284568 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| TV-46763 | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| TV-46763 | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| TV-46763 | Other | Phase PHASE3 | Pain | COMPLETED | NCT02487108 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00308685 |
| Albuterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00308685 |
| Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00308685 |
| Albuterol | Other | Phase PHASE3 | Asthma | COMPLETED | NCT00308685 |
| Avonex® | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00605215 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00605215 |
| Laquinimod | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00605215 |
| pegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| lipegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| pegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| lipegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| pegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| lipegfilgrastim | Other | Phase PHASE3 | Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | COMPLETED | NCT02044276 |
| Placebo | Other | Phase PHASE2 | Lupus Arthritis | COMPLETED | NCT01085084 |
| Laquinimod | Other | Phase PHASE2 | Lupus Arthritis | COMPLETED | NCT01085084 |
| Placebo | Other | Phase PHASE2 | Lupus Arthritis | COMPLETED | NCT01085084 |
| Laquinimod | Other | Phase PHASE2 | Lupus Arthritis | COMPLETED | NCT01085084 |
| Albuterol-HFA-BAI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00530062 |
| Albuterol-HFA-MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00530062 |
| Albuterol-HFA-BAI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00530062 |
| Albuterol-HFA-MDI | Other | Phase PHASE4 | Asthma | COMPLETED | NCT00530062 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03893825 |
| Placebo | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Fremanezumab | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Placebo | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Fremanezumab | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Placebo | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Fremanezumab | Other | Phase PHASE2 | Post-Traumatic Headache | COMPLETED | NCT03347188 |
| Tbo-filgrastim | Other | Phase PHASE3 | Healthy Participants | TERMINATED | NCT03029000 |
| reslizumab | Other | Phase PHASE3 | Eosinophils, Asthma | TERMINATED | NCT03052725 |
| reslizumab | Other | Phase PHASE3 | Eosinophils, Asthma | TERMINATED | NCT03052725 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| Placebo | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| TV-46000 | Other | Phase PHASE3 | Schizophrenia | COMPLETED | NCT03503318 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04545385 |
| TEV-48574 | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04545385 |
| Standard of Care Rescue Medication | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Standard of Care Asthma Medication | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Fluticasone propionate/salmeterol (FS) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Standard of Care Rescue Medication | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Standard of Care Asthma Medication | Drug | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Fluticasone propionate/salmeterol (FS) | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04677959 |
| Chemotherapy | Drug | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Pegfilgrastim | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Neugranin | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Chemotherapy | Drug | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Pegfilgrastim | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Neugranin | Other | Phase PHASE3 | Chemotherapy-induced Neutropenia | COMPLETED | NCT01126190 |
| Placebo | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Fremanezumab | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Placebo | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Fremanezumab | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Placebo | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Fremanezumab | Other | Phase PHASE2 | Fibromyalgia | TERMINATED | NCT03965091 |
| Bradykinesia subscale of UPDRS Motor Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| Bradykinesia UPDRS Motor Full Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| Bradykinesia subscale of UPDRS Motor Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| Bradykinesia UPDRS Motor Full Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| Bradykinesia subscale of UPDRS Motor Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| Bradykinesia UPDRS Motor Full Examination | Other | Preclinical | Parkinson's Disease | COMPLETED | NCT00932581 |
| tDCS | Other | Approved | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02266121 |
| Lotensin® 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836537 |
| Benazepril HCl 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836537 |
| Lotensin® 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836537 |
| Benazepril HCl 40 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836537 |
| BeEAM | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02416206 |
| BeEAM | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02416206 |
| Bendamustine hydrochloride | Other | Phase PHASE3 | Non-Hodgkin Lymphoma | COMPLETED | NCT01596621 |
| Bendamustine hydrochloride | Other | Phase PHASE3 | Non-Hodgkin Lymphoma | COMPLETED | NCT01596621 |
| Lamisil® 250 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833664 |
| Terbinafine HCl 250mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833664 |
| Lamisil® 250 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833664 |
| Terbinafine HCl 250mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833664 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| TEV-53275 Dose B | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| TEV-53275 Dose A | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| Placebo | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| TEV-53275 Dose B | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| TEV-53275 Dose A | Other | Phase PHASE2 | Asthma | TERMINATED | NCT04847674 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Flonase® | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Fluticasone propionate | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Placebo | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Flonase® | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Fluticasone propionate | Other | Phase PHASE3 | Seasonal Allergic Rhinitis | TERMINATED | NCT02246920 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| CEP-18770 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| CEP-18770 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01348919 |
| topical placebo cream with no active ingredients | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| 1% Steroid Cream | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| AGEE cream | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| topical placebo cream with no active ingredients | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| 1% Steroid Cream | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| AGEE cream | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT00988988 |
| Placebo | Other | Phase PHASE3 | Huntington's Disease | COMPLETED | NCT00665223 |
| ACR16 | Other | Phase PHASE3 | Huntington's Disease | COMPLETED | NCT00665223 |
| Placebo | Other | Phase PHASE3 | Huntington's Disease | COMPLETED | NCT00665223 |
| ACR16 | Other | Phase PHASE3 | Huntington's Disease | COMPLETED | NCT00665223 |
| Placebo | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT00724048 |
| ACR16 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT00724048 |
| Placebo | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT00724048 |
| ACR16 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT00724048 |
| Placebo | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | COMPLETED | NCT03813238 |
| TEV-50717 | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | COMPLETED | NCT03813238 |
| Placebo | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | COMPLETED | NCT03813238 |
| TEV-50717 | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | COMPLETED | NCT03813238 |
| Placebo | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Fremanezumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Placebo | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Fremanezumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Placebo | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Fremanezumab | Other | Phase PHASE4 | Migraine | COMPLETED | NCT04041284 |
| Protocol Intervention Group | Other | Approved | Huntington Disease | COMPLETED | NCT03417583 |
| Protocol Intervention Group | Other | Approved | Huntington Disease | COMPLETED | NCT03417583 |
| Protocol Intervention Group | Other | Approved | Huntington Disease | COMPLETED | NCT03417583 |
| Digihaler Albuterol Device by TEVA | Device | Approved | Asthma in Children | COMPLETED | NCT04896645 |
| Digihaler Albuterol Device by TEVA | Device | Approved | Asthma in Children | COMPLETED | NCT04896645 |
| SPIROMAX Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| SYMBICORT placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| SYMBICORT® TURBOHALER® | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| Budesonide/Formoterol SPIROMAX® | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| SPIROMAX Placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| SYMBICORT placebo | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| SYMBICORT® TURBOHALER® | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| Budesonide/Formoterol SPIROMAX® | Other | Phase PHASE3 | Asthma | COMPLETED | NCT01803555 |
| anti-myelin oligodendrocyte glycoprotein | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT03087136 |
| anti-aquaporin-4 antibody | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT03087136 |
| anti-myelin oligodendrocyte glycoprotein | Other | Preclinical | Multiple Sclerosis | UNKNOWN | NCT03087136 |
| anti-aquaporin-4 antibody | Other | Preclinical | Multiple Sclerosis | UNKNOWN | NCT03087136 |
| Albuterol eMDPI DS | Other | Approved | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT05241288 |
| CEP-9722 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT01311713 |
| CEP-9722 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT01311713 |
| TV-46046 - 200 mg/mL | Other | Phase PHASE1 | Pregnancy | COMPLETED | NCT02817464 |
| TV-46046 - 400 mg/mL | Other | Phase PHASE1 | Pregnancy | COMPLETED | NCT02817464 |
| TV-46046 - 200 mg/mL | Other | Phase PHASE1 | Pregnancy | COMPLETED | NCT02817464 |
| TV-46046 - 400 mg/mL | Other | Phase PHASE1 | Pregnancy | COMPLETED | NCT02817464 |
| Depo-subQ Provera | Other | Phase PHASE1 | Contraception | COMPLETED | NCT04682353 |
| TV-46046 | Other | Phase PHASE1 | Contraception | COMPLETED | NCT04682353 |
| SYMBICORT TURBOHALER budesonide and formoterol fumarate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02062463 |
| Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02062463 |
| SYMBICORT TURBOHALER budesonide and formoterol fumarate | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02062463 |
| Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX | Other | Phase PHASE3 | Asthma | COMPLETED | NCT02062463 |
| Chemotherapy Regimen | Drug | Phase PHASE2 | Chemotherapy-induced Neutropenia | COMPLETED | NCT00837265 |
| Pegfilgrastim | Other | Phase PHASE2 | Chemotherapy-induced Neutropenia | COMPLETED | NCT00837265 |
| Balugrastim | Other | Phase PHASE2 | Chemotherapy-induced Neutropenia | COMPLETED | NCT00837265 |
| Placebo | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Imvexxy | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Estradiol | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Placebo | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Imvexxy | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Estradiol | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Placebo | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Imvexxy | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Estradiol | Other | Phase PHASE3 | Dyspareunia | COMPLETED | NCT05617820 |
| Prolia® | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT04729621 |
| TVB-009 | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT04729621 |
| Prolia® | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT04729621 |
| TVB-009 | Other | Phase PHASE3 | Osteoporosis, Postmenopausal | COMPLETED | NCT04729621 |
| TEV-50717 | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | TERMINATED | NCT04200352 |
| TEV-50717 | Other | Phase PHASE3 | Cerebral Palsy, Dyskinetic | TERMINATED | NCT04200352 |
| PROSCAR® 5mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835796 |
| Finasteride 5 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835796 |
| PROSCAR® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835666 |
| Finasteride 5 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835666 |
| Lamictal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| Lamotrigine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| Lamictal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| Lamotrigine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| Lamictal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| Lamotrigine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835263 |
| DURICEF® capsules 500 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835081 |
| Cefadroxil 500 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835081 |
| DURICEF® capsules 500 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835081 |
| Cefadroxil 500 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835081 |
| Effexor® 25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834964 |
| Venlafaxine 25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834964 |
| COREG® 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834873 |
| Carvedilol 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834873 |
| COREG® 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834873 |
| Carvedilol 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834873 |
| COREG® 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834795 |
| Carvedilol 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834795 |
| COREG® 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834795 |
| Carvedilol 25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834795 |
| Zithromax® 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Azithromycin 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Zithromax® 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Azithromycin 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Zithromax® 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Azithromycin 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834756 |
| Metformin ER 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834743 |
| Glucophage® XR 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834743 |
| Metformin ER 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834743 |
| Glucophage® XR 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834743 |
| Kytril® 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834717 |
| Granisetron hydrochloride 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834717 |
| Kytril® 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834717 |
| Granisetron hydrochloride 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834717 |
| Metformin ER 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834613 |
| Glucophage® XR 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834613 |
| Metformin ER 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834613 |
| Glucophage® XR 750 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834613 |
| Lamictal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834561 |
| Lamotrigine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834561 |
| Lamictal® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834561 |
| Lamotrigine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834561 |
| Kytril® 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Granisetron hydrochloride 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Kytril® 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Granisetron hydrochloride 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Kytril® 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Granisetron hydrochloride 1 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834522 |
| Leflunomide 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834405 |
| ARAVA® 20 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834405 |
| AMARYL® 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834340 |
| Glimepiride 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834340 |
| AMARYL® 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834340 |
| Glimepiride 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834340 |
| DURICEF® capsules 500 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834275 |
| Cefadroxil 500 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834275 |
| DURICEF® capsules 500 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834275 |
| Cefadroxil 500 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834275 |
| Effexor® 25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834249 |
| Venlafaxine 25 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834249 |
| Zithromax® 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834132 |
| Azithromycin 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834132 |
| Zithromax® 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834132 |
| Azithromycin 600 mg Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834132 |
| AMBIEN® 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833937 |
| Zolpidem 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833937 |
| AMBIEN® 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833937 |
| Zolpidem 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833937 |
| Lamisil® 250 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| Terbinafine HCl 250mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| Lamisil® 250 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| Terbinafine HCl 250mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| Lamisil® 250 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| Terbinafine HCl 250mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833586 |
| medroxyprogesterone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830414 |
| medroxyprogesterone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830414 |
| medroxyprogesterone acetate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830414 |
| Risperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830349 |
| Risperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830349 |
| Pravachol® 80 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830258 |
| Pravastatin sodium 80 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830258 |
| Pravachol® 80 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830258 |
| Pravastatin sodium 80 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830258 |
| Risperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829894 |
| Risperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829894 |
| Risperidone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829894 |
| Doxycycline Monohydrate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829790 |
| Doxycycline Monohydrate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829790 |
| Doxycycline Monohydrate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829764 |
| Dexmethylphenidate Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829712 |
| Dexmethylphenidate Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829712 |
| Dexmethylphenidate Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829673 |
| Altace® 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829530 |
| Ramipril 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829530 |
| Altace® 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829452 |
| Ramipril 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829452 |
| Altace® 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829452 |
| Ramipril 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829452 |
| Altace® 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00828321 |
| Ramipril 10 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00828321 |
| Tamsulosin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149733 |
| Tamsulosin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149733 |
| Losartan potassium/Hydrochlorothiazide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149473 |
| Losartan potassium/Hydrochlorothiazide | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149473 |
| Applesauce | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topamax® 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topiramate 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Applesauce | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topamax® 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topiramate 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Applesauce | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topamax® 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Topiramate 25 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905346 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859521 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859521 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859430 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859430 |
| Keppra® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859430 |
| Levetiracetam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00859430 |
| Norvasc® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841815 |
| Amlodipine Besylate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841815 |
| Norvasc® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841542 |
| Amlodipine Besylate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841542 |
| Norvasc® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841542 |
| Amlodipine Besylate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00841542 |
| Cefzil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840866 |
| cefprozil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840866 |
| Cefzil® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840866 |
| cefprozil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840866 |
| Augmentin ES-600™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840840 |
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840840 |
| Augmentin ES-600™ | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840840 |
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840840 |
| Mavik® 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840632 |
| Trandolapril 4 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840632 |
| Cefprozil 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840281 |
| Cefzil® 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840281 |
| Cefprozil 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840281 |
| Cefzil® 500 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840281 |
| Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00840099 |
| UNIRETIC® 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835042 |
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835042 |
| OMNICEF® for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| Cefdinir for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| OMNICEF® for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| Cefdinir for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| OMNICEF® for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| Cefdinir for oral suspension 250 mg/5mL | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834574 |
| OMNICEF® Capsule 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834535 |
| Cefdinir Capsules 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834535 |
| OMNICEF® Capsule 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834535 |
| Cefdinir Capsules 300 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834535 |
| Famvir® 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famciclovir 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famvir® 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famciclovir 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famvir® 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famciclovir 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834444 |
| Famvir® 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834431 |
| Famciclovir 500 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834431 |
| ARAVA™ 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| Leflunomide 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| ARAVA™ 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| Leflunomide 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| ARAVA™ 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| Leflunomide 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| ARAVA™ 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| Leflunomide 20 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834418 |
| REMERON SolTab® 15 mg Orally Disintegrating Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| Mirtazapine 15 mg (Orally Disintegrating) Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| REMERON SolTab® 15 mg Orally Disintegrating Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| Mirtazapine 15 mg (Orally Disintegrating) Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| REMERON SolTab® 15 mg Orally Disintegrating Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| Mirtazapine 15 mg (Orally Disintegrating) Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834197 |
| UNIRETIC® 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| UNIRETIC® 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| UNIRETIC® 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| Moexipril HCl/hydrochlorothiazide 15/25 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834067 |
| Zithromax® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Azithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Zithromax® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Azithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Zithromax® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Azithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830336 |
| Zithromax® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830206 |
| Azithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830206 |
| Zithromax® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830206 |
| Azithromycin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830206 |
| Alprazolam Extended-Release 3 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830024 |
| Alprazolam Extended-Release 3 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00830024 |
| Pravastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829309 |
| Pravastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829309 |
| Valacyclovir | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01149460 |
| Zofran® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934921 |
| Ondansetron | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934921 |
| Zofran® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934921 |
| Ondansetron | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934921 |
| Zofran® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934180 |
| Ondansetron | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934180 |
| Zofran® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934180 |
| Ondansetron | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00934180 |
| Augmentin® | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836901 |
| amoxicillin-clavulanic acid | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00836901 |
| Lotrel® 10 mg-20 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835367 |
| Amlodipine-benazepril 10 mg-20 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835367 |
| Lotrel® 10 mg-20 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835367 |
| Amlodipine-benazepril 10 mg-20 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00835367 |
| AMBIEN® 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833521 |
| Zolpidem 10 mg tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00833521 |
| Sonata® 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829998 |
| Zaleplon 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829998 |
| Sonata® 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829998 |
| Zaleplon 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829998 |
| SONATA® 10 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| Zaleplon 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| SONATA® 10 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| Zaleplon 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| SONATA® 10 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| Zaleplon 10 mg Capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829868 |
| Topamax® Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905164 |
| Topiramate Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00905164 |
| Topamax® Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00904943 |
| Topiramate Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00904943 |
| Topamax® Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00904943 |
| Topiramate Capsules, 25 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00904943 |
| Lotrel® 10 mg-20 mg capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834977 |
| Amlodipine-benazepril 10 mg-20 mg capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00834977 |
| Alprazolam Extended-Release 3 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829426 |
| Alprazolam Extended-Release 3 mg Tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00829426 |
| Deutetrabenazine 6 MG | Other | Phase PHASE1 | Dystonia, Primary | COMPLETED | NCT04173260 |
| Deutetrabenazine 6 MG | Other | Phase PHASE1 | Dystonia, Primary | COMPLETED | NCT04173260 |
| Placebo | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT05550337 |
| AKLIEF® | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT05550337 |
| Trifarotene 0.005 % Topical Cream | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT05550337 |
| Rituximab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Bendamustine | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| CD56-Enriched Donor Lymphocyte Infusion | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Haploidentical Stem Cell Transplantation | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Total Body Irradiation | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Rituximab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Bendamustine | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| CD56-Enriched Donor Lymphocyte Infusion | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Haploidentical Stem Cell Transplantation | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| Total Body Irradiation | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT03524235 |
| [14C]-TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| [14C]-TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| TEV-56286 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06627231 |
| Paclitaxel | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Cyclophosphamide | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Myocet | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Paclitaxel | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Cyclophosphamide | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Myocet | Other | Phase PHASE3 | Early Primary Breast Cancer | COMPLETED | NCT02214381 |
| Budesonide/Formoterol fumarate dihydrate | Other | Phase PHASE3 | Asthma | RECRUITING | NCT05831566 |
| Digihaler | Other | Preclinical | COPD | COMPLETED | NCT04821869 |
| ProAir Digihaler | Other | Preclinical | COPD | COMPLETED | NCT04821869 |
| Digihaler | Other | Preclinical | COPD | COMPLETED | NCT04821869 |
| ProAir Digihaler | Other | Preclinical | COPD | COMPLETED | NCT04821869 |
| Fremanezumab | Other | Preclinical | Migraine | RECRUITING | NCT07029126 |
| Fremanezumab | Other | Preclinical | Migraine | RECRUITING | NCT07029126 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04458857 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04458857 |
| ProAir Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| AirDuo Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| ProAir Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| AirDuo Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| ProAir Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| AirDuo Digihaler | Other | Phase PHASE4 | Asthma | COMPLETED | NCT04997304 |
| Fremanezumab | Other | Preclinical | Migraine | AVAILABLE | NCT03539393 |
| Fremanezumab | Other | Preclinical | Migraine | AVAILABLE | NCT03539393 |
| Oral Olanzapine | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06253546 |
| TV-44749 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT06253546 |
| Fp MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| TEV-56248 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| Fp MDPI | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| TEV-56248 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT06290102 |
| XOLAIR® Injection | Other | Phase PHASE3 | Chronic Urticaria | COMPLETED | NCT04976192 |
| TEV-45779 | Other | Phase PHASE3 | Chronic Urticaria | COMPLETED | NCT04976192 |
| XOLAIR® Injection | Other | Phase PHASE3 | Chronic Urticaria | COMPLETED | NCT04976192 |
| TEV-45779 | Other | Phase PHASE3 | Chronic Urticaria | COMPLETED | NCT04976192 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT05458011 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT05458011 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT05458011 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT05458011 |
| Placebo | Other | Phase PHASE3 | Plaque Type Psorisis | COMPLETED | NCT06742957 |
| VTAMA® | Other | Phase PHASE3 | Plaque Type Psorisis | COMPLETED | NCT06742957 |
| Tapinarof Cream 1% | Other | Phase PHASE3 | Plaque Type Psorisis | COMPLETED | NCT06742957 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04464707 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04464707 |
| Placebo | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04464707 |
| Fremanezumab | Other | Phase PHASE3 | Migraine | COMPLETED | NCT04464707 |
| Deutetrabenazine | Other | Phase PHASE2 | Huntington Disease | ACTIVE_NOT_RECRUITING | NCT04713982 |
| Deutetrabenazine Oral Capsule | Other | Phase PHASE4 | Tardive Dyskinesia | NOT_YET_RECRUITING | NCT06997198 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06480552 |
| TEV-56278 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06480552 |
| Radiotherapy | Drug | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Quality of Life Measurements | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| DTIC | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Cyclophosphamide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Filgrastim | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Prednisone | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vinblastine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vincristine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Bleomycin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Doxorubicin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Etoposide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| bendamustine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Placebo | Other | Phase PHASE4 | Migraine | ACTIVE_NOT_RECRUITING | NCT06173661 |
| Fremanezumab | Other | Phase PHASE4 | Migraine | ACTIVE_NOT_RECRUITING | NCT06173661 |
| Placebo | Other | Phase PHASE4 | Migraine | ACTIVE_NOT_RECRUITING | NCT06173661 |
| Fremanezumab | Other | Phase PHASE4 | Migraine | ACTIVE_NOT_RECRUITING | NCT06173661 |
| Fremanezumab Prefilled Syringe [Ajovy] | Other | Phase PHASE4 | Migraine Disorders | TERMINATED | NCT04693533 |
| Fremanezumab Prefilled Syringe [Ajovy] | Other | Phase PHASE4 | Migraine Disorders | TERMINATED | NCT04693533 |
| albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT03890666 |
| Albuterol eMDPI DS | Other | Phase PHASE4 | Asthma | COMPLETED | NCT03890666 |
| albuterol | Other | Phase PHASE4 | Asthma | COMPLETED | NCT03890666 |
| Albuterol eMDPI DS | Other | Phase PHASE4 | Asthma | COMPLETED | NCT03890666 |
| Placebo | Other | Phase PHASE3 | Asthma | RECRUITING | NCT06664619 |
| ABS | Other | Phase PHASE3 | Asthma | RECRUITING | NCT06664619 |
| Fp/ABS | Other | Phase PHASE3 | Asthma | RECRUITING | NCT06664619 |
| Radiotherapy | Drug | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Quality of Life Measurements | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| DTIC | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Cyclophosphamide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Brentuximab Vedotin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Filgrastim | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Prednisone | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vinblastine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Vincristine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Bleomycin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Doxorubicin | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| Etoposide | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
| bendamustine | Other | Phase PHASE2 | Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT03755804 |
Total products: 1884